

05-31-00

PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Please type a plus sign (+) inside this box →

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))

Attorney Docket No.

PC8605C

First Named Inventor or Application Identifier

YUHPYNG L. CHEN

Title

CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Express Mail Label No.

EL162815459US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 145]  
(preferred arrangement set forth below)
- Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference in Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☐ Drawing(s) (35 U.S.C. 11.3) [Total sheets     ]
4. ☐ Oath or Declaration [Total pages     ]
- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR §1.63(d))  
(for continuation/divisional with Box 17 completed)  
[Note Box 5 below]
- i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. §3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ \*Small Entity ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Other: Priority Claim of Serial No. 09/254,387  
(filed June 6, 1995); and of 08/741,066 (filed Oct. 30, 1996)

\*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP)

of prior application No: 08/741,066 and 09/254,387

Prior application information:

Examiner

Group/Art Unit:

## 18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	Paul H. Ginsburg				
Address	Pfizer Inc				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755
Country	United States Of America	Telephone	(212)573-2369	Fax	(212)573-1939
NAME (Print/type)	Kristina L. Konstas	Registration No. (Attorney/Agent)	37,864		
Signature	<i>Kristina L. Konstas</i>	Date	5/30/00		

EXPRESS MAIL NO. EL162815459US

UTILITY TRANSMITTAL PTO SB 05, 3/99, (1/1)

CORTICOTROPIN RELEASING FACTOR ANTAGONISTSBackground Of The Invention

5 This invention relates to pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones, processes for preparing them, pharmaceutical compositions containing them, and methods of using them to treat certain central nervous system (CNS) and other disorders.


CRF antagonists are mentioned in U.S. Patents 4,605,642, issued August 12, 1986, and 5,063,245, issued November 5, 1991, referring to peptides and pyrazolinones, respectively. CRF antagonists are also described in U.S. Patent 5,962,479, issued October 5, 1999. The importance of CRF antagonists is set out in the literature, e.g., as discussed in U.S. Patent 5,063,245, which is incorporated herein by reference. A recent outline of the different activities possessed by CRF antagonists is found in M. J. Owens et al., Pharm. Rev., Vol. 43, pages 425 to 473 (1991), also incorporated herein by reference. Based on the research described in these two and other references, CRF antagonists are effective in the treatment of a wide range of stress-related illnesses, such as depression, anxiety, headache, irritable bowel syndrome, inflammatory diseases, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, infertility, head trauma, stroke, and stress-induced infections in humans and animals. The use of CRF antagonists for treatment of Syndrome X has also been described in U.S. Provisional Patent Application No. 60/162,340, filed October 29, 1999, which is also incorporated in its entirety herein by reference. Methods for using CRF antagonists to treat congestive heart failure are described in U.S. Serial No. 09/248,073, filed February 10, 1999, which is also incorporated herein in its entirety by reference.

Summary of the Invention


25 The present invention provides compounds of the formula

EXPRESS MAIL NO. EL162815459US

-2-




I



II

or



III

5

and pharmaceutically acceptable salts thereof, wherein

the dashed lines represent optional double bonds, with the proviso that when the dashed line in C---G represent a double bond, then the dashed line in N(R<sub>6</sub>)---C does not represent a double bond; and with the proviso that when the dashed line in N(R<sub>6</sub>)---C represents a double bond, R<sub>6</sub> is absent in formula III and the dashed line in C---G does not represent a double bond;

10

A is -CR<sub>7</sub> or N;

B is -NR<sub>1</sub>R<sub>2</sub>, -CR<sub>1</sub>R<sub>2</sub>R<sub>11</sub>, -C(=CR<sub>2</sub>R<sub>12</sub>)R<sub>1</sub>, -NHCHR<sub>1</sub>R<sub>2</sub>, -OCHR<sub>1</sub>R<sub>2</sub>, -SCHR<sub>1</sub>R<sub>2</sub>, -CHR<sub>2</sub>OR<sub>1</sub>, -CHR<sub>1</sub>OR<sub>2</sub>, -CHR<sub>2</sub>SR<sub>1</sub>, -C(S)R<sub>2</sub>, -C(O)R<sub>2</sub>, -CHR<sub>2</sub>NR<sub>1</sub>R<sub>2</sub>, -CHR<sub>1</sub>NHR<sub>2</sub>, -CHR<sub>1</sub>N(CH<sub>3</sub>)R<sub>2</sub>, or -NR<sub>12</sub>NR<sub>1</sub>R<sub>2</sub>;

EXPRESS MAIL NO. EL16281545905

when the dashed line in C—G represents a double bond, then G is hydrogen, oxygen, sulfur, NH, or N(C<sub>1</sub>-C<sub>4</sub> alkyl);

when the dashed line in C—G does not represent a double bond, then C—G is - C(H)(NH<sub>2</sub>), CH<sub>2</sub>, -C(H)(methoxy), -C(H)(ethoxy), -C(H)(O(C<sub>3</sub>-C<sub>4</sub> alkyl)), -C(H)(halo), -  
5 C(H)(trifluoromethoxy), -C(H)(methyl), -C(H)(ethyl), -C(H)(C<sub>3</sub>-C<sub>4</sub> alkyl), -C(H)(S(C<sub>1</sub>-C<sub>4</sub> alkyl)), - C(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>4</sub> alkyl), cyclopropyl, -C(H)(cyclopropyl), thiomethoxy, -C(H)(NH<sub>2</sub>), - C(H)(NHCH<sub>3</sub>), -C(H)(N(CH<sub>3</sub>)<sub>2</sub>), or -C(H)(trifluoromethyl);

wherein said cyclopropyl, methoxy, ethoxy, C<sub>3</sub>-C<sub>4</sub> alkyl, and C<sub>1</sub>-C<sub>4</sub> alkyl groups of C—G  
may optionally be substituted by one OH, methoxy, or trifluoromethoxy, or may optionally be  
10 substituted by from one to six fluoro atoms;

Y is CH or N;

Z is NH, O, S, -N(C<sub>1</sub>-C<sub>2</sub> alkyl), -NC(O)CF<sub>3</sub>, or -C(R<sub>13</sub>R<sub>14</sub>), wherein R<sub>13</sub> and R<sub>14</sub> are each,  
independently, hydrogen, trifluoromethyl or methyl, or one of R<sub>13</sub> and R<sub>14</sub> is cyano and the other is  
hydrogen or methyl, or -C(R<sub>13</sub>R<sub>14</sub>) is a cyclopropyl group, or Z is nitrogen or CH and forms a five  
15 or six membered heterocyclic ring fused with R<sub>5</sub>, which ring optionally comprises two or three  
further hetero members selected independently from oxygen, nitrogen, NR<sub>12</sub>, and S(O)<sub>m</sub>, and  
optionally comprises from one to three double bonds, and is optionally substituted with halo, C<sub>1</sub>-  
C<sub>4</sub> alkyl, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), NH<sub>2</sub>, NHCH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, CF<sub>3</sub>, or OCF<sub>3</sub>, with the proviso that said ring does  
not contain any -S-S-, -S-O-, -N-S-, or -O-O- bonds, and does not comprise more than two  
20 oxygen or S(O)<sub>m</sub> heterologous members;

R<sub>1</sub> is C(O)H, C(O)(C<sub>1</sub>-C<sub>6</sub> alkyl), C(O)(C<sub>1</sub>-C<sub>6</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), C(O)(C<sub>3</sub>-C<sub>8</sub>  
cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), C(O)(C<sub>1</sub>-C<sub>6</sub> alkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), -C(O)(C<sub>3</sub>-C<sub>8</sub>  
cycloalkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl, -(C<sub>1</sub>-  
C<sub>6</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>1</sub>-C<sub>6</sub> alkylene)(C<sub>4</sub>-C<sub>8</sub>  
25 heterocycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), or -O-aryl, or -O-(C<sub>1</sub>-C<sub>6</sub>  
alkylene)-aryl; wherein said aryl, C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub>  
cycloalkylene, and C<sub>1</sub>-C<sub>6</sub> alkylene groups may each independently be optionally substituted with  
from one to six fluoro and may each independently be optionally substituted with one or two  
substituents R<sub>8</sub> independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, -C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
30 hydroxy, fluoro, chloro, bromo, iodo, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -O-CO-(C<sub>1</sub>-C<sub>4</sub>  
alkyl), -O-CO-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-N(R<sub>24</sub>)(R<sub>25</sub>), -N(R<sub>24</sub>)(R<sub>25</sub>), -S(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>3</sub>-C<sub>5</sub>  
cycloalkyl), -N(C<sub>1</sub>-C<sub>4</sub>alkyl)CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -NHCO(C<sub>1</sub>-C<sub>4</sub> alkyl), -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CONH(C<sub>1</sub>-C<sub>4</sub>  
alkyl), -CON(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), CN, NO<sub>2</sub>, -OSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), S<sup>+</sup>(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl)<sup>-</sup>,  
-SO(C<sub>1</sub>-C<sub>4</sub> alkyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl); and wherein the C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylene, C<sub>5</sub>-C<sub>8</sub>  
35 cycloalkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkylene, and C<sub>5</sub>-C<sub>8</sub> heterocycloalkyl moieties of R<sub>1</sub> may optionally  
independently contain from one to three double or triple bonds; and wherein the C<sub>1</sub>-C<sub>4</sub> alkyl  
moieties and the C<sub>1</sub>-C<sub>6</sub> alkyl moieties of R<sub>8</sub> can optionally independently be substituted with



hydroxy, C<sub>1</sub>-C<sub>4</sub> alkyl, amino, aryl, -CH<sub>2</sub>-aryl, -C<sub>3</sub>-C<sub>5</sub> cycloalkyl, or -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), and can optionally independently be substituted with from one to five fluoro, and can optionally contain one or two double or triple bonds; and wherein each heterocycloalkyl group of R<sub>1</sub> contains from one to three heteromoiety selected from oxygen, S(O)<sub>m</sub>, nitrogen, and NR<sub>12</sub>;

- 5 R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>1</sub>-C<sub>6</sub> alkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), aryl, -(C<sub>1</sub>-C<sub>6</sub> alkylene)aryl, or -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(aryl); wherein each of the foregoing R<sub>2</sub> groups may optionally be substituted with from one three substituents independently selected from chloro, fluoro, and C<sub>1</sub>-C<sub>6</sub> alkyl, wherein one of said one to three substituents can further be selected from bromo, iodo, C<sub>1</sub>-C<sub>6</sub> alkoxy, -OH, -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(O)(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), S<sup>+</sup>(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl)I<sup>-</sup>, CN, and NO<sub>2</sub>; and wherein the C<sub>1</sub>-C<sub>12</sub> alkyl, -(C<sub>1</sub>-C<sub>6</sub> alkylene), -(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene), and -(C<sub>3</sub>-C<sub>8</sub> heterocycloalkyl) moieties of R<sub>2</sub> may optionally independently contain from one to three double or triple bonds; and  
10  
15 wherein each heterocycloalkyl group of R<sub>2</sub> contains from one to three heteromoiety selected from oxygen, S(O)<sub>m</sub>, nitrogen, and NR<sub>12</sub>;

- or where R<sub>1</sub> and R<sub>2</sub> are as in -NHCHR<sub>1</sub>R<sub>2</sub>, -OCHR<sub>1</sub>R<sub>2</sub>, -SCHR<sub>1</sub>R<sub>2</sub>, -CHR<sub>1</sub>R<sub>2</sub> or -NR<sub>1</sub>R<sub>2</sub>, R<sub>1</sub> and R<sub>2</sub> of B may form a saturated 5- to 8-membered ring which may optionally contain one or two double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen, S(O)<sub>m</sub>, nitrogen or NR<sub>12</sub>; and which carbocyclic ring can optionally be substituted with  
20 from 1 to 3 substituents selected from the group consisting of hydroxy, C<sub>1</sub>-C<sub>4</sub> alkyl, fluoro, chloro, bromo, iodo, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -NHCO(C<sub>1</sub>-C<sub>4</sub> alkyl), -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CONH(C<sub>1</sub>-C<sub>4</sub> alkyl), -CON(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), CN, NO<sub>2</sub>, -OSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO(C<sub>1</sub>-C<sub>4</sub> alkyl), and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl),  
25 wherein one of said one to three substituents can further be selected from phenyl;

- R<sub>3</sub> is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF<sub>3</sub>, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>2</sub> alkyl), N(CH<sub>3</sub>)<sub>2</sub>, -NHCOCF<sub>3</sub>, -NHCH<sub>2</sub>CF<sub>3</sub>, S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), CONH<sub>2</sub>, -CONHCH<sub>3</sub>, CON(CH<sub>3</sub>)<sub>2</sub>, -CF<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>;
- 30 R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>5</sub> cycloalkylene)(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), cyano, fluoro, chloro, bromo, iodo, -OR<sub>24</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -O-(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -O-(C<sub>3</sub>-C<sub>5</sub> cycloalkylene)(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -CH<sub>2</sub>SC(S)O(C<sub>1</sub>-C<sub>4</sub> alkyl), -CH<sub>2</sub>OCF<sub>3</sub>, CF<sub>3</sub>, amino, nitro, -NR<sub>24</sub>R<sub>25</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)-OR<sub>24</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)Cl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)NR<sub>24</sub>R<sub>25</sub>, -NHCOR<sub>24</sub>, -NHCONR<sub>24</sub>R<sub>25</sub>, -C=NOR<sub>24</sub>, -NHNOR<sub>24</sub>R<sub>25</sub>, -S(O)<sub>m</sub>R<sub>24</sub>, -C(O)R<sub>24</sub>, -OC(O)R<sub>24</sub>, -C(O)CN, -C(O)NR<sub>24</sub>R<sub>25</sub>, -C(O)NHNOR<sub>24</sub>R<sub>25</sub>, and -COOR<sub>24</sub>,  
35 wherein the alkyl and alkylene groups of R<sub>4</sub> may optionally independently contain one or two double or triple bonds and may optionally independently be substituted with one or two

substituents  $R_{10}$  independently selected from hydroxy, amino,  $-NHCOCH_3$ ,  $-NHCOCH_2Cl$ ,  $-NH(C_1-C_2 \text{ alkyl})$ ,  $-N(C_1-C_2 \text{ alkyl})(C_1-C_2 \text{ alkyl})$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-COOH$ ,  $-CO(C_1-C_4 \text{ alkyl})$ ,  $C_1-C_6$  alkoxy,  $C_1-C_3$  thioalkyl, cyano and nitro, and with one to four substituents independently selected from fluoro and chloro;

- 5  $R_5$  is aryl or heteroaryl and is substituted with from one to four substituents  $R_{27}$  independently selected from halo,  $C_1-C_{10}$  alkyl,  $-(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_1-C_4 \text{ alkylene})(C_4-C_8 \text{ heterocycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_4-C_8 \text{ heterocycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkylene})(C_4-C_8 \text{ heterocycloalkyl})$ ,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  haloalkoxy, nitro, cyano,  $-NR_{24}R_{25}$ ,  $-NR_{24}COR_{25}$ ,  $-NR_{24}CO_2R_{26}$ ,  $-COR_{24}$ ,  $-OR_{25}$ ,  $-CONR_{24}R_{25}$ ,  $-CO(NOR_{22})R_{23}$ ,  $-CO_2R_{26}$ ,  $-C=N(OR_{22})R_{23}$ , and  $-S(O)_mR_{23}$ ; wherein said  $C_1-C_{10}$  alkyl,  $C_3-C_8$  cycloalkyl,  $(C_1-C_4 \text{ alkylene})$ ,  $(C_3-C_8 \text{ cycloalkyl})$ ,  $(C_3-C_8 \text{ cycloalkylene})$ , and  $(C_4-C_8 \text{ heterocycloalkyl})$  groups can be optionally substituted with from one to three substituents independently selected from  $C_1-C_4$  alkyl,  $C_3-C_8$  cycloalkyl,  $(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $C_1-C_4$  haloalkyl, hydroxy,  $C_1-C_6$  alkoxy, nitro halo, cyano,  $-NR_{24}R_{25}$ ,  $-NR_{24}COR_{25}$ ,  $NR_{24}CO_2R_{26}$ ,  $-COR_{24}$ ,  $-OR_{25}$ ,  $-CONR_{24}R_{25}$ ,  $CO_2R_{26}$ ,  $-CO(NOR_{22})R_{25}$ , and  $-S(O)_mR_{23}$ ; and wherein two adjacent substituents of the  $R_5$  group can optionally form a 5-7 membered ring, saturated or unsaturated, fused to  $R^5$ , which ring optionally can contain one, two, or three heterologous members independently selected from O,  $S(O)_m$ , and N, but not any  $-S-S-$ ,  $-O-O-$ ,  $-S-O-$ , or  $-N-S-$  bonds, and which ring is optionally substituted with  $C_1-C_4$  alkyl,  $C_3-C_8$  cycloalkyl,  $-(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $C_1-C_4$  haloalkyl, nitro, halo, cyano  $-NR_{24}R_{25}$ ,  $NR_{24}COR_{25}$ ,  $NR_{24}CO_2R_{26}$ ,  $-COR_{24}$ ,  $-OR_{25}$ ,  $-CONR_{24}R_{25}$ ,  $CO_2R_{26}$ ,  $-CO(NOR_{26})R_{25}$ , or  $-S(O)_mR_{23}$ ; wherein one of said one to four optional substituents  $R_{27}$  can further be selected from  $-SO_2NH(C_1-C_4 \text{ alkyl})$ ,  $-SO_2NH(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-SO_2NH(C_3-C_8 \text{ cycloalkyl})$ ,  $-SO_2NH(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-SO_2N(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$ ,  $-SO_2NH_2$ ,  $-NHSO_2(C_1-C_4 \text{ alkyl})$ ,  $-NHSO_2(C_3-C_8 \text{ cycloalkyl})$ ,  $-NHSO_2(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$ , and  $-NHSO_2(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ ; and wherein the alkyl, and alkylene groups of  $R_5$  may independently optionally contain one double or triple bond;

- 20  $R_6$  is hydrogen,  $C_1-C_6$  alkyl,  $C_3-C_8$  cycloalkyl,  $-(C_1-C_6 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$ , or  $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ , wherein said alkyl and cycloalkyl may optionally be substituted with one hydroxy, methoxy, ethoxy or fluoro group;

- 30 or, wherein the compound is a compound of formula II,  $R_6$  and  $R_4$  can together form an oxo ( $=O$ ) group or can be connected to form a 3-8 membered carbocyclic ring, optionally containing one to three double bonds, and optionally containing one, two, or three heterologous ring members selected from O,  $SO_m$ , N, and  $NR_{12}$ , but not containing any  $-O-O-$ ,  $-S-O-$ ,  $-S-S-$ , or  $-N-S-$  bonds, and further optionally substituted with  $C_1-C_4$  alkyl or  $C_3-C_6$  cycloalkyl, wherein said  $C_1-C_4$  alkyl substituent may optionally contain one double or triple bond;

R<sub>7</sub> is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, -O(C<sub>1</sub>-C<sub>2</sub> alkyl), -O(cyclopropyl), -COO(C<sub>1</sub>-C<sub>2</sub> alkyl), -COO(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -OCF<sub>3</sub>, CF<sub>3</sub>, -CH<sub>2</sub>OH, or CH<sub>2</sub>OCH<sub>3</sub>;

R<sub>11</sub> is hydrogen, hydroxy, fluoro, ethoxy, or methoxy;

R<sub>12</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

5 R<sub>16</sub> and R<sub>17</sub> are each, independently, hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy, except that R<sub>16</sub> and R<sub>17</sub> are not both methoxy or ethoxy;

or R<sub>16</sub> and R<sub>17</sub> together form an oxo (=O) group;

or R<sub>16</sub> and R<sub>17</sub> are connected to form a 3-8 membered carbocyclic ring, optionally containing one to three double bonds, and optionally containing from one to three heterologous  
10 ring members selected from O, SO<sub>m</sub>, N, and NR<sub>12</sub>, but not containing any -O-O-, -S-O-, -S-S-, or -N-S- bonds, and further optionally substituted with C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>3</sub>-C<sub>8</sub> cycloalkyl, wherein said C<sub>1</sub>-C<sub>4</sub> alkyl substituent may optionally contain one double or triple bond;

R<sub>22</sub> is independently at each occurrence selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl, C<sub>3</sub>-C<sub>8</sub> alkynyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl),  
15 and (C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl);

R<sub>23</sub> is independently at each occurrence selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), aryl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl, piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, and thiomorpholine;


20 R<sub>24</sub> and R<sub>25</sub> are independently at each occurrence selected from hydrogen, -C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, especially CF<sub>3</sub>, -CHF<sub>2</sub>, CF<sub>2</sub>CF<sub>3</sub>, or CH<sub>2</sub>CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)OH, -(C<sub>1</sub>-C<sub>4</sub> alkylene)-O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkylene)-O-(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), aryl, and  
25 -(C<sub>1</sub>-C<sub>4</sub> alkylene)(aryl), wherein the -C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl groups can each independently optionally be substituted with aryl, CH<sub>2</sub>-aryl, or C<sub>1</sub>-C<sub>4</sub> alkyl, and can optionally contain one or two double or triple bonds; or, when R<sub>24</sub> and R<sub>25</sub> are as NR<sub>24</sub>R<sub>25</sub>, -C(O)NR<sub>24</sub>R<sub>25</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)NR<sub>24</sub>R<sub>25</sub>, or -NHCONR<sub>24</sub>R<sub>25</sub>, then NR<sub>24</sub>R<sub>25</sub> may further optionally form a 4 to 8 membered heterocyclic ring optionally containing one or two further hetero members  
30 independently selected from S(O)<sub>m</sub>, oxygen, nitrogen, and NR<sub>12</sub>, and optionally containing from one to three double bonds;

R<sub>26</sub> is independently at each occurrence selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), aryl, and -(C<sub>1</sub>-C<sub>4</sub> alkylene)(aryl); and


35 wherein each m is independently zero, one, or two,

with the proviso that heterocycloalkyl groups of the compound of formula I, II, or III do not comprise any -S-S-, -S-O-, -N-S-, or -O-O- bonds, and do not comprise more than two oxygen or S(O)<sub>m</sub> heterologous members.

In one embodiment of the invention, the compound of the invention is of formula




I



II

or



III

, wherein

the dashed lines represent optional double bonds;

A is -CR<sub>7</sub> or N;

B is -NR<sub>1</sub>R<sub>2</sub>, -CR<sub>1</sub>R<sub>2</sub>R<sub>11</sub>, -C(=CR<sub>2</sub>R<sub>12</sub>)R<sub>1</sub>, -NHCHR<sub>1</sub>R<sub>2</sub>, -OCHR<sub>1</sub>R<sub>2</sub>, -SCHR<sub>1</sub>R<sub>2</sub>, -CHR<sub>2</sub>OR<sub>12</sub>, -CHR<sub>2</sub>SR<sub>12</sub>, -C(S)R<sub>2</sub> or -C(O)R<sub>2</sub>;

G is oxygen, sulfur, NH, NH<sub>3</sub>, hydrogen, methoxy, ethoxy, trifluoromethoxy, methyl, ethyl, thiomethoxy, NH<sub>2</sub>, NHCH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub> or trifluoromethyl;

Y is -CH or N;

Z is NH, O, S, -N(C<sub>1</sub>-C<sub>2</sub> alkyl) or -C(R<sub>13</sub>R<sub>14</sub>), wherein R<sub>13</sub> and R<sub>14</sub> are each, independently, hydrogen, trifluoromethyl or methyl, or one of R<sub>13</sub> and R<sub>14</sub> is cyano and the other is hydrogen or methyl;

EXPRESS MAIL NO. EL16281549US

R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl which may optionally be substituted with one or two substituents R<sub>8</sub> independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkoxy, -O-CO-(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -NHCO(C<sub>1</sub>-C<sub>4</sub> alkyl), -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CONH(C<sub>1</sub>-C<sub>4</sub> alkyl), -CON(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), CN, NO<sub>2</sub>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), and wherein said C<sub>1</sub>-C<sub>6</sub> alkyl and the (C<sub>1</sub>-C<sub>4</sub>)alkyl moieties in the foregoing R<sub>1</sub> groups may optionally contain one carbon-carbon double or triple bond;

R<sub>2</sub> is C<sub>1</sub>-C<sub>12</sub> alkyl, aryl or -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R<sub>9</sub> wherein R<sub>9</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and wherein each of the foregoing R<sub>2</sub> groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C<sub>1</sub>-C<sub>4</sub> alkyl, or with one substituent selected from bromo, iodo, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, NO<sub>2</sub>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl), and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), and wherein said C<sub>1</sub>-C<sub>12</sub> alkyl and the C<sub>1</sub>-C<sub>4</sub> alkylene moiety of said -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR<sub>1</sub>R<sub>2</sub> or -CR<sub>1</sub>R<sub>2</sub>R<sub>11</sub> may form a saturated 5- to 8-membered carbocyclic ring which may optionally contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom;

R<sub>3</sub> is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF<sub>3</sub>, methylthio, methylsulfonyl, CH<sub>2</sub>OH, or CH<sub>2</sub>OCH<sub>3</sub>;

R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, fluoro, chloro, bromo, iodo, C<sub>1</sub>-C<sub>4</sub> alkoxy, trifluoromethoxy, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OF<sub>3</sub>, CF<sub>3</sub>, amino, nitro, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(CH<sub>3</sub>)<sub>2</sub>, -NHCOCH<sub>3</sub>, -NHCONHCH<sub>3</sub>, -SO<sub>n</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CHO, cyano or -COO(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein said C<sub>1</sub>-C<sub>4</sub> alkyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH<sub>3</sub>, -NH(C<sub>1</sub>-C<sub>2</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)<sub>2</sub>, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> thioalkyl, fluoro, chloro, cyano and nitro;

R<sub>5</sub> is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each of the above groups R<sub>5</sub> is substituted with from one to three substituents independently selected from fluoro, chloro, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro,

trifluoromethyl, amino,  $-(C_1-C_6 \text{ alkyl})O(C_1-C_6 \text{ alkyl})$ ,  $-NHCH_3$ ,  $-N(CH_3)_2$ ,  $-COOH$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-CO(C_1-C_4 \text{ alkyl})$ ,  $-SO_2NH(C_1-C_4 \text{ alkyl})$ ,  $-SO_2N(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$ ,  $-SO_2NH_2$ ,  $-NHSO_2(C_1-C_4 \text{ alkyl})$ ,  $-S(C_1-C_6 \text{ alkyl})$  and  $-SO_2(C_1-C_6 \text{ alkyl})$ , and wherein the  $C_1-C_4 \text{ alkyl}$  and  $C_1-C_6 \text{ alkyl}$  moieties of the foregoing  $R_5$  groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

$R_6$  is hydrogen or  $C_1-C_6 \text{ alkyl}$ , wherein said  $C_1-C_6 \text{ alkyl}$  may optionally be substituted with one hydroxy, methoxy, ethoxy or fluoro group;

$R_7$  is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy,  $-O(C_1-C_4 \text{ alkyl})$ ,  $-C(O)(C_1-C_4 \text{ alkyl})$ ,  $-C(O)O(C_1-C_4 \text{ alkyl})$ ,  $-OCF_3$ ,  $CF_3$ ,  $-CH_2OH$ ,  $-CH_2OCH_3$  or  $-CH_2OCH_2CH_3$ ;

$R_{11}$  is hydrogen, hydroxy, fluoro, or methoxy;

$R_{12}$  is hydrogen or  $C_1-C_4 \text{ alkyl}$ ; and

$R_{16}$  and  $R_{17}$  are each, independently, hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy, except that  $R_{16}$  and  $R_{17}$  are not both methoxy or ethoxy;

or  $R_{16}$  and  $R_{17}$  together form an oxo ( $=O$ ) group;

with the proviso that when  $G$  is oxygen, sulfur,  $NH$  or  $NCH_3$ , it is double bonded to the five membered ring of structure III, and with the further proviso that  $R_6$  is absent when the nitrogen to which it is attached is double bonded to an adjacent ring carbon atom;

or a pharmaceutically acceptable salt of such compound.

More specific embodiments of this invention include compounds of the formula I, II or III wherein: (a)  $B$  is  $-NR_1R_2$ ,  $-NHCHR_1R_2$ ,  $-SCHR_1R_2$  or  $-OCHR_1R_2$ ;  $R_1$  is  $C_1-C_6 \text{ alkyl}$ , which may optionally be substituted with one hydroxy, fluoro,  $CF_3$ , or  $C_1-C_2 \text{ alkoxy}$  group and may optionally contain one double or triple bond; and  $R_2$  is benzyl or  $C_1-C_6 \text{ alkyl}$  which may optionally contain one carbon-carbon double or triple bond, wherein said  $C_1-C_6 \text{ alkyl}$  or the phenyl moiety of said benzyl may optionally be substituted with fluoro,  $CF_3$ ,  $C_1-C_2 \text{ alkyl}$ , or  $C_1-C_2 \text{ alkoxy}$ ; or (b)  $B$  is  $-CR_1R_2R_{11}$  wherein  $R_1$  is  $C_1-C_6 \text{ alkyl}$  which may optionally be substituted with one  $C_1-C_2 \text{ alkoxy}$ ,  $CF_3$ , fluoro or hydroxy group;  $R_2$  is benzyl or  $C_1-C_6 \text{ alkyl}$  wherein said  $C_1-C_6 \text{ alkyl}$  or the phenyl moiety of said benzyl may optionally be substituted with one  $C_1-C_2 \text{ alkyl}$ ,  $CF_3$ ,  $C_1-C_2 \text{ alkoxy}$ , fluoro, chloro or bromo group; and  $R_{11}$  is hydrogen or fluoro.

Other more specific embodiments of this invention include compounds of the formula I, II or III wherein  $R_1$  is  $C_1-C_6 \text{ alkyl}$  which may optionally be substituted by fluoro,  $CF_3$ , hydroxy,  $C_1-C_2 \text{ alkyl}$  or  $C_1-C_2 \text{ alkoxy}$  and may optionally contain one carbon-carbon double or triple bond, and  $R_2$  is  $C_1-C_4 \text{ alkyl}$  which may optionally be substituted with fluoro, chloro,  $CF_3$ ,  $C_1-C_4 \text{ alkyl}$  or  $C_1-C_4 \text{ alkoxy}$ .

Other more specific embodiments of this invention include compounds of the formula I, II or III wherein  $R_3$  is methyl, chloro, or methoxy,  $R_4$  is methyl,  $-CH_2OH$ , cyano, trifluoromethoxy, methoxy, trifluoromethyl, chloro,  $-COOCH_3$ ,  $-CH_2OCH_3$ ,  $-CH_2Cl$ ,  $-CH_2F$ , amino or nitro;  $R_6$  is hydrogen, methyl or ethyl and  $R_5$  is phenyl or pyridyl wherein said phenyl or pyridyl is substituted

by two or three substituents independently selected from fluoro, chloro, bromo, iodo, C<sub>1</sub>-C<sub>4</sub> alkoxy, trifluoromethyl, C<sub>1</sub>-C<sub>6</sub> alkyl which may optionally be substituted with one hydroxy, C<sub>1</sub>-C<sub>2</sub> alkoxy or fluoro group and may optionally contain one carbon-carbon double or triple bond, -(C<sub>1</sub>-C<sub>4</sub> alkylene)O(C<sub>1</sub>-C<sub>2</sub> alkyl), C<sub>1</sub>-C<sub>3</sub> hydroxyalkyl, hydroxy, formyl, -COO(C<sub>1</sub>-C<sub>2</sub> alkyl), -(C<sub>1</sub>-C<sub>2</sub> alkylene)amino, and -(C(O)(C<sub>1</sub>-C<sub>4</sub> alkyl).

Examples of preferred compounds of this invention are:

- 4-(1-ethyl-propoxy)-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine;  
2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;  
2-(4-ethyl-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;  
3-ethyl-4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;  
2-(2,6-dimethyl-4-propyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;  
4-(1-ethyl-propoxy)-2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine;  
2-(4-ethoxy-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;  
2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;  
4-(1-methoxymethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;  
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-diethyl-amine;  
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-propyl-amine;  
[2,5-dimethyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-4-yl](1-ethyl-propyl)-amine;  
butyl-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine;  
4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenylsulfanyl)-pyridine;  
butyl-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-amine;  
4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;  
[3,6-dimethyl-[2-(2,4,6-trimethyl-phenylsulfanyl)-pyridin-4-yl]-ethyl-propyl-amine;  
4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-methanol;  
[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-propyl-amine;  
1-(ethyl-propyl)-[6-methyl-3-nitro-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine;  
N4-(1-ethyl-propyl)-6-methyl-3-nitro-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine;  
N4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;  
3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-(2,2,2-trifluoro-ethyl)-amine;  
N4-(1-ethyl-propyl)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine;  
[3-chloromethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)pyridin-4-yl]-(1-ethyl-propyl)-amine;  
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine;  
(1-ethyl-propyl)-[2-methyl-5-nitro-6-(2,4,6-trimethyl-pyridin-3-yloxy)-pyrimidin-4-yl]-amine;  
(1-ethyl-propyl)-[3-methoxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-  
amine;  
(N-(1-ethyl-propyl)-2-methyl-5-nitro-N'-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,6-diamine;

- [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-diethyl-amine;  
4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine;  
butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-  
ethyl-amine;
- 5 4-(butyl-ethylamino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-  
d]pyrimidin-6-one;  
4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;  
N-butyl-N-ethyl-2,5-dimethyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine;  
(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-amine;
- 10 [2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-  
amine;  
N4-(1-ethyl-propyl)-6,N3-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;  
N4-(1-ethyl-propyl)-6,N3,N3-trimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;  
6-(1-ethyl-propoxy)-2-methyl-N4-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5-diamine;
- 15 [4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethylphenyl)-amine; and  
6-(ethyl-propyl-amino)-2,7-dimethyl-9-(2,4,6-trimethylphenyl)-7,9-dihydro-purin-8-one.  
Other preferred compounds of this invention are:  
4-(1-ethyl-propoxy)-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine;  
2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;
- 20 2-(4-ethyl-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;  
3-ethyl-4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;  
2-(2,6-dimethyl-4-propyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;  
4-(1-ethyl-propoxy)-2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine;  
2-(4-ethoxy-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;
- 25 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine;  
4-(1-methoxymethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;  
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-diethyl-amine;  
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-propyl-amine;  
[2,5-dimethyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-4-yl](1-ethyl-propyl)-amine;
- 30 butyl-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine;  
4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenylsulfanyl)-pyridine;  
butyl-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-amine;  
4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;  
[3,6-dimethyl-[2-(2,4,6-trimethyl-phenylsulfanyl)-pyridin-4-yl]-ethyl-propyl-amine;
- 35 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-methanol;  
[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-propyl-amine;  
1-(ethyl-propyl)-[6-methyl-3-nitro-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine;



- N4-(1-ethyl-propyl)-6-methyl-3-nitro-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine;  
N4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;  
3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-(2,2,2-trifluoro-ethyl)-amine;  
N4-(1-ethyl-propyl)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine;  
5 [3-chloromethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)pyridin-4-yl]-(1-ethyl-propyl)-amine;  
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine;  
(1-ethyl-propyl)-[2-methyl-5-nitro-6-(2,4,6-trimethyl-pyridin-3-yloxy)-pyrimidin-4-yl]-amine;  
(1-ethyl-propyl)-[3-methoxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-  
amine;  
10 (N-(1-ethyl-propyl)-2-methyl-5-nitro-N'-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,6-  
diamine;  
[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-diethyl-amine;  
4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine;  
butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-  
15 ethyl-amine;  
4-(butyl-ethylamino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-  
d]pyrimidin-6-one;  
4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;  
N-butyl-N-ethyl-2,5-dimethyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine;  
20 (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-amine;  
[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-  
amine;  
N4-(1-ethyl-propyl)-6,N3-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;  
N4-(1-ethyl-propyl)-6,N3,N3-trimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;  
25 6-(1-ethyl-propoxy)-2-methyl-N4-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5-diamine;  
[4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethylphenyl)-amine; and  
6-(ethyl-propyl-amino)-2,7-dimethyl-9-(2,4,6-trimethylphenyl)-7,9-dihydro-purin-8-one.  
Examples of preferred compounds of this invention are:  
2-[2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-3-nitro-pyridin-4-(S)-  
30 ylamino]-butan-1-ol;  
(1-methoxymethyl-propyl)-[6-methyl-3-nitro-2-(4-trifluoromethoxy-  
phenoxy)-pyridin-4-yl]-amine;  
2-(2-amino-4,6-dichloro-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-  
propyl)-amine;  
35 3-methoxy-2-[4-(1-methoxymethyl-propylamino)-6-methyl-3-nitro-pyridin-2-yloxy]-  
benzaldehyde;

[2-(2,6-dibromo-4-trifluoromethoxy-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;

[2-(2-bromo-4-chloro-6-methoxy-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;

5 [2-(2,4-dichloro-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;

[2-(2-bromo-6-chloro-4-methoxy-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;

10 (1-methoxymethyl-propyl)-[6-methyl-3-nitro-2-(2,4,6-trimethoxy-phenoxy)-pyridin-4-yl]-amine;

2-chloro-N-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-acetamide;

3-chloro-N-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-propionamide;

15 2-chloro-N-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-propionamide;

N3-allyl-N4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;

N3-(3-chloro-propyl)-N4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;

20 N4-(1-ethyl-propyl)-6-methyl-N3-propa-1,2-dienyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine;

2-[3-amino-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol;

25 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid methyl ester;

2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid methyl ester;

4-(1-ethyl-prop-2-ynylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;

30 4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;

4-(1-ethyl-2-hydroxy-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;

35 2-(4-bromo-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester;

2-(4-bromo-2,6-dimethyl-phenoxy)-4-(S)-(1-methoxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester;

- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester;
- 2-(4-chloro-2-methoxy-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester;
- 5 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-hydroxy-propylamino)-6-methyl-nicotinic acid methyl ester;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-methoxy-propylamino)-6-methyl-nicotinic acid methyl ester;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-oxo-propylamino)-6-methyl-nicotinic acid methyl ester;
- 10 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-oxo-propylamino)-6-methyl-nicotinic acid methyl ester;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-(4-ethyl-2-oxo-oxazolidin-3-yl)-6-methyl-nicotinic acid methyl ester;
- 15 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-{1-[(2-hydroxy-ethylamino)-methyl]-propylamino}-6-methyl-nicotinic acid methyl ester;
- 4-[ethyl-(2-hydroxy-ethyl)-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;
- 4-[ethyl-(2-methanesulfonyloxy-ethyl)-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;
- 20 4-[(2-hydroxy-ethyl)-thiophen-2-ylmethyl-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;
- 4-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-ylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;
- 25 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid ethyl ester;
- 4-[ethyl-(2-methoxy-ethyl)-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S,R)-&(S,S)-(1-ethyl-2-hydroxy-propylamino)-6-methyl-nicotinic acid methyl ester;
- 30 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(R)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester;
- 4-(2-hydroxy-1-hydroxymethyl-ethylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;
- 35 4-(2-methoxy-1-methoxymethyl-ethylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;

- 4-(1-hydroxymethyl-2-methoxy-ethylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-  
nicotinic acid methyl ester;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-hydroxy-butylamino)-6-methyl-nicotinic  
acid methyl ester;
- 5 [2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-  
methanol;
- [2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-  
methanol;
- 2-[3-hydroxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-(S)-ylamino]-butan-  
10 1-ol;
- 3-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-  
pentan-2-ol;
- 2-[2-(2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-butan-1-ol;
- 3-[3-hydroxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-pentan-2-  
15 ol;
- 2-[2-(4-chloro-2-methoxy-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-  
butan-1-ol;
- 2-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-  
butan-1-ol;
- 20 2-[ethyl-[3-hydroxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amino]-  
ethanol;
- 4-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-  
hexan-3-ol;
- 2-[2-(4-chloro-2-methoxy-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-(S)-ylamino]-  
25 butan-1-ol;
- 4-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-  
hexan-3-ol;
- [2-(2,4-dimethoxy-phenylamino)-4-(1-methoxymethyl-propoxy)-6-methyl-pyridin-3-yl]-  
methanol;
- 30 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-  
nicotinic acid;
- 4-(1-ethyl-prop-2-ynylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid;
- 2-(4-bromo-2,6-dimethyl-phenoxy)-4-(S)-(1-methoxymethyl-propylamino)-6-methyl-  
nicotinic acid;
- 35 4-(2-methoxy-1-methoxymethyl-ethylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-  
nicotinic acid;

- [2-(4-chloro-2,6-dimethyl-phenoxy)-3-isobutoxymethyl-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- [3-ethoxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- 5 2-[3-butoxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-butan-1-ol;
- 1-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-ethanol;
- acetic acid 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl ester;
- 2-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-(1-hydroxy-1-methyl-ethyl)-6-methyl-pyridin-4-
- 10 (S)-ylamino]-butan-1-ol;
- [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- [2-(2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- [2-(4-bromo-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- 4-[4-(1-ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-benzaldehyde;
- 15 {4-[4-(1-ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl}-methanol;
- (1-ethyl-propyl)-[2-(4-methoxymethyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine;
- [2-(4-ethyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- 20 2-[4-[4-(1-ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl]-propan-2-ol;
- 1-[4-[4-(1-ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl]-ethanol;
- (1-ethyl-propyl)-[2-(4-isopropenyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-
- 25 amine;
- (1-ethyl-propyl)-[2-(4-isopropyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine;
- [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-allyl)-amine;
- (1-ethyl-propyl)-[2-(4-fluoro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine;
- 2-[2-(2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-butan-1-ol;
- 30 2-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-(S)-ylamino]-butan-1-ol;
- 3-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-pentan-2-ol;
- 3-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-pentan-2-ol;
- benzyl-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine;
- [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-
- 35 amine;
- 2-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-3-phenyl-propan-1-ol;

- [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;
- [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethoxymethyl-propyl)-amine;
- 5 [3,6-dimethyl-2-(2,4,6-trimethoxy-phenoxy)-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;
- [2-(4-bromo-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- (1-ethyl-propyl)-[3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine;
- 10 [2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-3-propyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- [2-(4-bromo-2,6-dimethyl-phenoxy)-6-methyl-3-propyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- (1-ethyl-propyl)-[6-methyl-3-propyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine;
- 15 [2-(2,4-dichloro-6-methyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- [2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
- [2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;
- 20 [2-(2,4-dichloro-6-methyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;
- [2-(4-chloro-2-methoxy-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;
- 25 [2-(3-chloro-2,6-dimethoxy-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;
- (1-methoxymethyl-propyl)-[3-methoxy-6-methyl-2-(2,4,6-trimethoxy-phenoxy)-pyridin-4-yl]-amine;
- [3-methoxy-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-yl]-(1-ethoxymethyl-propyl)-amine;
- 30 [2-(4-chloro-2,6-dimethyl-phenoxy)-3-ethoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;
- 2-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-(S)-ylamino]-butan-1-ol;
- 2-[3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-(S)-ylamino]-butan-1-ol;
- 35 2-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-ylamino]-butan-1-ol;

- 4-[4-(1-hydroxymethyl-propylamino)-3-methoxy-6-methyl-pyridin-2-yloxy]-3,5-dimethyl-benzonitrile;
- 3-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-pentan-2-ol;
- 2-[2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-butan-1-ol;
- 5 (1-ethyl-prop-2-ynyl)-[2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine];
- 2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-ol;
- 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ol;
- 4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ol;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-pyridin-
- 10 3-ol;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-ol;
- chloro-acetic acid 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-
- 3-yl ester;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-[(1-ethyl-propyl)-methyl-amino]-6-methyl-pyridin-
- 15 ol;
- [4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-acetonitrile;
- 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3-carbaldehyde;
- (1-ethyl-propyl)-[3-[(1-ethyl-propylimino)-methyl]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-
- pyridin-4-yl]-amine;
- 20 2-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl]-
- malonic acid dimethyl ester;
- 2-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl]-
- malonic acid diisopropyl ester;
- 4-(1-ethyl-propoxy)-6-methyl-3-nitro-2-(2,4,6-trimethyl-phenoxy)-pyridine;
- 25 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylamine;
- [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin- 3-yl]-dimethyl-amine;
- N-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-succinamic
- acid;
- 4-(1-ethyl-propoxy)-3,6-dimethyl-2-[3-(2,4,6-trimethyl-pyridinoxy)]-pyridine;
- 30 6-ethyl-4-(1-ethyl-propoxy)-3-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;
- 4-(1-ethyl-propoxy)-2-(4-fluoro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine;
- [4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine;
- [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-methanol;
- [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-oxo-
- 35 acetonitrile;
- [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-imidazol-1-
- yl-methanone;

- 2-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-propan-2-ol;
- 2-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-ylmethyl]-malonic acid dimethyl ester;
- 5 3-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-propionic acid;
- [3-aminomethyl-4-(1-ethyl-propoxy)-6-methyl-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine;
- 2-chloro-N-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-ylmethyl]-acetamide;
- 10 [3-dimethylaminomethyl-4-(1-ethyl-propoxy)-6-methyl-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine hydrochloride salt;
- dithiocarbonic acid O-ethyl ester S-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-ylmethyl] ester;
- 15 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinamide;
- 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinonitrile;
- 4-(1-ethyl-propoxy)-6,N,N-trimethyl-2-(2,4,6-trimethyl-phenylamino)-nicotinamide;
- [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-acetonitrile;
- [2-(4-bromo-2,6-dimethyl-phenylamino)-4-(1-ethyl-propoxy)-6-methyl-pyridin-3-yl]-
- 20 methanol;
- [2-(4-chloro-2,6-dimethyl-phenylamino)-4-(1-ethyl-propoxy)-6-methyl-pyridin-3-yl]-methanol;
- [2-(2,4-dichloro-phenylamino)-4-(1-ethyl-propoxy)-6-methyl-pyridin-3-yl]-methanol;
- [2-(2,4-dimethoxy-phenylamino)-4-(1-methoxymethyl-propoxy)-6-methyl-pyridin-3-yl]-
- 25 methanol;
- [4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-imidazol-1-yl-methanone;
- 1-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-ethanone;
- (1-ethyl-propyl)-[6-methyl-3-propyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine;
- 30 2-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl]-2-methyl-malonic acid dimethyl ester;
- [4-(1-ethyl-propoxy)-6-methyl-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine;
- 2-ethyl-1-[3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-butan-1-ol;
- 1-[3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-2-methyl-butan-1-ol;
- 35 1-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-propan-1-ol;
- 4-(1-methoxy-propyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;
- 4-(1-ethoxy-propyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;



- 4-(1-allyloxy-propyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;  
4-(1-butoxy-propyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;  
1-[2-(2,4-dichloro-6-methyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-  
ol;
- 5 1-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-2,2,2-trifluoro-ethanol;  
1-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-2,2,2-trifluoro-ethanol;  
[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-pyridin-2-yl-methanol;  
1-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-  
ol;
- 10 1-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-propan-1-one;  
1-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-2,2,2-trifluoro-ethanone;  
[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-pyridin-2-yl-methanone;  
1-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-  
one;
- 15 4-(1-ethoxy-2,2,2-trifluoro-ethyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine;  
2-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-butan-2-ol;  
3-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-pentan-3-ol;  
1-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-hydroxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-  
one;
- 20 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinamide;  
4-(1-ethyl-propylamino)-6,N-dimethyl-2-(2,4,6-trimethyl-phenoxy)-nicotinamide;  
2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-  
nicotinamide;
- 25 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-  
nicotinic acid hydrazide;  
2-(4-chloro-2,6-dimethyl-phenoxy)-N-ethyl-4-(S)-(1-hydroxymethyl-propylamino)-6-  
methyl-nicotinamide;
- 30 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-  
nicotinamide;  
2-(4-chloro-2,6-dimethyl-phenoxy)-N-cyclopentyl-4-(S)-(1-hydroxymethyl-propylamino)-6-  
methyl-nicotinamide;
- 35 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinamide;  
4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carboxylic  
acid amide;  
4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinonitrile;

- [4-(1-ethyl-propoxy)-6-methyl-3-nitro-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine;  
4-(1-ethyl-propoxy)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3-diamine;  
2-chloro-N-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-  
acetamide;
- 5 N-butyl-N-ethyl-6-methyl-3-nitro-N-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine;  
4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid;  
4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid methyl  
ester;
- 10 N4-(1-ethyl-propyl)-3,6-dimethyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine;  
2-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-  
ylmethyl]-malonic acid dimethyl ester;  
[2-(4-bromo-2,6-dimethyl-phenylamino)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-  
methanol;
- 15 N2-(2,4-dichloro-phenyl)-N4-(1-ethyl-propyl)-3,6-dimethyl-pyridine-2,4-diamine;  
[2-(2,4-dichloro-phenylamino)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-methanol;  
2-[6-methyl-3-nitro-2-(2,4,6-trimethyl-phenylamino)-pyridin-4-ylamino]-butan-1-ol;  
2-[4-(1-ethyl-propylamino)-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-5-yl]-  
propionic acid ethyl ester;
- 20 [3-aminomethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-  
amine;  
[2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-  
acetonitrile;
- [2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-  
acetonitrile hydrogen chloride;
- 25 [6-(1-ethyl-propoxy)-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-amine;  
2-[2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol;  
[3-aminomethyl-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-yl]-(1-  
chloromethyl-propyl)-amine;
- 30 2-[2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-3-methylaminomethyl-pyridin-4-(S)-  
ylamino]-butan-1-ol;  
2-[3-aminomethyl-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-  
butan-1-ol;
- 35 [3-bromo-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine;  
2-[3,5-dibromo-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-ylamino]-butan-1-ol;  
2-[3-bromo-6-(4-chloro-2,6-dimethyl-phenoxy)-2-methyl-pyridin-4-(S)-ylamino]-butan-1-  
ol;
- 2-[3-chloro-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol;

- 2-[3,5-dichloro-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-ylamino]-butan-1-ol;
- 2-[3-chloro-6-(4-chloro-2,6-dimethyl-phenoxy)-2-methyl-pyridin-4-(S)-ylamino]-butan-1-ol;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-(4-ethyl-2-oxo-oxazolidin-3-yl)-6-methyl-
- 5 nicotinonitrile;
- 2-(2,4-dimethoxy-phenylamino)-4-(1-methoxymethyl-propoxy)-6-methyl-nicotinic acid;
- 4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carbonitrile;
- N-(1-ethyl-propyl)-2,5-dimethyl-N'-(2,4,6-trimethyl-phenyl)-pyrimidine-4,6-diamine;
- 5-chloro-N4-(1-ethyl-propyl)-2-methyl-N6-(2,4,6-trimethyl-phenyl)-pyrimidine-4,6-
- 10 diamine;
- 5-bromo-N-(1-ethyl-propyl)-2-methyl-N'-(2,4,6-trimethyl-phenyl)-pyrimidine-4,6-diamine;
- 4-(1-ethyl-propylamino)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-
- carboxylic acid;
- [4-(cyclopropylmethyl-propyl-amino)-2-methyl-6-(2,4,6-trichloro-phenylamino)-
- 15 pyrimidin-5-yl]-methanol;
- 6-(1-ethyl-propoxy)-2,N5,N5-trimethyl-N4-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5-
- diamine;
- [5-bromo-6-(1-ethyl-propoxy)-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-amine;
- 4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carboxylic
- 20 acid;
- [4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidin-5-yl]-methanol;
- [6-(1-ethyl-propoxy)-5-methoxymethyl-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-
- amine;
- [5-aminomethyl-6-(1-ethyl-propoxy)-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-
- 25 amine;
- 4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carbonitrile;
- 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-
- ylamine;
- 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridine;
- 30 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-1,3-dihydro-imidazo[4,5-
- b]pyridin-2-one;
- 7-(1-ethyl-propoxy)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1,3-dihydro-imidazo[4,5-
- b]pyridin-2-one;
- (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-
- 35 amine;
- [2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-
- amine;

- N7-(1-ethyl-propyl)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridine-2,7-diamine;
- 6-(1-ethyl-propylamino)-2,7-dimethyl-9-(2,4,6-trimethyl-phenyl)-7,9-dihydro-purin-8-one;
- 5 6-(1-ethyl-propoxy)-2,7-dimethyl-9-(2,4,6-trimethyl-phenyl)-7,9-dihydro-purin-8-one;  
[2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine;
- (1-ethyl-propyl)-[2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine;
- 2-[2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-butan-1-ol;
- 10 sec-butyl-[3-methoxy-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-yl]-amine;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(4-ethyl-oxazolidin-3-yl)-3,6-dimethyl-pyridine;
- 4-(4-ethyl-oxazolidin-3-yl)-2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine;
- 2-(4-methoxy-2,6-dimethyl-phenoxy)-N<sup>4</sup>-(1-methoxymethyl-propyl)-6-methyl-pyridine-3,4-diamine;
- 15 3-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-pentan-2-ol;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-oxo-propylamino)-6-methyl-nicotinic acid methyl ester;
- 20 3-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxymethyl-6-methyl-pyridin-4-ylamino]-pentan-2-ol;
- 3-[2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-pentan-2-ol;
- 4-sec-butylamino-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester;
- 25 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-hydroxy-2-methyl-propylamino)-6-methyl-nicotinic acid methyl ester;
- 4-(1-hydroxymethyl-propylamino)-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-3-methylsulfanyl-propylamino)-6-methyl-nicotinic acid methyl ester;
- 30 6-methyl-nicotinic acid methyl ester;
- 2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-4-(tetrahydro-furan-3-ylamino)-nicotinic acid methyl ester;
- {3-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxycarbonyl-6-methyl-pyridin-4-ylamino]-4-hydroxy-butyl}-dimethyl-sulfonium iodide;
- 35 4-(1-hydroxymethyl-3-methylsulfanyl-propylamino)-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester;

4-(1-hydroxymethyl-propylamino)-2-(4-methoxy-2,6-dimethyl-phenoxy)-6,N-dimethyl-nicotinamide;

4-sec-butylamino-2-(4-methoxy-2,6-dimethyl-phenoxy)-6,N-dimethyl-nicotinamide;

- 2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-4-(tetrahydro-furan-3-ylamino)-nicotinic  
5 acid methyl ester;  
4-sec-butylamino-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-nicotinamide; and  
and pharmaceutically acceptable salts thereof.

The invention also relates to a pharmaceutical composition for the treatment of (a) a  
disorder or condition the treatment of which can be effected or facilitated by antagonizing CRF,  
10 including but not limited to disorders induced or facilitated by CRF, or (b) a disorder or condition  
selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain,  
asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias, including social  
phobia, agoraphobia, and specific phobias; obsessive-compulsive disorder; post-traumatic stress  
disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood  
15 disorders such as depression, including major depression, single episode depression, recurrent  
depression, child abuse induced depression, mood disorders associated with premenstrual  
syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue  
syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic  
colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus  
20 infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and  
Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia  
nervosa; hemorrhagic stress; chemical dependencies or addictions, including dependencies or  
addictions to alcohol, cocaine, heroin, benzodiazapines, or other drugs; drug or alcohol  
withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of  
25 inappropriate antidiuretic hormone; obesity; infertility; head trauma; spinal cord trauma; ischemic  
neuronal damage, including cerebral ischemia, for example cerebral hippocampal ischemia;  
excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced  
immune dysfunctions, including porcine stress syndrome, bovine shipping fever, equine  
paroxysmal fibrillation, confinement dysfunction in chicken, sheering stress in sheep, and human-  
30 animal interaction stress in dogs; muscular spasms; urinary incontinence; senile dementia of the  
Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia;  
congestive heart failure; osteoporosis; premature birth; hypoglycemia, and Syndrome X in a  
mammal, including a human, or bird comprising an amount of a compound of the formula I, II or  
III, or a pharmaceutically acceptable salt thereof, that is effective in the treatment of such disorder  
35 or condition, and a pharmaceutically acceptable carrier.

The invention further includes a method for the treatment of (a) a disorder or condition  
the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited

to disorders induced or facilitated by CRF, or (b) a disorder or condition selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias, including social phobia, agoraphobia, and specific phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthymia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies or addictions, including dependencies or addictions to alcohol, cocaine, heroin, benzodiazapines, or other drugs; drug or alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone; obesity; infertility; head trauma; spinal cord trauma; ischemic neuronal damage, including cerebral ischemia, for example cerebral hippocampal ischemia; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions, including porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, confinement dysfunction in chicken, sheering stress in sheep, and human-animal interaction stress in dogs; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; hypoglycemia, and Syndrome X in a mammal, including a human, or bird comprising administering to a subject in need of said treatment an amount of a compound of the formula I, II or III or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.

Specific embodiments of the invention provide a pharmaceutical composition and a method for treatment of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CR, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthymia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's

disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; and hypoglycemia in a mammal, including a human.

The present invention also provides a pharmaceutical composition for and a method of treating a condition comprising administering a compound of I, II, or III, in an amount effective to treat said condition, wherein said condition is selected from the group consisting of: a) abnormal circadian rhythm; b) depression, further wherein a second compound for treating depression is administered, said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist; and c) emesis. The aforementioned method can be practiced according to the information provided in U.S. Provisional Patent Application No. 60/151,183, filed August 27, 1999, which describes treatment of the aforementioned conditions using CRF antagonists in general and which is incorporated herein by reference in its entirety.

The compounds of formula I, II, and III, described herein can also be used to treat forms of heart failure described in U.S. Serial No. 09/248,073, *supra*, and can be made into pharmaceutical compositions therefore.


Examples of more specific forms or manifestations of abnormal circadian rhythm that can be treated according to the present invention include, but are not limited to, time zone change syndrome resulting, seasonal affective disorder, shift-work sleep disorder, irregular sleep-wake pattern, delayed sleep phase syndrome resulting from said abnormal circadian rhythm, advanced sleep phase syndrome, or non-24 hour sleep wake disorder resulting from said abnormal circadian rhythm. Moreover, the compound of formula I, II, or III can be combined in the method or pharmaceutical composition for treatment of abnormal circadian rhythm with a second compound that is useful for treating a sleep disorder, for example tachykinin antagonists, agonists for GABA brain receptors, metabotropic compounds, GABA brain receptor agonists, 5HT<sub>2</sub> receptor antagonists, and D4 receptor binding compounds. However, other compounds or substances useful for treating a sleep disorder can be combined with a compound of formula I, II, or III. Such methods and compositions are described in greater detail in U.S. Provisional Patent Application No. 60/151,183, *supra*.

In another embodiment, said condition is depression, and the second compound having delayed action for treating depression is selected from the group consisting of selective serotonin reuptake inhibitors, tricyclic antidepressants, norepinephrine uptake inhibitors, lithium, bupropion, sertraline, fluoxetine, trazodone, and a tricyclic antidepressant selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine, and pharmaceutically acceptable salts and esters of the above-recited compounds.


In another embodiment, the condition being treated is emesis, and the method further comprises administering a second compound for treating emesis. The second compound for treating emesis can be selected from, but is not limited to, tachykinin antagonists, 5HT<sub>3</sub> antagonists, GABA agonists, and substance P inhibitors. More specific categories of emesis encompassed in the present invention include emesis induced by a condition or agent selected from the group consisting of pregnancy, vestibular disorder, post-operative sickness, gastrointestinal obstruction, reduced gastrointestinal motility, visceral pain, migraine, change in intercranial pressure, chemotherapy, radiation, toxins, and opioid analgesics.

The invention further includes intermediate compounds of formula






IV



XI

and




X

wherein  $R_4$  and  $R_7$  are defined as they are for formula I above; D is chloro, hydroxy or cyano;  $R_{19}$  is methyl or ethyl;  $R_5$  is phenyl or pyridyl and  $R_5$  is substituted by two or three substituents independently selected from  $C_1$ - $C_4$  alkyl, chloro and bromo, except that no more than one such substituent can be bromo; A is N, CH or  $CCH_3$ ; and Z is O, NH,  $N(CH_3)$ , S or  $CH_2$ , with the proviso that when A is CH or  $CCH_3$ , then Z must be O or S.

More specific embodiments of this invention relate to compounds of the formula X or XI wherein  $R_7$  is hydrogen or methyl.

This invention further include intermediate compounds of formula




XII

wherein R<sub>19</sub> is methyl or ethyl; A is N, CH or CCH<sub>3</sub>; and wherein when A is N, then B'' and R<sub>4</sub> are defined, respectively, as B and R<sub>4</sub> are defined for formula I, and when A is CH or CH<sub>3</sub>, then B'' is -NR<sub>1</sub>R<sub>2</sub>, -NHR<sub>1</sub>R<sub>2</sub>, -OCHR<sub>1</sub>R<sub>2</sub> or cyano and R<sub>4</sub> is an electron deficient group such as NO<sub>2</sub>, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -C(=O)CH<sub>3</sub>, -COOH or CN.

A more specific embodiment of this invention relates to compounds of the formula XII wherein B'' is -NR<sub>1</sub>R<sub>2</sub> or -NHCHR<sub>1</sub>R<sub>2</sub> and A is CH or CH<sub>3</sub>.

This invention also relates to a process for preparing a compound of the formula I,



I

or a pharmaceutically acceptable salt thereof, wherein

A is -CR<sub>7</sub> or N;

B is -NR<sub>1</sub>R<sub>2</sub>, -NHCHR<sub>1</sub>R<sub>2</sub>, -OCHR<sub>1</sub>R<sub>2</sub> or -SCHR<sub>1</sub>R<sub>2</sub>;

Z is NH, O, S, -N(C<sub>1</sub>-C<sub>2</sub> alkyl) or -C(R<sub>13</sub>R<sub>14</sub>), wherein R<sub>13</sub> and R<sub>14</sub> are each, independently, hydrogen, trifluoromethyl or methyl, or one of R<sub>13</sub> and R<sub>14</sub> is cyano and the other is hydrogen or methyl;

R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl which may optionally be substituted with one or two substituents R<sub>8</sub> independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF<sub>3</sub> and C<sub>1</sub>-C<sub>4</sub> alkoxy, and wherein said C<sub>1</sub>-C<sub>6</sub> alkyl and the (C<sub>1</sub>-C<sub>4</sub>)alkyl moiety of said C<sub>1</sub>-C<sub>4</sub> alkoxy may optionally contain one carbon-carbon double or triple bond;

R<sub>2</sub> is C<sub>1</sub>-C<sub>12</sub> alkyl, aryl or -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R<sub>9</sub> wherein R<sub>9</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and wherein each of the foregoing R<sub>2</sub> groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C<sub>1</sub>-C<sub>4</sub> alkyl, or with one substituent selected from bromo, iodo, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, NO<sub>2</sub>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl), and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), and wherein said C<sub>1</sub>-C<sub>12</sub> alkyl and the C<sub>1</sub>-C<sub>4</sub> alkylene moiety of said -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR<sub>1</sub>R<sub>2</sub> may form a saturated 5- to 8-membered carbocyclic ring which may optionally contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom;

R<sub>3</sub> is methyl or ethyl;

R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, fluoro, chloro, bromo, iodo, C<sub>1</sub>-C<sub>4</sub> alkoxy, trifluoromethoxy, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OF<sub>3</sub>, CF<sub>3</sub>, amino, nitro, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(CH<sub>3</sub>)<sub>2</sub>, -NHCOCH<sub>3</sub>, -NHCONHCH<sub>3</sub>, -SO<sub>n</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CHO, cyano or -COO(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein said C<sub>1</sub>-C<sub>4</sub> alkyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH<sub>3</sub>, -NH(C<sub>1</sub>-C<sub>2</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)<sub>2</sub>, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> thioalkyl, fluoro, chloro, cyano and nitro;


R<sub>5</sub> is phenyl or pyridyl, and R<sub>5</sub> is substituted with from one to three substituents independently selected from fluoro, chloro, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, -(C<sub>1</sub>-C<sub>6</sub> alkyl)O(C<sub>1</sub>-C<sub>6</sub> alkyl), -NHCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, -COOH, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -SO<sub>2</sub>NH<sub>2</sub>, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), and wherein the C<sub>1</sub>-C<sub>4</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkyl moieties of the foregoing R<sub>5</sub> groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl; and

R<sub>7</sub> is hydrogen or methyl;

or a pharmaceutically acceptable salt of such compound;

comprising reacting a compound of the formula


-31-



#### IV

wherein R<sub>19</sub> is methyl or ethyl, D is chloro and A, Z, R<sub>4</sub> and R<sub>5</sub> are defined as above, with a compound of the formula BH, wherein B is defined as above, in the presence of a base; and then optionally converting the compound of formula I formed in such reaction into a pharmaceutically acceptable salt.

This invention also relates to a process for preparing a compound of the formula



#### I

or a pharmaceutically acceptable salt thereof, wherein

A is -CR<sub>7</sub> or N;

B is -NR<sub>1</sub>R<sub>2</sub>, -CR<sub>1</sub>R<sub>2</sub>R<sub>11</sub>, -C(=CR<sub>2</sub>R<sub>12</sub>)R<sub>1</sub>, -NHCHR<sub>1</sub>R<sub>2</sub>, -OCHR<sub>1</sub>R<sub>2</sub>, -SCHR<sub>1</sub>R<sub>2</sub>, -CHR<sub>2</sub>OR<sub>12</sub>, -CHR<sub>2</sub>SR<sub>12</sub>, -C(S)R<sub>2</sub> or -C(O)R<sub>2</sub>;

Z is NH, O, S, -N(C<sub>1</sub>-C<sub>2</sub> alkyl) or -C(R<sub>13</sub>R<sub>14</sub>), wherein R<sub>13</sub> and R<sub>14</sub> are each, independently, hydrogen, trifluoromethyl or methyl, or one of R<sub>13</sub> and R<sub>14</sub> is cyano and the other is hydrogen or methyl;

R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl which may optionally be substituted with one or two substituents R<sub>8</sub> independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF<sub>3</sub> and C<sub>1</sub>-C<sub>4</sub> alkoxy, and wherein said C<sub>1</sub>-C<sub>6</sub> alkyl and the (C<sub>1</sub>-C<sub>4</sub>)alkyl moiety of said C<sub>1</sub>-C<sub>4</sub> alkoxy may optionally contain one carbon-carbon double or triple bond;

R<sub>2</sub> is C<sub>1</sub>-C<sub>12</sub> alkyl, aryl or -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of

EXPRESS MAIL NO. EL162815459WS

said -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R<sub>9</sub> wherein R<sub>9</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and wherein each of the foregoing R<sub>2</sub> groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C<sub>1</sub>-C<sub>4</sub> alkyl, or with one substituent selected from

5 bromo, iodo, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, NO<sub>2</sub>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl), and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), and wherein said C<sub>1</sub>-C<sub>12</sub> alkyl and the C<sub>1</sub>-C<sub>4</sub> alkylene moiety of said -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR<sub>1</sub>R<sub>2</sub> may form a saturated 5- to 8-membered carbocyclic ring which may optionally

10 contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom;

R<sub>3</sub> is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF<sub>3</sub>, methylthio, methylsulfonyl, CH<sub>2</sub>OH, or CH<sub>2</sub>OCH<sub>3</sub>;

R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, fluoro, chloro, bromo, iodo, C<sub>1</sub>-C<sub>4</sub> alkoxy, trifluoromethoxy, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OF<sub>3</sub>, CF<sub>3</sub>, amino, nitro, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -

15 N(CH<sub>3</sub>)<sub>2</sub>, -NHCOCH<sub>3</sub>, -NHCONHCH<sub>3</sub>, -SO<sub>n</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CHO, cyano or -COO(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein said C<sub>1</sub>-C<sub>4</sub> alkyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH<sub>3</sub>, -NH(C<sub>1</sub>-C<sub>2</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)<sub>2</sub>, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-

20 C<sub>4</sub> alkyl), C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> thioalkyl, fluoro, chloro, cyano and nitro;

R<sub>5</sub> is phenyl or pyridyl and R<sub>5</sub> is substituted with from one to three substituents independently selected from fluoro, chloro, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, -(C<sub>1</sub>-C<sub>6</sub> alkyl)O(C<sub>1</sub>-C<sub>6</sub>)alkyl, -NHCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, -COOH, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>NH(C<sub>1</sub>-


25 C<sub>4</sub> alkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -SO<sub>2</sub>NH<sub>2</sub>, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), and wherein the C<sub>1</sub>-C<sub>4</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkyl moieties of the foregoing R<sub>5</sub> groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl; and

R<sub>7</sub> is hydrogen or methyl;

30 with the proviso that when A is CH or CCH<sub>3</sub>, then R<sub>4</sub> is an electron deficient group such as NO<sub>2</sub>, -COO(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(=O)CH<sub>3</sub>, -COOH or CN;

or a pharmaceutically acceptable salt of such compound;

comprising reacting a compound of the formula




## XII

wherein  $R_{19}$  is methyl or ethyl and A is N, CH or  $CCH_3$ ; and wherein when A is N, then  $B''$  and  $R_4$  are defined, respectively, as B and  $R_4$  are defined in claim 1, and when A is CH or  $CH_3$ , then  $B''$  is  $-NR_1R_2$ ,  $-NHR_1R_2$ ,  $-OCHR_1R_2$  or cyano and  $R_4$  is an electron deficient group such as  $NO_2$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-C(=O)CH_3$ ,  $-COOH$  or CN;

with a compound of the formula  $R_5ZH$ , wherein  $R_5$  and Z are defined as above, and then optionally converting the compound of formula I formed by such reaction into a pharmaceutically acceptable salt.

This invention also relates to a process for preparing a compound of the formula



## IV

10

a wherein  $R_{19}$  is methyl or ethyl;

D is chloro;


A is  $-CR_7$  or N;

15 Z is NH, O, S,  $-N(C_1-C_2 \text{ alkyl})$  or  $-C(R_{13}R_{14})$ , wherein  $R_{13}$  and  $R_{14}$  are each independently, hydrogen, trifluoromethyl or methyl, or one of  $R_{13}$  and  $R_{14}$  is cyano and the other is hydrogen or methyl;

20  $R_4$  is hydrogen,  $C_1-C_4$  alkyl, fluoro, chloro, bromo, iodo,  $C_1-C_4$  alkoxy, trifluoromethoxy,  $-CH_2OCH_3$ ,  $-CH_2OCH_2CH_3$ ,  $-CH_2CH_2OCH_3$ ,  $-CH_2OF_3$ ,  $CF_3$ , amino, nitro,  $-NH(C_1-C_4 \text{ alkyl})$ ,  $-N(CH_3)_2$ ,  $-NHCOCH_3$ ,  $-NHCONHCH_3$ ,  $-SO_n(C_1-C_4 \text{ alkyl})$  wherein n is 0, 1 or 2, cyano, hydroxy,  $-CO(C_1-C_4 \text{ alkyl})$ ,  $-CHO$ , cyano or  $-COO(C_1-C_4 \text{ alkyl})$  wherein said  $C_1-C_4$  alkyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino,  $-NHCOCH_3$ ,  $-NH(C_1-C_2 \text{ alkyl})$ ,  $-N(C_1-C_2 \text{ alkyl})_2$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-CO(C_1-C_4 \text{ alkyl})$ ,  $C_1-C_3$  alkoxy,  $C_1-C_3$  thioalkyl, fluoro, chloro, cyano and nitro; and

$R_5$  is phenyl or pyridyl, and  $R_5$  is substituted with from one to three substituents independently selected from fluoro, chloro,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino,  $-(C_1-C_6 \text{ alkyl})O(C_1-C_6 \text{ alkyl})$ ,  $-NHCH_3$ ,  $-N(CH_3)_2$ ,  $-COOH$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-CO(C_1-C_4 \text{ alkyl})$ ,  $-SO_2NH(C_1-C_4 \text{ alkyl})$ ,  $-SO_2N(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$ ,  $-SO_2NH_2$ ,  $-NHSO_2(C_1-C_4 \text{ alkyl})$ ,  $-S(C_1-C_6 \text{ alkyl})$  and  $-SO_2(C_1-C_6 \text{ alkyl})$ , and wherein the  $C_1$ - $C_4$  alkyl and  $C_1$ - $C_6$  alkyl moieties of the foregoing  $R_5$  groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;


comprising reacting a compound of the formula



X

wherein  $R_{19}$ ,  $R_4$  and  $R_5$  are defined as above and  $R_7$  is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy,  $-O(C_1-C_4 \text{ alkyl})$ ,  $-C(O)(C_1-C_4 \text{ alkyl})$ ,  $-C(O)O(C_1-C_4 \text{ alkyl})$ ,  $-OCF_3$ ,  $CF_3$ ,  $-CH_2OH$ ,  $-CH_2OCH_3$  or  $-CH_2OCH_2CH_3$ , with phosphorus trichloride.

This invention also relates to a process for preparing a compound of the formula



X

wherein  $R_{19}$  is methyl or ethyl;


A is  $-CR_7$  or N;

Z is O, S, or  $-C(R_{13}R_{14})$ , wherein  $R_{13}$  and  $R_{14}$  are each, independently, hydrogen, trifluoromethyl or methyl, or one of  $R_{13}$  and  $R_{14}$  is cyano and the other is hydrogen or methyl;

R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, fluoro, chloro, bromo, iodo, C<sub>1</sub>-C<sub>4</sub> alkoxy, trifluoromethoxy, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OF<sub>3</sub>, CF<sub>3</sub>, amino, nitro, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(CH<sub>3</sub>)<sub>2</sub>, -NHCOCH<sub>3</sub>, -NHCONHCH<sub>3</sub>, -SO<sub>n</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CHO, cyano or -COO(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein said C<sub>1</sub>-C<sub>4</sub> alkyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH<sub>3</sub>, -NH(C<sub>1</sub>-C<sub>2</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)<sub>2</sub>, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> thioalkyl, fluoro, chloro, cyano and nitro; and

R<sub>5</sub> is phenyl or pyridyl, and R<sub>5</sub> is substituted with from one to three substituents independently selected from fluoro, chloro, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, -(C<sub>1</sub>-C<sub>6</sub> alkyl)O(C<sub>1</sub>-C<sub>6</sub> alkyl), -NHCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, -COOH, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -SO<sub>2</sub>NH<sub>2</sub>, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), and wherein the C<sub>1</sub>-C<sub>4</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkyl moieties of the foregoing R<sub>5</sub> groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

comprising reacting a compound of the formula



XI

wherein R<sub>4</sub>, R<sub>7</sub> and R<sub>19</sub> are defined as above, with a compound of the formula R<sub>5</sub>OH or R<sub>5</sub>SH, wherein R<sub>5</sub> is defined as above, in the presence of a base.

#### Detailed Description of the Invention

Methods of preparing the compounds and compositions of this invention are described below. In the discussion and reaction schemes that follow, R<sub>1</sub> through R<sub>9</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>16</sub>, R<sub>17</sub>, R<sub>19</sub>, A, B, G, the dashed lines and structural formulae I, II, III, X, XI, XII and IV, unless otherwise indicated, are defined as above.

Whenever reference is made herein to alkyl, both straight and branched chain alkyl groups are encompassed. For example, "C<sub>1</sub>-C<sub>6</sub> alkyl" encompasses both straight and branched chain alkyl groups of one to six carbon atoms, including (but not limited to) methyl, ethyl, isopropyl, *t*-butyl and hexyl.



Whenever R<sub>2</sub> or R<sub>5</sub> is a heterocyclic group, attachment of the group is through a carbon atom.

Whenever reference is made herein to C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkyl which "may contain one double or triple bond" in the above definitions, it is understood that at least two carbons are present in the alkyl for one double or triple bond.

Whenever reference is made herein to halo or halogen; fluoro, chloro, bromo or iodo is meant unless indicated otherwise.

The terms "treatment", "treating", and the like, are meant to include both slowing or reversing the progression of a disorder, as well as curing the disorder. These terms also include alleviating or reducing the symptoms of a disorder or condition, even if the disorder or condition is not actually eliminated and even if progression of the disorder or condition is not itself slowed or reversed. The term "treatment" and like terms also include prophylactic treatment of disorders and conditions.

The term "haloalkyl" refers to an alkyl group substituted by one or more halogen atoms, *i.e.* one or more fluoro, bromo, iodo, or chloro atoms. Moreover, it is understood that when an alkyl group can be, according to this specification and claims, substituted with, *e.g.*, one to nine, *e.g.*, nine atoms, that the optional one to nine fluorine atoms are only an option when a sufficient number of carbon atoms is present in the alkyl group.

The term "aryl" in the definitions above means, unless otherwise indicated, an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen atom, which aromatic hydrocarbon. Examples of aryl groups are phenyl and naphthyl.

The term "heterocycloalkyl", unless otherwise specified means a 4 to 8 membered mono-carbocyclic ring or bicyclic ring, wherein at least one carbon atom is replaced with a hetero member selected from oxygen, nitrogen, N-(alkyl), or S(O)<sub>m</sub>, wherein m is zero, 1, 2, or 3. Generally, heterocycloalkyl groups comprise up to four hetero members, preferably 1, 2, or 3 hetero members. Heterocycloalkyl groups of the compounds of the invention can contain optionally from one to three double bonds. The term "heterocycloalkyl" also includes heteroaryl groups. Examples of heteroaryl groups include thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, and benzoxazolyl. Other examples of aryl groups are pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, isoquinolyl, cinnolyl, indazolyl, indolizyl, phthalazyl, pyridazyl, triazyl, isoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Preferred heteroaryl groups are thiazolyl, thienyl, benzothienyl, pyridyl, quinolyl, quinazolinyl, quinoxalinyl, pyrazinyl, pyrimidinyl, indazolyl, imidazolyl, furanyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzisoxazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, benzoxazolyl, and

benzothiadiazolyl. Other preferred heterocycloalkyl groups are tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazino, [2,2,1]-azabicyclic rings, [2,2,2]-azabicyclic rings, [3,3,1]azabicyclic rings, quinuclidino, azetidino, azetidinono, oxindolo, dihydroimidazolo, and pyrrolidinono. Heterocyclolalkyl groups in the compounds of the invention may be C-attached or N-attached where such is possible.

Compounds of the formula I wherein B is  $-NR_1R_2$ ,  $-NHCHR_1R_2$ ,  $-OCHR_1R_2$  or  $-SCHR_1R_2$ , and  $R_3$  is methyl, ethyl or chloro (hereinafter  $R_{19}$ ) may be prepared by reaction of a compound of the formula IV wherein D is Cl, and A,  $R_4$ ,  $R_5$ , and Z are as defined above with reference to formula I, with a compound of the formula BH wherein B is as defined immediately above. The reaction is carried out in a solvent in the presence of a base at a temperature of between about 0° to about 230°C. Suitable solvents are organic solvents such as tetrahydrofuran (THF), acetonitrile, dimethylsulfoxide (DMSO), acetone,  $C_2$ - $C_{15}$  alkyl alcohol, chloroform ( $CHCl_3$ ), benzene, xylene, toluene, sulfolane, pyridine, quinoline, 2,4,6-trimethylpyridine, acetamide, di- $(C_1-C_2)$ alkylacetamide or 1-methyl-2-pyrrolidinone.

A preferred method of preparing compounds of the formula I wherein A is  $-CR_7$  and B is  $-NR_1R_2$  or  $-NHCHR_1R_2$  is the two step procedure described below. First, a compound of the formula IV is reacted with an excess of  $R_1NH_2$  or  $NH_3$  or an equivalent  $NH_3$  precursor (e.g.,  $NaN_3$ ,  $nBu_4N^+N_3^-$  or  $NH_2OH$ ) at temperature from about 75°C to about 250°C and at a pressure from about 0 to about 300 psi, in an appropriate solvent, as described above, to form a compound of the formula I wherein B is  $-NHR_1$ ,  $-NH_2$ ,  $-NH_2OH$  or  $-N_3$ . Compounds of the formula I wherein B is  $-N_3$  or  $-NH_2OH$  can be converted into the corresponding compounds of formula I wherein B is  $-NH_2$  by methods well known in the art such as hydrogenation or reduction. Alkylation of a compound of the formula I wherein B is  $-NHR_1$  or  $-NH_2$  with an appropriate alkyl halide in the presence of an appropriate base such as lithium or sodium bistrimethylsilylamide, lithium or sodium diisopropylamide, n-butyllithium or potassium t-butoxide, in an appropriate solvent such as THF, dioxane or methylene chloride, will yield the corresponding compound of formula I wherein B is  $-NR_1R_2$ . Alternatively, reductive amination of a compound of the formula I wherein B is  $-NHR_1$  or  $-NH_2$ , for example, acylation, followed by reduction with a borohydride (e.g., sodium borohydride) will form the corresponding compound of formula I wherein B is  $-NR_1R_2$  or  $-NHCHR_1R_2$ .


When B is  $-NR_1R_2$  or  $-NHCHR_1R_2$ , an excess of BH may be used both as a reagent and as a base. Bases other than BH such as potassium carbonate, tri- $(C_1-C_6)$ alkylamine or sodium hydride may also be used. The reaction is carried out at a temperature of about 75° to 230°C. When the reaction is carried out in the presence of a base, such as sodium hydride, potassium  $C_1$ - $C_4$  alkoxide, or an organolithium compound such as n-butyllithium, a molar equivalent of the amine is used.

When B is  $-\text{OCHR}_1\text{R}_2$  or  $-\text{SCHR}_1\text{R}_2$ , a base which is capable of deprotonating BH may be used, such as an alkali metal hydride such as sodium or potassium hydride, or an organometallic base such as sodium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium or potassium  $\text{C}_1\text{-C}_4$  alkoxide, or n-butyllithium. The solvent used can be, for example, tetrahydrofuran, acetonitrile, dimethylsulfoxide, acetone, methylene chloride, toluene, a  $\text{C}_2\text{-C}_5$  alcohol, chloroform, benzene, xylene, or 1-methyl-2-pyrrolidinone, and the reaction temperature can range from about  $0^\circ\text{C}$  to about  $180^\circ\text{C}$ , and is preferably from about  $50^\circ\text{C}$  to about  $80^\circ\text{C}$ .

Compounds of the formulae I, II and III wherein B is as defined with reference to formulae I, II and III and  $\text{R}_3$  is defined with reference to the same except that  $\text{R}_3$  is not methyl or ethyl (hereinafter  $\text{R}_{20}$ , which is defined as  $\text{R}_3$  with the exception that it can not be methyl or ethyl) may be prepared by reacting a compound of the formulae I, II or III wherein  $\text{R}_3$  is chloro with a nucleophile of the formula  $\text{R}_{20}\text{H}$  with or without an organic or inorganic base. Suitable bases include sodium and sodium hydride, when  $\text{R}_{20}\text{H}$  is an alkanol or an alkane thiol; and weaker bases such as potassium carbonate or triethylamine when  $\text{R}_{20}\text{H}$  is an amine. The compounds of formula I wherein  $\text{R}_{20}$  is fluoro may be prepared from the corresponding compounds wherein  $\text{R}_{20}$  is chloro on reaction with tetrabutylammonium fluoride. Suitable solvents are dimethylsulfoxide, tetrahydrofuran, or methylene chloride, preferably tetrahydrofuran.

Compounds of the formula I wherein B is  $-\text{CR}_1\text{R}_2\text{R}_{11}$ ,  $-\text{C}(\text{C}=\text{CR}_2\text{R}_{12})\text{R}_1$ ,  $-\text{CHR}_2\text{OR}_{12}$ ,  $-\text{CHR}_2\text{SR}_{12}$ , or  $-\text{C}(\text{O})\text{R}_2$ , and  $\text{R}_3$  is  $\text{R}_{19}$ , as defined above, may be prepared as depicted in Scheme I.




SCHEME 1



Compounds of the formula IV wherein D is cyano and A, R<sub>4</sub>, R<sub>5</sub>, and R<sub>19</sub> are as defined above having formula IVA (not shown), prepared by reacting the corresponding compound wherein D is chloro with potassium cyanide or copper cyanide in dimethylsulfoxide, 1-methyl-2-pyrrolidinone, N,N-dimethylformamide (DMF) or acetamide, are reacted with a Grignard reagent containing group R<sub>2</sub>, as defined above, to form the compounds of formula IA. Further reaction of the compound of formula IA with a Grignard reagent containing R<sub>1</sub> as defined above provides the compound of formula IB. Corresponding compounds of formula IC wherein B'' is -CR<sub>1</sub>R<sub>2</sub>R<sub>11</sub>, or -C(C=CR<sub>2</sub>R<sub>12</sub>)R<sub>1</sub> may be prepared by conventional methods. Thus, reaction of IB with an acid, such as concentrated sulfuric acid in acetic acid, or Burgess inner salt, such as (carboxysulfamoyl)triethylammonium hydroxide methyl ester, gives a compound of formula IC wherein B' is -C(=CR<sub>2</sub>R<sub>12</sub>)R<sub>1</sub>. Hydrogenation of a compound wherein B' is -C(=CR<sub>2</sub>R<sub>12</sub>)R<sub>1</sub> using a palladium/carbon (Pd/C) or platinum dioxide catalyst gives a compound IC wherein B' is CHR<sub>1</sub>R<sub>2</sub>. Reaction of compound IB with diethylaminosulfur trifluoride or triphenylphosphine/carbontetrachloride affords a compound IC wherein B' is -CR<sub>1</sub>R<sub>2</sub>F or -CR<sub>1</sub>R<sub>2</sub>Cl, respectively. Reduction of a compound of formula IA with sodium borohydride gives a compound I wherein B is -CHR<sub>2</sub>OH. Alkylation of this -CHR<sub>2</sub>OH group with alkyl halide such as alkyl iodide in the presence of a base such as sodium hydride at room temperature affords a compound of formula I wherein B is -CHR<sub>2</sub>OR<sub>12</sub>.

Compounds of the formula II wherein R<sub>3</sub> is R<sub>19</sub> as defined above may be prepared from compounds of the formula IV wherein R<sub>19</sub>, R<sub>4</sub>, R<sub>5</sub> and A are as defined before, D is chloro, and YR<sub>21</sub> is NH or -CHR<sub>21</sub> wherein R<sub>21</sub> is cyano or -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), hereafter formula IVB, as shown in Scheme 2.

SCHEME 2



Compounds of the formula VII wherein  $R_4$  and  $R_6$  are each hydrogen and Y is N may be prepared by heating compounds of formula IVB with an acid catalyst in a suitable solvent such as toluene, benzene, t-butanol, acetonitrile and acetone, preferably toluene. The acid catalyst may be sulfuric acid, hydrochloric acid, p-toluene sulfonic acid, or methanesulfonic acid, preferably p-toluene sulfonic acid.

When Y in formula IVB is CH or N, a base may be used to deprotonate the proton of the compound of formula IVB. Suitable solvents are tetrahydrofuran, toluene, and methylene chloride, suitable reaction temperatures are between about  $-78^{\circ}\text{C}$  and  $100^{\circ}\text{C}$ , preferably  $-78^{\circ}$  to  $50^{\circ}\text{C}$ , and suitable bases are sodium hydride, potassium hydride, potassium t-butoxide, lithium bis(trimethylsilyl) amide, and lithium or sodium diisopropylamide.

Compounds of the formula VII wherein  $R_4$  and  $R_6$  are each hydrogen may be deprotonated with a base such as sodium hydride, or an organometallic compound such as lithium bis(trimethylsilyl)amide followed by quenching with an electrophile compound containing the group  $R_4$ , such as  $R_4\text{L}$  wherein L is a leaving group such as iodo, bromo, mesylate, tosylate or with p-tolyl-N-fluoro-N- $\text{C}_1\text{-C}_6$  alkyl sulfonamide, iodine, p-nitrobenzene, dimethylformamide, di( $\text{C}_1\text{-C}_4$  alkyl)ketone, formaldehyde, ( $\text{C}_1\text{-C}_4$  alkyl) aldehyde or bromine, to provide a compound of formula VII wherein  $R_4$  is fluoro, chloro, bromo, iodo, hydroxy,  $\text{C}_1\text{-C}_4$  alkyl,  $\text{S}(\text{C}_1\text{-C}_4$  alkyl),  $\text{CHO}$ ,  $\text{CH}(\text{OH})(\text{C}_1\text{-C}_4$  alkyl),  $\text{C}(\text{OH})(\text{di-}\text{C}_1\text{-C}_4$  alkyl) or  $\text{CH}_2\text{OH}$ . Further conventional alkylation of the hydroxy group or oxidation of the thioalkyl group leads to compounds of formula VII wherein  $R_4$  is  $\text{C}_1\text{-C}_4$  alkoxy and  $\text{SO}_n(\text{C}_1\text{-C}_4$  alkyl) wherein n is 1 or 2, respectively. Oxidation of compounds of formula VII wherein  $R_4$  is hydroxy and  $R_6$  is hydrogen affords corresponding compounds wherein  $\text{CR}_4\text{R}_6$  is  $\text{C}=\text{O}$ , which on reductive amination with an appropriate amine convert into corresponding compounds wherein  $R_4$  is amino. The compounds of formula VII wherein  $R_4$  is nitro or amino may be formed by reacting compounds of formula VII wherein  $R_4$  and  $R_6$  are both hydrogen with alkyl nitrite to form compounds wherein  $\text{CR}_4\text{R}_6$  is  $\text{C}=\text{NOH}$  and oxidizing or reducing to give the compounds of formula VII wherein  $R_4$  is nitro or amine, respectively.

Compounds of the formula VII, when one of  $R_4$  and  $R_6$  is hydrogen, may be converted into corresponding compounds wherein  $R_{16}$  and  $R_{17}$  are both hydrogen by reduction with a reducing agent such as lithium aluminum hydride in tetrahydrofuran. The same reduction leads to compounds wherein  $R_{16}$  is hydrogen and  $R_{17}$  is hydroxy, when both of  $R_4$  and  $R_6$  are not hydrogen. Alkylation of  $R_{17}$  is hydroxy with  $\text{C}_1\text{-C}_4$  alkyl iodide in the presence of sodium hydride gives the corresponding compound wherein  $R_{17}$  is  $\text{O}(\text{C}_1\text{-C}_4$  alkyl). Reaction of compounds of formula VII with an organometallic compound such as di( $\text{C}_1\text{-C}_6$  alkyl)zinc,  $\text{C}_1\text{-C}_6$  alkyl lithium, or  $\text{C}_1\text{-C}_6$  alkyl magnesiumbromide affords compounds of formula VIII wherein one of  $R_{16}$  or  $R_{17}$  is  $\text{C}_1\text{-C}_6$  alkyl and the other is hydroxy.

The conversion of compounds of formula VIII to corresponding compounds of formula IIA is by the methods described above for preparation of compounds of formula I.


The compounds of formula III wherein G is oxygen or sulfur and R<sub>6</sub> is hydrogen may be prepared by reacting compounds of formula I wherein R<sub>4</sub> is amino and Z is NH with phosgene, diphosgene, triphosgene or thiophosgene. The reaction is in the presence of a base such as tri(C<sub>1</sub>-C<sub>4</sub> alkyl)amine in a suitable solvent, preferable tetrahydrofuran at about -78° to about 50°C, preferably at 0°C to room temperature. Standard alkylation of these compounds wherein R<sub>6</sub> is hydrogen with a suitable base such as sodium hydride in a suitable solvent such as dry tetrahydrofuran provides compounds of the formula III wherein R<sub>6</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl.

Compounds of the formula III wherein G is alkyl may be prepared by reacting a compound of the formula I wherein R<sub>4</sub> is amino and Z is NH with a compound of the formula GC(OC<sub>1</sub>-C<sub>2</sub> alkyl)<sub>3</sub> in the presence of an acid such as p-toluenesulfonic acid (p-TsOH), methanesulfonic acid (MsOH), hydrogen chloride gas (HCl<sub>g</sub>) or concentrated sulfuric acid (H<sub>2</sub>SO<sub>4</sub>) in an appropriate solvent such as toluene, xylene, benzene, dioxane or THF at a temperature from about room temperature to about 140°C, preferably from about 50°C to about the reflux temperature. Alternatively, a compound of the formula I wherein R<sub>4</sub> is amino and Z is NH can be reacted with [G(C=O)]<sub>2</sub>O, G(C=O)Cl or G(C=O)F in the presence of a base such as pyridine, a derivative of pyridine or a tri-(C<sub>1</sub>-C<sub>4</sub>)alkylamine, in an appropriate solvent such as CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, THF, dioxane, toluene or benzene, at a temperature from about 0°C to about the reflux temperature of the reaction mixture, preferably from about 0°C to about room temperature, followed by ring cyclization under acidic conditions (e.g., with pTSH, MSOH, HCl<sub>g</sub>, hydrogen bromide gas (HBr<sub>g</sub>) or concentrated H<sub>2</sub>SO<sub>4</sub>). The ring cyclization can be carried out in an appropriate solvent such as a C<sub>1</sub>-C<sub>5</sub> alcohol, toluene, xylene, benzene, dioxane or THF. Suitable temperatures for this reaction can range from about room temperature to about 140°C. Preferably, the reaction temperature is between about 50°C and about the reflux temperature.

Compounds of the formula III wherein G is -O-(C<sub>1</sub>-C<sub>2</sub> alkyl) or -OCF<sub>3</sub> may be prepared by reacting a compound of the formula III wherein G is oxygen and R<sub>6</sub> is hydrogen with a compound of the formula GOSO<sub>2</sub>CF<sub>3</sub> in the presence of a base such as tri(C<sub>1</sub>-C<sub>4</sub> alkyl)amine, or with lithium bistrimethylsilylamide in HMPA or DMF, and then quenching the reaction with a compound of the formula GOSO<sub>2</sub>OG or G-X wherein X is bromo, chloro or SO<sub>3</sub>CF<sub>3</sub>.

The compounds of formula IV wherein D is chloro and ZR<sub>5</sub> is NHR<sub>5</sub> may be prepared from compounds of formula V:







V

wherein A and R<sub>4</sub> are as defined with reference to formula I and R<sub>19</sub> is as defined above, by reaction with R<sub>5</sub>NH<sub>2</sub>. The reaction is in tetrahydrofuran or dimethylsulfoxide at about 0°C to about 150°C, preferably 50° to 130°C. The compounds of formula IV wherein D is chloro and Z is O, S, CHR<sub>21</sub> wherein R<sub>21</sub> is an electron deficient group such as cyano, C(=O)R, COOR, wherein R is C<sub>1</sub>-C<sub>4</sub> alkyl, benzoyl or allyl, or SO<sub>n</sub>- phenyl wherein n = 0, 1 or 2 may be prepared by reacting compounds of formula V with R<sub>5</sub>OH, R<sub>5</sub>SH, R<sub>5</sub>NH<sub>2</sub> or R<sub>5</sub>CHR<sub>21</sub>. The reaction proceeds in the presence of a base which is capable of deprotonating R<sub>5</sub>ZH, such as sodium hydride, potassium hydride, potassium carbonate, lithium or sodium bis(trimethylsilyl)amide, lithium or sodium dialkylamide, sodium or potassium (C<sub>1</sub>-C<sub>4</sub> alkoxide) or n-butyllithium, with or without other organometal halides such as copper (I) bromide, iodide or chloride, copper (II) oxide, copper (I) oxide, copper metal and trialkyltinchloride. Examples of solvents that may be used are tetrahydrofuran, dimethylsulfoxide, acetonitrile, methylene chloride, 1-methyl-2-pyrrolidinone, pyridine, quinoline, N,N-dialkylacetamides, 2,4,6-trimethylpyridine, N,N-dialkylformamides, e.g., N,N-dimethylformamide (DMF), hexamethyl phosphoramidate and toluene. The reaction temperature may range from about 0°C to about 180°C, and is preferably from about 0° to about 150°C.

Compounds of the formula IV wherein A is CR<sub>7</sub>, D is chloro and Z is O, S, CHR<sub>21</sub> may be prepared by reduction of compounds of formula X, depicted below, wherein R<sub>7</sub> and Z are as defined immediately above, with a reducing agent such as phosphorous trichloride in an appropriate solvent such as methylene chloride or chloroform at temperature from about 0°C to about 100°C, preferably from about room temperature to about the reflux temperature of the solvent.



X



XI

Compounds of the formula X may be prepared from compounds of the formula XI, depicted above, wherein  $R_4$  is as defined as it is for formula I and  $R_{19}$  is as defined above (i.e., methyl or ethyl), by reaction with a compound of the formula  $R_5OH$ ,  $R_5SH$  or  $R_5CHR_{21}$ . This reaction proceeds in the presence of a base which is capable of deprotonating  $R_5ZH$ , such as sodium hydride, potassium hydride, lithium, sodium or potassium bis(trimethylsilyl)amide, lithium, sodium or potassium dialkylamide, sodium or potassium  $C_1$ - $C_4$ alkoxide, or n-butyllithium. Suitable solvents include tetrahydrofuran, dioxane, dimethylsulfoxide, 1-methyl-2-pyrrolidinone, pyridine, N,N-di-( $C_1$ - $C_4$  alkyl)acetamides, acetamide, N,N-di-( $C_1$ - $C_4$  alkyl)formamides, acetonitrile, methylene chloride, toluene and xylene. Suitable reaction temperatures may range from about -78°C to about 150°C, and are preferably between about -40°C to about 150°C.

Compounds of the formula XI may be prepared by reacting the corresponding compounds of formula V wherein A is  $-CR_7$  and  $R_4$  and  $R_{19}$  are defined as above, with an oxidizing agent such as m-chloroperbenzoic acid, peracetic acid or pertrifluoroacetic acid, in a solvent such as methylene chloride, chloroform, acetic acid, DMF, methanol or a mixture of one or more of the foregoing solvents, at temperature from about 0°C to about 100°C, preferably from about room temperature to about 60°C.

When  $R_4$  is an electron withdrawing group such as a  $NO_2$ ,  $-COO(C_1-C_4$  alkyl),  $-COOH$ , CN or  $-CO(C_1-C_4)$ alkyl, the reaction order for the coupling reactions that introduce the B and  $ZR_5$  groups in the synthesis of compounds of formula I may be reversed. The B group may be introduced before the  $ZR_5$  coupling step using the methods analogous to those described above. For example, compounds of the formula I wherein  $R_4$  is an election deficient group may be prepared by reacting a compound of the formula XII with a compound of the formula  $HZR_5$ . Compounds of the formula XII may be prepared by reacting a compound of the formula V wherein A is  $CR_7$  and  $R_{19}$  and  $R_4$  are defined as above with a compound of the formula  $B''H$  in the presence of a base.

Compounds of the formula IV wherein D is chloro and Z is  $-N(C_1-C_4 \text{ alkyl})$  may be prepared by reacting the corresponding compounds wherein Z is NH with a base, at a temperature from about  $-78^\circ\text{C}$  to about  $100^\circ\text{C}$ , preferably from about  $0^\circ\text{C}$  to about room temperature, followed by quenching with  $C_1-C_4$  alkyl iodide or bromide. Suitable bases include, for example, sodium hydride, lithium or sodium bis(trimethylsilyl)amide, lithium or sodium dialkylamide, and n-butyllithium. Suitable solvents include, for example, tetrahydrofuran, dimethylsulfoxide, toluene, benzene or methylene chloride.


Compounds of the formula IV wherein D is chloro, hydroxy or OP wherein P is a standard protecting group for hydroxy and Z is  $-CR_{13}R_{14}$  may be prepared by alkylation, using an  $R_{13}$  containing alkylating agent such as  $R_{13}I$ , compounds of the formula IV wherein Z is  $-CHR_{21}$  in the presence of a base that is capable of deprotonating the proton in the Z group, as mentioned above, followed by quenching with an  $R_{14}$  containing alkylating agent such as  $R_{14}I$ . Heating compounds of the formula IV wherein D is chloro or hydrogen and Z is  $-CH(CN)$  in about 85% phosphoric acid at about the reflux temperature yields the corresponding compounds of formula IV wherein D is hydroxy and Z is  $CH_2$ . Deprotonation of the compounds of formula IV wherein Z is  $CH_2$  with a base, such as described above for deprotonation of  $R_5ZH$ , followed by quenching with a suitable electrophile such as a  $(C_1-C_6 \text{ alkyl})$ iodide, iodine, bromine, acetylchloride, formaldehyde, acetone, p-tolyl-N-fluoro-N- $(C_1-C_6 \text{ alkyl})$ sulfonamide, nitrobenzene,  $C_1-C_6$  alkyl nitrite, ethylene oxide or dihaloethane yields the corresponding compounds of formula IV wherein Z is  $-CHR_{13}$ ,  $-CH(OH)$ , cyclopropyl or  $-C(NO_2H)$ . Further alkylation of compounds wherein Z is  $-CHR_{13}$ , e.g., as described immediately above, with an alkylating agent of the formula  $R_{14}I$ , produces the corresponding compounds wherein Z is  $-C(R_{13}R_{14})$ .

Conversion of  $-C(R_5)NOH$  or  $-CH(OH)R_5$  to  $C(O)R_5$  may be accomplished by known methods. Hydrogenation or reduction of compounds wherein Z is  $-C=NOH$  provides compounds wherein Z is  $-CHNH_2$ . Some of the intermediates may require a protecting or deprotecting procedure to control the reaction selectivity using standard organic chemistry.

Compounds of the formula V wherein A is N (hereinafter referred to as compounds of the formula VB) or A is  $CR_7$  (i.e., compounds of the formula VA), and  $R_4$  and  $R_{19}$  are defined as they are for formula I, may be prepared by reacting the corresponding compounds of formulae VIB and VIA, respectively, with 1 equivalent or an excess of  $POCl_3$  at a temperature from about room temperature to about  $180^\circ\text{C}$ , preferably at the reflux temperature, with or without a solvent. Compounds of formula VIA may be prepared by the methods analogous to those described in the literature and well known to those skilled in the art. (See Helv. Chimica Acta., 25, p. 1306-1313 (1942)).

Compounds of formula VIB may be prepared by reacting 1 equivalent of the HCl salt of  $R_{19}C(=NH)(NH_2)$ , 1 equivalent of  $R_4CH(COO-(C_1-C_2 \text{ alkyl}))_2$ , and 2 equivalents of a base such as

a sodium alkoxide, e.g., sodium methoxide in a mixture of an alcohol (e.g., methanol), and acetone at a temperature from about 50°C to about 200°C, preferably at the reflux temperature.



VIA, A = CR<sub>7</sub>

VIB, A = N

When compounds of this invention contain one or more chiral centers, it is understood  
5 that the invention includes the racemic mixtures as well as all individual enantiomers and diastereomers of such compounds, and mixtures thereof.

The acid addition salts of compounds of the formulae I, II and III ("the active compounds  
of this invention) can be prepared in a conventional manner by treating a solution or suspension  
of the corresponding free base with one chemical equivalent of a pharmaceutically acceptable  
10 acid. Conventional concentration or crystallization techniques can be employed to isolate the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p-toluenesulfonic, and related acids.

15 The active compounds of this invention may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formulae I, II and III and their pharmaceutically acceptable carriers can then be readily  
20 administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch,  
25 methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight

polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

5 For parenteral administration, solutions containing an active compound of this invention or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, 10 subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

The effective dosages for compounds of the formulae I, II or III and their salts will depend on the intended route of administration and factors such as the age and weight of the patient, as generally known to a physician. The dosages will also depend on the particular illness to be 15 treated. For instance, the daily dosage for stress-induced illnesses, inflammatory disorders, Alzheimer's disease, gastro-intestinal diseases, anorexia nervosa, hemorrhagic stress and drug and alcohol withdrawal symptoms will generally range from about 0.1 to about 50 mg/kg body weight of the patient to be treated. The effective dose can be determined by those of ordinary skill in the art by reference to texts pertaining to treatment of the particular disorder or condition to 20 be treated.

Methods that may be used to determine the CRF antagonist activity of the active compounds of this invention and their pharmaceutically acceptable salts are described in Endocrinology, 116, 1653-1659 (1985) and Peptides, 10, 179-188 (1985). The binding activities for compounds of formulae I, II and III, expressed as  $IC_{50}$  values, generally range from about 0.5 25 nanomolar to about 10 micromolar.

The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these examples. Melting points are uncorrected. Proton nuclear magnetic resonance spectra ( $^1H$  NMR) and  $C^{13}$  nuclear magnetic resonance spectra ( $C^{13}$  NMR) were measured for solutions in deuteriochloroform 30 ( $CDCl_3$ ) and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane (TMS). The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad.

The following abbreviations are used in the Examples: Ph=phenyl; iPr=isopropyl; HRMS=high resolution mass spectrum.

Example 1

A. Butyl-(6-chloro-2,5-dimethyl-pyrimidin-4-yl)-ethylamine

A mixture of 2,5-dimethyl-4,6-dichloro-pyrimidine (0.999 g, 5.64 mmol) in 5ml of acetonitrile was treated with triethylamine (0.571 g, 5.65 mmol) and N-butyl-ethyl-amine (0.570 g, 5.65 mmol) and heated at reflux overnight. The mixture was cooled, diluted with water and dilute hydrogen chloride, and extracted with ethyl acetate. The organic layer was neutralized with saturated potassium carbonate, washed with brine, dried and concentrated to give 0.877 g (64%) of title compound as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.90 (t, 3H), 1.15 (t, 3H), 1.22-1.36(m, 2H), 1.5-1.6(m, 2H), 2.20 (s, 3H), 2.45 (s, 3H), 3.25-3.48 (m, 4H) ppm.

B. N-Butyl-N-ethyl-2,5-dimethyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine

A mixture of butyl-(6-chloro-2,5-dimethyl-pyrimidin-4-yl)-ethylamine (398 mg, 1.65 mmol), 2,4,6-trimethylaniline (4.04 g, 30 mmol) and diisopropyl-ethyl-amine (200 mg, 1.55 mmol) was heated at 210 to 230°C overnight. The mixture was quenched with water and dilute hydrogen chloride, and extracted with ethyl acetate. The organic layer was neutralized with saturated potassium carbonate, washed with brine, dried and concentrated to give a dark oil. The oil was distilled to give 579 mg of dark oil which was then purified through silica gel column chromatography using 1:1 hexane to chloroform as eluent to give 327 mg of title compound as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.92 (t, 3H), 1.14 (t, 3H), 1.2-1.4 (m, 2h), 1.45-1.60 (m, 2H), 1.85 (s, 3H), 2.16 (s, 6H), 2.30 (s, 3H), 2.33 (s, 3H), 3.2-3.4 (m, 4H), 5.8 (brs, 1H), 6.90 (s, 2H) ppm.

Example 2

A. Butyl-(6-chloro-2-methyl-pyrimidin-4-yl)-ethylamine

A mixture of 2-methyl-4,6-dichloro-pyrimidine (1.63 g, 10 mmol) in 5ml of acetonitrile was treated with N-butyl-ethyl-amine (2.000 g, 20 mmol) and heated at reflux for 0.5 hours. The mixture was cooled, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give 2.271 g (100%) of title compound as a light-brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.93 (t, 3H), 1.13 (t, 3H), 1.22-1.36 (m, 2H), 1.45-1.6 (m, 2H), 2.43 (s, 3H), 3.25-3.60 (m, 4H), 6.15 (s, 1H) ppm.

B. N-Butyl-N-ethyl-2-methyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine

A mixture of butyl-(6-chloro-2-methyl-pyrimidin-4-yl)-ethylamine (1.006 g, 4.42 mmol), and 2,4,6-trimethylaniline (3ml) was heated at reflux overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 2.862 g of a brown oil. The oil was purified through silica gel column chromatography to give 981 mg (68%) of title compound as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.80 (t, 3H), 1.1-1.3 (m, 2H), 1.3-1.5 (m, 2H), 2.17 (s, 6H), 2.27 (s, 3H), 2.41 (s, 3H), 3.2 (m, 2H), 3.36 (m, 2H), 4.66 (s, 1H), 6.90 (s, 2H) ppm.

Example 3

A. Butyl-(6-chloro-2-methyl-5-ethyl-pyrimidin-4-yl)-ethylamine

A mixture of 2-methyl-5-ethyl-4,6-dichloro-pyrimidine (1.009 g, 5.28 mmol) in 5 ml of acetonitrile was treated with triethylamine (0.571 g, 5.65 mmol) and N-butyl-ethyl-amine (0.540 g, 5.31 mmol) and heated at reflux overnight. The mixture was diluted with water and dilute hydrogen chloride, and extracted with ethyl acetate. The organic layer was neutralized with saturated potassium carbonate and washed with brine, dried and concentrated to give 1.193 g of yellow oil which was purified through silica gel column chromatography to give 1.157 g (86%) of title compound as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.90 (t, 3H), 1.13 (t, 3H), 1.18 (t, 3H), 1.1-1.33 (m, 2H), 1.4-1.6 (m, 2H), 2.41 (s, 3H), 2.62 (q, 2H), 3.25-3.48 (m, 4H) ppm.

B. N-Butyl-N-ethyl-2-methyl-5-ethyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine

A mixture of butyl-(6-chloro-2-methyl-5-ethyl-pyrimidin-4-yl)-ethylamine (200 mg, 0.78 mmol) and 2,4,6-trimethylaniline (0.963 g, 7.1 mmol) was heated at reflux for 4 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with saturated potassium carbonate and brine, dried and concentrated to give a dark oil. The oil was distilled to give 579 mg of the dark oil which was then purified through silica gel column chromatography using chloroform as eluent to give the title compound as a brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.93 (t, 3H), 1.14 (t, 3H), 1.1-1.4 (m, 4H), 1.45-1.60 (m, 2H), 2.17 (s, 6H), 2.30 (s, 3H), 2.33 (s, 3H), 3.2-3.4 (m, 4H), 6.90 (s, 2H) ppm.

Example 4

2-Methyl-5-nitro-N,N'-bis-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine

A mixture of 2-methyl-5-nitro-4,6-dichloropyrimidine (0.513 g, 2.47 mmol) in 6 ml of acetonitrile was treated with 2,4,6-trimethylaniline (0.333 g, 2.46 mmol) and triethylamine (1 ml) and stirred at room temperature for 4 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give 0.622 g of bright yellow solid. The solid was purified through silica gel column chromatography to give (6-chloro-2-methyl-5-nitro-pyrimidin-4-yl)-(2,4,6-trimethylphenyl) amine and the title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>) for 6-(chloro-2-methyl-5-nitro-pyrimidin-4-yl)-(2,4,6-trimethylphenyl)amine δ 2.16 (s, 6H), 2.33 (s, 3H), 2.43 (s, 3H), 6.95 (s, 2H), 8.79 (s, 1H) ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>) for 2-methyl-5-nitro-N,N'-bis-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine: δ 2.11 (s, 3H), 2.22 (s, 12H), 2.33 (s, 3H), 6.96 (s, 4H), 10.44 (s, 2H) ppm.

Example 5

N-Butyl-N-ethyl-2-methyl-5-nitro-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine

A mixture of 6-(chloro-2-methyl-5-nitropyrimidin-4-yl)-(2,4,6-trimethyl-phenyl)amine (838 mg, 2.10 mmol) and N-ethyl-n-butyl-amine (555 mg, 5.48 mmol) in 15 ml acetonitrile was heated at reflux for 2 hours. The mixture was quenched with water and extracted with ethyl acetate. The

organic layer was washed with brine, dried and concentrated to give 0.837 g of yellow oil. The solid was purified through silica gel column chromatography using 1:1 hexane to chloroform as eluent to give 753 mg of the title compound as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.95 (t, 3H), 1.26 (t, 3H), 1.2-1.4 (m, 2H), 1.55-1.75 (m, 2H), 2.17 (s, 6H), 2.23 (s, 3H), 2.31 (s, 3H), 3.4-3.6 (m, 4H), 6.93 (s, 2H), 9.43 (s, 1H) ppm.

#### Example 6

The following compounds were prepared by a method analogous to that of Examples 3 or 5 starting with an appropriate amine and appropriate (6-chloro-2-methyl-5-substituted-pyrimidin-4-yl)-(2,4,6-trimethylphenyl)amine.

10 N-Propyl-N-ethyl-2-methyl-5-nitro-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.93 (t, 3H), 1.26 (t, 3H), 1.6-1.8 (m, 2H), 2.17 (s, 6H), 2.23 (s, 3H), 2.31 (s, 3H), 3.4-3.55 (m, 4H), 6.93 (s, 2H), 9.41 (s, 1H) ppm.

15 N-Butyl-5-ethyl-2-methyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.98 (t, 3H), 1.12 (t, 3H), 1.3-1.5 (m, 2H), 1.5-1.7 (m, 2H), 2.17 (s, 3H), 2.30 (s, 3H), 3.4-3.5 (m, 2H), 4.30 (brs, 1H), 5.65 (brs, 1H), 6.91 (s, 2H) ppm.

5,N-Diethyl-2-methyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.09 (t, 3H), 1.25 (t, 3H), 2.17 (s, 3H), 2.30 (s, 3H), 2.31 (s, 3H), 3.4-3.6 (m, 2H), 4.35 (brs, 1H), 6.90 (s, 2H) ppm.

#### Example 7

20 N-Butyl-N-ethyl-2-methyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,5,6-triamine

A mixture of N-butyl-N-ethyl-2-methyl-5-nitro-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine (242 mg, 0.65 mmol) and platinum oxide (35 mg) in 50 ml ethanol was hydrogenated at 40 psi for 24 hours. The mixture was filtered through celite and concentrated to dryness to give 217 mg of yellow oil. The oil was purified through silica gel column chromatography to give 135 mg (61%) of title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.91 (t, 3H), 1.09 (t, 3H), 1.2-1.4 (m, 2H), 1.4-1.6 (m, 2H), 2.18 (s, 6H), 2.30 (s, 3H), 2.34 (s, 3H), 3.0 (brs, 2H), 3.1-3.3 (m, 4H), 5.89 (s, 1H), 6.92 (s, 2H) ppm.

#### Example 8

30 The following compounds were prepared by the method of Example 7 by hydrogenation of the corresponding 5-nitro derivatives.

N-Propyl-N-ethyl-2-methyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,5,6-triamine:

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.89 (t, 3H), 1.09 (t, 3H), 1.45-1.60 (m, 2H), 2.18 (s, 6H), 2.30 (s, 3H), 2.34 (s, 3H), 3.80 (brs, 2H), 3.1-3.30 (m, 4H), 5.95 (brs, 1H), 6.92 (s, 2H) ppm.

2-Methyl-N,N'-bis-(2,4,6-trimethylphenyl)-pyrimidine-4,5,6-triamine:

35 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.04 (brs, 2H), 2.21 (s, 12H), 2.22 (s, 3H), 2.30 (s, 6H), 6.30 (s, 2H), 6.92 (s, 4H) ppm.

#### Example 9



6-(Ethyl-propyl-amino-2-methyl-9-(2,4,6-trimethylphenyl)-7,9-dihydropurin-8-one

A mixture of N-propyl-N-ethyl-2-methyl-N'-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5,6-triamine (120 mg, 0.35 mmol) and triethylamine (87 mg, 0.86 mmol) in 5 ml of dry tetrahydrofuran was treated with triphosgene (41 mg, 0.14 mmol) at 0°C. Precipitate formed immediately and the reaction mixture was warmed to room temperature. After stirring for 30 minutes the mixture was filtered. The filtrate was concentrated to dryness to give 125 mg (100%) of title compound of a greenish color. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.90 (t, 3H), 1.21 (t, 3H), 1.65 (m, 2H), 2.10 (s, 6H), 2.34 (s, 3H), 2.39 (s, 3H), 3.48 (dd, 2H), 3.58 (q, 2H), 6.99 (s, 2H), 9.63 (s, 1H) ppm.

Example 10

6-(Ethyl-propyl-amino)-2,7-dimethyl-9-(2,4,6-trimethylphenyl)-7,9-dihydropurin-8-one

A mixture of the title compound of Example 9 (54 mg, 0.15 mmol) in 3 ml of dry tetrahydrofuran was treated with sodium hydride (9 mg, 0.23 mmol, 60% in oil) at room temperature. The mixture was then treated with 0.02 ml of methyl iodide and stirred at room temperature overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 60 mg of brown oil. The oil was purified through silica gel column chromatography using chloroform as eluent to give 56 mg of the title compound as a yellow oil which crystallized on standing. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.92 (t, 3H), 1.17 (t, 3H), 1.63 (m, 2H), 2.06 (s, 6H), 2.33 (s, 3H), 2.46 (s, 3H), 3.32 (dd, 2H), 3.40 (q, 2H), 3.63 (s, 3H), 7.00 (s, 2H) ppm.

Example 11

The following compounds were prepared by the method of Example 10 by reacting the title compound of Example 9 with an appropriate alkyl iodide.

7-Ethyl-6-(ethyl-propyl-amino)-2-methyl-9-(2,4,6-trimethylphenyl)-7,9-dihydropurin-8-one:

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.92 (t, 3H), 1.14 (t, 3H), 1.23 (m, 3H), 1.58 (m, 2H), 2.04 (s, 6H), 2.31 (s, 3H), 2.45 (s, 3H), 3.32 (dd, 2H), 3.36 (q, 2H), 4.08 (q, 2H), 7.00 (s, 2H) ppm.

6-(Ethyl-propyl-amino)-2-methyl-7-propyl-9-(2,4,6-trimethylphenyl)-7,9-dihydropurin-8-one:

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.87 (t, 3H), 0.90 (t, 3H), 1.15 (t, 3H), 1.5-12.8 (m, 4H), 2.05 (s, 6H), 2.33 (s, 3H), 2.47 (s, 3H), 3.32 (dd, 2H), 3.38 (q, 2H), 4.01 (q, 2H), 7.00 (s, 2H) ppm.

Example 12

[4-Chloro-2-methyl-6-(2,4,6-trimethylphenylamino)-pyrimidin-5-yl]-acetic acid ethyl ester

A mixture of (2-methyl-4,6-dichloro-pyrimidine-5-yl)-acetic acid ethyl ester (1.470 g, 5.9 mmol) and 2,4,6-trimethylaniline (2.56 ml, 17.7 mmol), in 15 ml of dimethylsulfoxide was heated at 120°C overnight and 138°C for 5 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give a brown oil. The oil was purified through silica gel column chromatography to give 1.070 g (52%) of

the title compound as a tan solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.30 (t, 3H), 2.14 (s, 6H), 2.32 (s, 3H), 2.37 (s, 3H), 3.79 (s, 2H), 4.23 (q, 2H), 7.00 (s, 2H), 7.02 (s, 1H) ppm.

Example 13

5 A. 4-Chloro-2-methyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one

A mixture of the title compound of Example 12 (960 mg, 2.76 mmol) and p-toluene sulfonic acid (105 mg, 0.55 mmol) in 10 ml of toluene was heated at reflux under Dean-Stark trap for 8 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give 800 mg of a brown mass which was purified through silica gel column chromatography to give 348 mg (42%) of the title compound as a yellow powder.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  2.06 (s, 6H), 2.34 (s, 3H), 2.56 (s, 3H), 3.75 (s, 2H), 7.02 (s, 2H) ppm.

10 B. 4-(1-Hydroxymethyl-propylamino)-2-methyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidine-6-one

15 A mixture of the compound prepared under A (168 mg, 0.557 mmol) and (S)-2-amino-butanol (0.27 ml, 2.78 mmol) in 5 ml of dimethyl sulfoxide was heated at 145°C for 5 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give an oil. The oil was purified through silica gel column chromatography, followed by recrystallization with diethyl ether to give 166 mg of the title compound as a grey solid.

20  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.25 (t, 6H), 1.5-1.8 (m, 2H), 2.07 (s, 6H), 2.31 (s, 3H), 2.37 (s, 3H), 3.50 (s, 2H), 3.4-3.9 (m, 2H), 4.0 (m, 1H), 4.\* (d, 1H), 7.00 (s, 2H) ppm.

Example 14

25 4-Diethylamino-2-methyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one

The title compound was prepared by the method of Example 13B with diethylamine instead of (S)-2-amino-butanol.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.02 (t, 3H), 2.08 (s, 6H), 2.31 (s, 3H), 2.37 (s, 3H), 3.55 (q, 4H), 3.85 (s, 2H), 6.95 (s, 2H) ppm.

Example 15

30 A. 4-Chloro-2,5,5-trimethyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one and 4-Chloro-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one

35 A mixture of 4-chloro-2-methyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (93 mg, 0.31 mmol) and sodium hydride (14 mg, 0.34 mmol, 60% in oil) in tetrahydrofuran (THF) was stirred for 5 minutes, then treated with an excess of methyl iodide and stirred for 1 hour. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give an oil. The oil was purified

through silica gel column chromatography to give 32 mg of 4-chloro-2,5,5-trimethyl-7-(2,4,6-trimethylphenyl-amino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one and 64 mg of 4-chloro-2,5-dimethyl-7-(2,4,6-trimethyl-phenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) (4-chloro-2,5,5-trimethyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one) δ 1.61 (s, 6H), 2.03 (s, 6H), 2.32 (s, 3H), 2.53 (s, 3H), 7.00 (s, 2H) ppm.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) (4-chloro-2,5-dimethyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one) δ 1.65 (d, 2H), 2.03 (s, 3H), 2.06 (s, 3H), 2.34 (s, 3H), 2.56 (s, 3H), 3.72 (q, 1H), 7.00 (s, 2H) ppm.

10 B. 4-(1-hydroxymethylpropylamino)-2,5,5-trimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one

The title compound was prepared by the method of Example 13B from 4-chloro-2,5,5-trimethyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one) and (S)-2-amino-butanol in dimethylsulfoxide at 140°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.02 (t, 3H), 1.53 (s, 6H), 1.5-1.8 (m, 2H), 2.04 (s, 6H), 2.32 (s, 3H), 2.38 (s, 3H), 3.6-3.9 (m, 2H), 4.0 (m, 1H), 4.5 (d, 1H), 5.25 (brs, 1H), 7.00 (s, 2H) ppm.

Example 16

5-Hydroxy-4-(1-hydroxymethylpropylamino)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one

20 The title compound was prepared by the method of Example 13B from 4-chloro-2,5-dimethyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one) and (S)-2-amino-butanol in dimethylsulfoxide (DMSO) at 140°C. Two diastereomers were obtained. The spectra for both diastereomers are shown below:

One isomer: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.03 (t, 3H), 1.55-1.75 (m, 2H), 1.77 (s, 3H), 2.05 (s, 3H), 2.07 (s, 3H), 2.32 (s, 3H), 2.37 (s, 3H), 3.55-3.85 (m, 2H), 4.0 (m, 1H), 5.1 (d, 1H), 5.3 (brs, 1H), 7.00 (s, 2H) ppm.

The other isomer: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.03 (t, 3H), 1.55-1.75 (m, 2H), 1.73 (s, 3H), 2.02 (s, 3H), 2.05 (s, 3H), 2.32 (s, 3H), 2.36 (s, 3H), 3.58 (dd, 1H), 3.77 (dd, 1H), 4.1 (m, 1H), 5.03 (d, 1H), 7.00 (s, 2H) ppm.

30 Example 17

5-Methoxy-4-(butyl-ethyl-amino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one

35 5-Hydroxy-4-(butyl-ethyl-amino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one was prepared by the method analogous to that of Example 16 starting with 4-chloro-2,5-dimethyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one) and N-butyl-ethyl-amine in DMSO at 140°C. Methylation of 5-hydroxy-4-(butyl-ethyl-amino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-

5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one with sodium hydride and methyl iodide using the method of Example 10 provides the title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.97 (d, 2H), 3.5-4.0 (m, 4H), 3.23 (s, 3H), 2.34 (s, 3H), 2.32 (s, 3H), 2.12 (s, 3H), 2.03 (s, 3H), 1.69 (s, 3H), 1.6-1.8 (m, 2H), 1.3-1.5 (m, 2H), 1.24 (t, 3H), 0.99 (t, 3H) ppm.

5      Example 18

4-(Butyl-ethyl-amino)-2-methyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one

10      The title compound was prepared by the method analogous to that of Example 13 (B) starting with 4-chloro-2-methyl-7-(2,4,6-trimethylphenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one) and N-butyl-ethyl-amine in DMSO at 135°C for 2.5 hours to give an oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) 7.00 (s, 2H), 3.85 (s, 2H), 3.62 (q, 2H), 3.53 (t, 2H), 2.35 (s, 3H), 2.32 (s, 3H), 2.10 (s, 3H), 1.55-1.70 (m, 2H), 1.35-1.50 (m, 2H), 1.25 (t, 3H), 1.00 (t, 3H) ppm.

Example 19

15      4-(Butyl-ethyl-amino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one

20      A solution of 4-(butyl-ethyl-amino)-2-methyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (285 mg, 0.78 mmol) in 5 ml of dry THF was treated with lithium bis(trimethylsilyl)amide (1.05 mmol) at -78°C and stirred for 5 minutes. The mixture was quenched with methyl iodide (0.054 ml, 0.858 mmol) at -78°C. After stirring for 10 minutes, the mixture was warmed to 0°C and stirred at that temperature for 20 minutes. The mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give a purple form. The form was purified through silica gel column chromatography to give 4-(butyl-ethyl-amino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (120 mg) as a purple glass, 4-(butyl-ethyl-amino)-2,5,5-trimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (35 mg) as a purple glass, and 98 mg of a mixture of the two components as a purple glass.

30      <sup>1</sup>H NMR (CDCl<sub>3</sub>) (4-(butyl-ethyl-amino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one) δ 6.96 (s, 2H), 3.7-3.9 (m, 2H), 3.51 (q, 1H), 3.15-3.4 (m, 2H), 2.34 (s, 3H), 2.30 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H), 1.53 (d, 3H), 1.5-1.65 (m, 2H), 1.3-1.4 (m, 2H), 1.17 (t, 3H), 0.95 (t, 3H) ppm.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) (4-(butyl-ethyl-amino)-2,5,5-trimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one) δ 6.98 (s, 2H), 3.45 (q, 2H), 3.34 (t, 2H), 2.34 (s, 3H), 2.33 (s, 3H), 2.06 (s, 6H), 1.55-1.7 (m, 2H), 1.3-1.45 (m, 2H), 1.23 (t, 3H), 0.99 (t, 3H) ppm.

Example 20

35      Butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine

A solution of (4-butyl-ethyl-amino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one) (111 mg, 0.292 mmol) in dry THF was treated with lithium aluminum hydride at room temperature. The resulting mixture was heated at reflux for 5 hours. After standard work-up, 97 mg of crude material as an oil was obtained. The oil was purified through a chromatotron using 10% ethyl acetate in hexane as eluent to give butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine as a clear pale yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.91 (d, 2H), 3.7-3.9 (m, 2H), 3.2-3.4 (m, 4H), 2.5 (q, 1H), 2.28 (s, 6H), 2.22 (s, 3H), 2.05 (s, 3H), 1.5-1.7 (m, 2H), 1.3-1.5 (m, 5H), 1.17 (t, 3H), 0.97 (t, 3H) ppm. High MS (C<sub>23</sub>H<sub>34</sub>N<sub>4</sub>) calc. 366.2776, found 366.27622.

10 Example 21

4-(Butyl-ethyl-amino)-2,5,5-trimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-6-ol

The title compound was prepared by the method of Example 20 starting from (4-(butyl-ethyl-amino)-2,5,5-trimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one) to give a pale yellow solid, mp 142-145°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.95 (d, 2H), 4.90 (s, 1H), 3.1-3.4 (m, 4H), 2.4 (brs, 1H), 2.33 (s, 3H), 2.31 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H), 1.50 (s, 3H), 1.45 (s, 3H), 1.25-1.60 (m, 4H), 1.11 (t, 3H), 0.93 (t, 3H) ppm.

Example 22

20 Butyl-ethyl-[6-methoxy-2,5,5-trimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine

To a solution of 4-(butyl-ethyl-amino)-2,5,5-trimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-6-ol] (20 mg, 0.05 mmol) in 1 ml of dry THF was treated with sodium hydride (60% in oil, 4 mg, 0.1 mmol) and then methyl iodide (0.3 ml) was added at room temperature. After stirring at room temperature for 2.5 hours, the mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give 26 mg of crude material. After silica gel column purification with 10% ethyl acetate in hexane, 19 mg of a colorless oil of the title compound was obtained. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.92 (s, 1H), 6.89 (s, 1H), 4.48 (s, 1H), 3.1-3.3 (m, 4H), 3.11 (s, 3H), 2.32 (s, 3H), 2.28 (s, 3H), 2.20 (s, 3H), 2.19 (s, 3H), 1.45 (s, 3H), 1.44 (s, 3H), 1.4-1.52 (m, 2H), 1.2-1.4 (m, 2H), 1.10 (t, 3H), 0.90 (t, 3H) ppm.

Example 23

4-(Butyl-ethyl-amino)-2-methyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione

To a solution of 4-(butyl-ethyl-amino)-2-methyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (76 mg, 0.207 mmol), POCl<sub>3</sub> (0.039 ml, 0.415 mmol), triethylamine (0.059 ml), and dimethylamine (1 ml) in 2 ml acetonitrile was heated at reflux for 1 hour. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried

and concentrated to give a brown form (105 mg). After silica gel column chromatography, the title compound was isolated as a yellow glass (10 mg).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.00 (s, 2H), 3.95-4.15 (m, 2H), 3.65-3.85 (m, 2H), 2.38 (s, 3H), 2.32 (s, 3H), 2.10 (s, 6H), 1.55-1.75 (m, 2H), 1.35-1.55 (m, 2H), 1.25 (t, 3H), 1.00 (t, 3H) ppm.

5      Example 24

N-Butyl-N-ethyl-2,5,N'-trimethyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine

A mixture of (6-chloro-2,5-dimethyl-pyrimidin-4-yl)-methyl-(2,4,6-trimethylphenyl)-amine (200 mg) and N-butyl-ethylamine (0.3 ml) in 1 ml of DMSO was heated in oil bath of 160°C for 15 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer  
10 was separated, dried and concentrated to give the crude material. After silica gel column purification using chloroform as eluent, the title compound was obtained as an oil.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.83 (s, 2H), 3.22 (s, 3H), 3.12 (m, 4H), 2.44 (s, 3H), 2.26 (s, 3H), 2.01 (s, 6H), 1.35-1.42 (m, 2H), 1.1-1.25(m, 2H), 1.00 (t, 3H), 0.90 (t, 3H) ppm.

Example 25

15      [2,5-Dimethyl-6-(tetrahydrofuran-3-yloxy)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine

A mixture of 3-hydroxy-tetrahydrofuran (0.5 ml) and sodium hydride (60% in oil, 53 mg, 1.33 mmol) in dry THF was stirred at room temperature for 5 minutes, (6-chloro-2,5-dimethyl-pyrimidin-4-yl)-(2,4,6-trimethylphenyl)-amine (107 mg, 0.388 mmol) was added. The mixture was heated at reflux for 15 hours. The mixture was quenched with water and extracted with ethyl  
20 acetate. The organic layer was separated, dried and concentrated to give a yellow oil. The oil was purified through silica gel column chromatography using 20% ethyl acetate in hexane as eluent to give 48 mg of the title compound as off-white crystals, mp 126-128°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.89 (s, 2H), 5.60 (brs, 2H), 3.8-4.0 (m, 4H), 2.27 (s, 6H), 2.13 (s, 6H), 2.1-2.25 (m, 2H), 1.93 (s, 3H) ppm.

25      Example 26

2-(S)-[2,5-Dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidin-4-ylamino]-butan-ol

A mixture of 4-chloro-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine (30 mg) and 2-(S)-amino-1-butanol (0.5 ml) in 0.5 ml of DMSO was heated at 130°C for 4 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated,  
30 dried and concentrated to give a crude material. The crude residue was purified through silica gel column chromatography to give 24 mg of the title compound as white crystals. High MS for ( $\text{C}_{19}\text{H}_{27}\text{N}_3\text{O}_2$ ) calc. 329.2103, found 329.21249; IR(KBr) 3400, 2940, 1580  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.841 (s, 2H), 5.72 (brs, 1H), 4.45 (d, 1H), 3.82-3.96 (m, 1H), 3.72-3.9 (m, 1H), 3.5-3.6 (m, 1H), 2.27 (s, 3H), 2.21 (s, 3H), 2.08 (s, 3H), 2.02 (s, 6H), 1.4-1.7 (m, 2H), 1.03 (t, 3H) ppm.

35      Example 27

4-(1-Ethyl-propoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine

A mixture of 3-pentanol (0.3 ml) and sodium hydride (60% in oil, 32 mg, 0.81 mmol) in DMSO was stirred at room temperature for 5 minutes. 4-Chloro-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine (150 mg, 0.54 mmol) was added and the resulting mixture was heated at 150°C for 5 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give a beige solid. The solid was purified through silica gel column chromatography using 20% chloroform in hexane as eluent to give the title compound as white crystals, mp 93.5-95.5°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 5.11 (t, 1H), 2.27 (s, 3H), 2.26 (s, 3H), 2.11 (s, 3H), 2.03 (s, 6H), 1.68 (p, 4H), 0.92 (t, 6H) ppm.

Example 28

[[6-(Butyl-N-ethylamino)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amino]-acetic acid ethyl ester

A mixture of [(6-chloro-2-methylpyrimidin-4-yl)-(2,4,6-trimethylphenyl)-amino]-acetic acid ethyl ester (85 mg, 0.244 mmol) and N-butyl-ethylamine (0.17 ml, 1.1 mmol) in 4 ml DMSO was heated at 135°C for 15 hours. An additional 1 ml of N-butyl-ethylamine was added and the reaction was heated at that temperature for an additional 15 hours (tlc showed no starting material). The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give 123 mg of a light amber oil. The oil was purified through silica gel chromatotron using 5% ethyl acetate in hexane as eluent to give 92 mg (91%) of the title compound as a white glass. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.94 (s, 2H), 4.69 (s, 1H), 4.23 (s, 2H), 4.22 (q, 2H), 3.35 (q, 2H), 3.15 (t, 2H), 2.36 (s, 3H), 2.31 (s, 3H), 2.21 (s, 6H), 1.3-1.5 (m, 2H), 1.34 (t, 3H), 1.1-1.3 (m, 2H), 1.01 (t, 3H), 0.80 (t, 3H) ppm.

Example 29

4-(1-Ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

To a solution of 3-pentanol (0.2 ml, 0.5205 mol) in DMSO (1 ml) was added 60% sodium hydride in oil (30 mg) in a portionwise. After stirring at room temperature for 5 min, a solution of 4-chloro-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyridine (98 mg) in 0.5 ml of dry THF was added and the resulting mixture was heated at 130°C for 5 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give a yellow solid. The solid was purified through silica gel column chromatography using 20% chloroform in hexane to chloroform as eluent to give 7 mg of the title compound as white crystals, mp 72.5-74°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.84 (s, 2H), 6.26 (s, 1H), 4.16 (m, 1H), 2.27 (s, 3H), 2.17 (s, 6H), 2.04 (s, 6H), 1.69 (m, 4H), 0.95 (t, 6H) ppm.

The mesylate salt of 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine was prepared by addition of 1 equivalent of methanesulfonic acid in ethyl acetate. The white crystals formed from ethyl acetate. Mp 117-119°C.

Example 30

EXPRESS MAIL NO. EL162813459 US

[6-(Butyl-ethyl-amino)-2,5-dimethylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)- acetonitrile

A solution of mesitylacetonitrile (66 mg, 0.41 mmol) in 1 ml of DMSO was treated with NaH (60% in oil, 20 mg, 0.50 mmol) and stirred at room temperature for 20 minutes, butyl-(6-chloro-2,5-dimethylpyrimidin-4-yl)-ethylamine (100 mg, 0.414 mmol) was added and the resulting mixture was heated at 130°C for 15 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give 160 mg of brown oil. The oil was purified through silica gel column chromatography using 5% ethyl acetate in hexane as eluent to give the title compound as a brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.83 (s, 2H), 5.49 (s, 1H), 3.2-3.4 (m, 2H), 3.0-3.2 (m, 2H), 2.51 (s, 3H), 2.24 (s, 3H), 2.21 (s, 6H), 1.66 (s, 3H), 1.35-1.50 (m, 2H), 1.1-1.3 (m, 2H), 1.05 (t, 3H), 0.84 (t, 3H) ppm.

Example 31

2-[6-(1-Ethyl-propoxy)-2,5-dimethylpyrimidin-4-yl]-2-(2,4,6-trimethylphenyl)-propionitrile

To a solution of 3-pentanol (140 mg, 1.59 mmol) in 2 ml of dry THF was added sodium hydride (60% in oil, 38 mg) and the mixture was stirred at room temperature for 5 minutes. 2-(6-Chloro-2,5-dimethylpyrimidin-4-yl)-2-(2,4,6-trimethylphenyl)-propionitrile (100 mg, 0.319 mmol) was added to the reaction mixture, and the resulting mixture was heated at reflux for 4 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give a brown oil (170 mg). The residue was purified through chromatotron using 20% ethyl acetate in hexane as eluent to give a mixture of two isomers as a yellow glass form and both having a M<sup>+</sup> of 365 from GC/MS. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.8 and 6.76 (s, 2H), 4.08 and 3.96 (m, 1H), 3.25 and 3.22 (s, 3H), 2.36 and 2.30 (s, 3H), 2.21, 2.20 and 2.06 (s, total of 9H), 1.5-1.7 (m, 4H), 1.04 (s, 3H), 0.96 and 0.90 (t, 3H) ppm.

Example 32

4-(1-Ethyl-propoxy)-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine

The title compound was prepared by the method analogous to that in Example 32 starting with 4-Chloro-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine and 3-pentanol. White crystals, mp. 82-84°C.

The title compounds of Example 33-39 were prepared by a method analogous to that of Example 27, starting with the appropriate 4-chloro-2-methyl-5-substituted 6-substituted-phenoxy)-pyrimidine and 3-pentanol.

Example 33

4-(2,4-Dimethyl-phenoxy)-6-(1-ethyl-propoxy)-2,5-dimethyl-pyrimidine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.8-7.0 (m, 3H), 5.13 (m, 1H), 2.30 (s, 6H), 2.10 (s, 3H), 2.09 (s, 3H), 1.68 (m, 4H), 0.92 (t, 6H) ppm.

Example 34

4-(2,6-Dimethyl-phenoxy)-6-(1-ethyl-propoxy)-2,5-dimethyl-pyrimidine



<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.04 (m, 3H), 5.12 (m, 1H), 2.25 (s, 3H), 2.13 (s, 3H), 2.07 (s, 6H), 1.66 (m, 4H), 0.92 (t, 6H) ppm.

Example 35

4-(1-Ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine-5-carbonitrile

5 mp 128-130°C, <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.8 (s, 2H), 5.18 (m, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.00 (s, 6H), 1.4-1.58 (m, 4H), 0.90 (t, 6H) ppm.

Example 36

5-tert-Butyl-4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 5.25 (m, 1H), 2.29 (s, 3H), 2.20 (s, 3H), 2.03 (s, 6H), 1.65-1.80 (m, 4H), 1.52 (s, 9H), 0.90 (t, 6H) ppm.

Example 37

4-(1-Ethyl-propoxy)-5-isopropyl-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 5.17 (m, 1H), 3.50 (m, 1H), 2.27 (s, 3H), 2.23 (s, 3H), 2.03 (s, 6H), 1.69 (m, 4H), 1.33 (s, 3H), 1.31 (s, 3H), 0.92 (t, 6H) ppm.

15 Example 38

5-Bromo-4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.86 (s, 2H), 5.16 (m, 1H), 2.29 (s, 3H), 2.28 (s, 3H), 2.06 (s, 6H), 1.65-1.80 (m, 4H), 1.52 (s, 9H), 0.95 (t, 6H) ppm.

Example 39

20 5-Chloro-4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.86 (s, 2H), 5.16 (m, 1H), 2.28 (s, 3H), 2.27 (s, 3H), 2.06 (s, 6H), 1.65-1.80 (m, 4H), 1.52 (s, 9H), 0.94 (t, 6H) ppm.

The title compounds of Examples 40-41 were prepared by a method analogous to that described in Example 24, starting from 4-chloro-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine and the appropriate amine.

25 Example 40

[2,5-Dimethyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-4-yl](1-ethyl-propyl)-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.84 (s, 2H), 4.10 (m, 2H, NH and CH), 2.27 (s, 3H), 2.21 (s, 3H), 2.04 (s, 9H), 1.3-1.6 (m, 4H), 0.91 (t, 6H) ppm.

30 Example 41

Butyl-[2,5-dimethyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-4-yl]-ethyl-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.87 (s, 2H), 3.76 (m, 2H), 3.68 (t, 2H), 2.73 (s, 3H), 2.28 (s, 6H), 1.99 (s, 6H), 1.5-1.7 (m, 4H), 1.27 (t, 3H), 0.94 (t, 3H) ppm.

The title compounds of Examples 42-54 were prepared by a method analogous to that described in Example 29, starting with the appropriate 4-chloro-2-methyl-6-(substituted phenoxy) or thiophenoxy-pyridine and the appropriate alcohol.

35 Example 42

2-(4-Bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.18 (s, 2H), 6.30 (s, 1H), 4.22 (m, 1H), 2.20 (s, 6H), 2.05 (s, 6H), 1.73 (m, 4H), 1.00 (t, 6H) ppm.

Example 43

5 2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.05 (s, 2H), 6.31 (s, 1H), 4.20 (m, 1H), 2.20 (s, 6H), 2.08 (s, 6H), 1.73 (m, 4H), 0.99 (t, 6H) ppm.

Example 44

10 3-Ethyl-4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 6.26 (s, 1H), 4.18 (m, 1H), 2.73(q,2H), 2.28 (s, 3H), 2.17 (s, 3H), 2.05 (s, 6H), (m, 4H), 1.18 (t, 3H), 0.96 (t, 6H) ppm.

Example 45

15 4-(1-ethyl-propenyloxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine (A mixture of cis and trans isomers)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 6.30 (s, 0.3H), 6.21 (s, 0.7H), 5.10 (m, 0.7H), 4.95 (m, 0.3H), 2.27 (s, 3H), 2.24 (s, 2.1H), 2.19 (s, 0.9H), 2.14 (s, 3H), 2.05 (s, 6H), 1.65 (d, 0.9H), 1.50 (d, 2.1H), 1.08 (t, 1.8H), 1.05 (t, 4.2H) ppm.

Example 46

20 Methanesulfonic acid salt of 4-(1-ethyl-propoxy)-2,3,5-trimethyl-6-(2,4,6-trimethyl-phenoxy)-pyridine

Mp 58-60°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.90 (s, 2H), 4.20 (m, 1H), 2.70 (s, 3H), 2.61 (s, 3H), 2.28 (s, 3H), 2.16 (s, 3H), 2.08 (s, 6H), 1.5-1.8 (m, 4H), 0.96 (t, 6H) ppm.

Example 47

25 4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.84 (s, 2H), 6.39 (s, 1H), 5.04 (m, 1H), 3.85 (s, 3H), 2.27 (s, 3H), 2.23 (s, 3H), 2.05 (s, 6H), 1.5-1.7 (m, 4H), 0.95 (s, 6H) ppm.

Example 48

30 4-(1-Ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyridine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.90 (s, 2H), 6.34 (d, J=2Hz,1H), 5.70 (d, J=2Hz,1H), 4.05 (m, 1H), 2.40 (s, 3H), 2.30 (s, 3H), 2.11 (s, 6H), 1.62 (m, 4H), 0.89 (t, 6H) ppm.

Example 49

35 3,6-Dimethyl-4-(tetrahydro-furan-3-yloxy)-2-(2,4,6-trimethyl-phenoxy)-pyridine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.25 (s, 1H), 4.99 (m, 1H), 3.9-4.1 (m, 4H), 2.31 (s, 3H), 2.23 (s, 3H), 2.20 (s, 3H), 2.1-2.3 (m, 2H), 2.07 (s, 6H) ppm.

Example 50

4-(1-Methoxymethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.38 (s, 1H), 4.42 (m, 1H), 3.5-3.7 (m, 2H), 3.42 (s, 3H), 2.31 (s, 3H), 2.21 (s, 6H), 2.07 (s, 6H), 1.7-1.85 (m, 2H), 1.02 (t, 3H) ppm.

Example 51

3-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yloxy]-pentan-2-ol

5 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.34 (s, 1H), 4.25-4.45 (m, 1H), 3.6-3.8 (m, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.20 (s, 3H), 2.06 (s, 6H), 1.2-1.4 (m, 5H), 1.07 (t, 3H) ppm.

Example 52

4-sec-Butoxy-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.31 (s, 1H), 4.35 (m, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.19 (s, 3H), 2.07 (s, 6H), 1.7-1.9 (m, 2H), 1.34 (d, 3H), 1.01 (t, 3H) ppm.

Example 53

2-(2,4-Dimethyl-phenylsulfanyl)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine

15 Golden oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.19 (d, J=8Hz, 1H), 7.06 (s, 1H), 6.94 (d, J=8Hz, 1H), 6.42 (s, 1H), 4.19 (m, 1H), 2.34 (s, 3H), 2.33 (s, 3H), 2.32 (s, 3H), 2.18 (s, 3H), 1.69 (m, 4H), 0.95 (t, 6H) ppm.

Example 54

4-(1-Ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenylsulfanyl)-pyridine

20 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.97 (s, 2H), 6.30 (s, 1H), 4.15 (m, 1H), 2.35 (s, 6H), 2.30 (s, 3H), 2.23 (s, 3H), 2.20 (s, 3H), 1.68 (m, 4H), 0.95 (t, 6H) ppm.

Example 55

2-(4-Ethyl-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine

To a solution of 2.5 N n-BuLi in hexane (0.47 ml, 1.18 mmol) in 5ml of dry THF was added a solution of 2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine (465 mg, 1.18 mmol) in 5 ml of dry THF at -78°C. After stirring at that temperature for 5 min, an excess of ethyl iodide (0.4 ml) was added and the resulting mixture was stirred at -78°C for 30 min, then at 0°C for 15 min. The mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was dried and concentrated to give a light brown oil. The oil was purified through silica gel column chromatography using chloroform as eluent to give 260 mg of the title compound as white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.90 (s, 2H), 6.38 (s, 1H), 4.20 (m, 1H), 2.61 (q, 2H), 2.24 (s, 3H), 2.21 (s, 3H), 2.10 (s, 6H), 1.70 (m, 4H), 1.30 (t, 3H), 0.98 (t, 6H) ppm.

The title compounds of Examples 56-62 were prepared by a method analogous to that described in Example 55, starting from n-BuLi and 2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine, followed by quenching with an appropriate electrophile.

Example 56

4-[4-(1-Ethyl-propoxy)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-benzaldehyde

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.94 (s, 1H), 7.61 (s, 2H), 6.32 (s, 1H), 4.20 (m, 1H), 2.21 (s, 3H), 2.16 (s, 9H), 1.70 (m, 4H), 0.98 (t, 6H) ppm.

Example 57

2-(2,6-Dimethyl-4-propyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine

5 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.30 (s, 1H), 4.20 (m, 1H), 2.54 (dd, 2H), 2.22 (s, 3H), 2.20 (s, 3H), 2.09 (s, 6H), 1.6-1.8 (m, 6H), 0.9-1.1 (m, 9H) ppm.

Example 58

2-(2,6-Dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.06 (m, 3H), 6.30 (s, 1H), 4.20 (m, 1H), 2.21 (s, 6H), 2.11 (s, 6H), 1.73 (m, 4H), 0.99 (t, 6H) ppm.

Example 59

2{4-[4-(1-Ethyl-propoxy)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl}-propan-2-ol

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.15 (s, 2H), 6.25 (s, 1H), 4.20 (m, 1H), 2.20 (s, 3H), 2.19 (s, 3H), 2.10 (s, 6H), 1.85 (brs, 1H), 1.70 (m, 4H), 1.60 (s, 6H), 0.95 (t, 6H) ppm.

15 Example 60

4-(1-Ethyl-propoxy)-2-(4-iodo-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.39 (s, 2H), 6.30 (s, 1H), 4.19 (m, 1H), 2.20 (s, 3H), 2.18 (s, 3H), 2.05 (s, 6H), 1.72 (m, 4H), 0.98 (t, 6H) ppm.

Example 61

20 4-[4-(1-Ethyl-propoxy)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenol

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.85 (brs, 1H), 6.36 (s, 1H), 6.24 (s, 2H), 4.24 (m, 1H), 2.39 (s, 3H), 2.20 (s, 3H), 2.02 (s, 6H), 1.74 (m, 4H), 1.00 (t, 6H) ppm.

Example 62

25 1-{4-[4-(1-Ethyl-propoxy)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl}-pyrrolidin-2-one

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.30 (s, 2H), 6.30 (s, 1H), 4.20 (m, 1H), 3.88 (t, 2H), 2.61 (t, 2H) ppm.

Example 63

{4-[4-(1-Ethyl-propoxy)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl} -methanol

30 A mixture of 4-[4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-benzaldehyde (114 mg, 0.41 mmol) and sodium borohydride (63 mg, 1.6 mmol) in 3 ml of methanol was stirred at room temperature for 2 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give yellow oil. The oil was purified through silica gel using chloroform as eluent to give 70 mg of the title compound as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.04 (s, 2H), 6.32 (s, 1H), 4.55 (s, 2H), 4.21 (m, 1H), 2.30 (brs, 1H), 2.22 (s, 3H), 2.21 (s, 3H), 2.12 (s, 6H), 1.73 (m, 4H), 0.91 (t, 6H) ppm.

35 Example 64

4-(1-Ethyl-propoxy)-2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine

To a solution of 4-[4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenol (40 mg, 0.12mmol) in 3 ml of dry THF was added 10 mg of 60% sodium hydride in oil at room temperature. After stirring for 5 min, 0.3 ml of methyl iodide was added and the resulting mixture was stirred at room temperature overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give a yellow solid. The solid was purified through silica gel column chromatography using hexane to 1:1 chloroform:hexane as eluent to yield 20 mg of the title compound as yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.66 (s, 2H), 6.28 (s, 1H), 4.20 (m, 1H), 3.79 (s, 3H), 2.20 (s, 3H), 2.19 (s, 3H), 2.08 (s, 6H), 1.71 (m, 4H), 0.97 (t, 6H) ppm.

Example 65

4-(1-Ethyl-propoxy)-2-(4-isopropoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine

To a solution of 4-[4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenol (58 mg, 0.176mmol) in 3 ml of dry THF was added triphenylphosphine (70 mg, 0.264mmol) and isopropanol (60 mg, 0.22 mmol). The resulting mixture was stirred at room temperature for 5 min, diethyl azodicarboxylate (46 mg, 0.264 mmol) was added. The mixture was stirred at room temperature overnight. An additional 20 mg of diethyl azodicarboxylate was added and the mixture was stirred for an additional 4 hours. The mixture was quenched with water and extracted with methylene chloride. The organic layer was dried and concentrated to give an oil. The oil residue was purified through silica gel column chromatography using 1:1 hexane:chloroform to 1:2 hexane: chloroform as eluent to give 38 mg (58%) of the title compound as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.60 (s, 2H), 6.28 (s, 1H), 4.50 (m, 1H), 4.18 (m, 1H), 2.20 (s, 3H), 2.19 (s, 3H), 2.079s,6H), 1.71 (m, 4H), 1.34 (d, 6H), 0.98 (t, 6H) ppm.

The title compounds of Examples 66-67 were prepared by a method analogous to that described in Example 64, starting with an appropriate pyridine-3,5-dimethylphenol or pyridine-3,5-dimethyl-phenyl methanol with a base, followed by quenching with an appropriate alkyl halide.

Example 66

2-(4-Ethoxy-2,6-dimethyl-phenoxy)-4-(1-ethyl-propoxy)-3,6-dimethyl-pyridine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.60 (s, 2H), 6.28 (s, 1H), 4.19 (m, 1H), 3.99(q,2H), 2.19 (s, 3H), 2.18 (s, 3H), 2.07 (s, 6H), 1.74 (m, 4H), 1.40 (t, 3H), 0.97 (t, 6H) ppm.

Example 67

4-(1-Ethyl-propoxy)-2-(4-methoxymethyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine

Mp 58-60°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.05 (s, 2H), 6.30 (s, 1H), 4.41 (s, 2H), 4.19 (m, 1H), 3.42 (s, 3H), 2.21 (s, 3H), 2.18 (s, 3H), 2.11 (s, 6H), 1.72 (m, 4H), 0.98 (s, 6H) ppm.

Example 68

[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine

A mixture of 4-chloro-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine (1.330 g, 4.822 mmol) and 20 ml of ethyl amine in 13 ml of 1-methyl-2-pyrrolidinone was heated at 150°C at 250

psi overnight in a pressure reactor. The reaction was heated an additional 24 hours at 175°C and 300 psi. The reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give a brown oil. The oil residue was purified through silica gel column chromatography using chloroform to 2% methanol in chloroform as eluent to give 0.820 g (60%) of the title compound as a white solid, mp 115-116°C.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.87 (s, 2H), 6.11 (s, 1H), 3.85 (t, 1H), 3.24 (m, 2H), 2.30 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H), 2.08 (s, 6H), 1.32 (t, 3H) ppm.

The title compounds of Examples 69-71 were prepared by the method analogous to that described in Example 68 starting with an appropriate 4-chloro-2-substituted phenoxy-pyridine and an appropriate amine.

Example 69

[3,6-Dimethyl-2-(2,4,6-trimethyl-phenylsulfanyl)-pyridin-4-yl]-(1-ethyl-propyl)-amine

Mp 108-110°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.95 (s, 2H), 6.09 (s, 1H), 3.63 (d, 1H), 3.28 (m, 1H), 2.36 (s, 6H), 2.30 (s, 3H), 2.17 (s, 3H), 2.11 (s, 3H), 1.4-1.75 (m, 4H), 0.93 (t, 6H) ppm. The hydrogen chloride salt, mp 148-150°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.95 (s, 2H), 6.30 (s, 1H), 5.75 (d, 1H), 3.38 (m, 1H), 2.69 (s, 3H), 2.33 (s, 6H), 2.28 (s, 3H), 2.02 (s, 3H), 1.72 (m, 4H), 0.93 (t, 6H) ppm.

Example 70

2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-amine; white solid

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.04 (s, 2H), 6.13 (s, 1H), 3.88 (t, 1H), 3.24 (m, 2H), 2.17 (s, 3H), 2.17 (s, 3H), 2.08 (s, 6H), 1.32 (t, 3H) ppm.

Example 71

[3,6-dimethyl-2-(2,4,6-trimethyl-phenylsulfanyl)-pyridin-4-yl]-ethyl-amine

Tan crystals, mp 114-116°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.94 (s, 2H), 6.12 (s, 1H), 3.76 (t, 1H), 3.21 (m, 2H), 2.35 (s, 6H), 2.30 (s, 3H), 2.19 (s, 3H), 2.10 (s, 3H), 1.29 (t, 3H) ppm.

Example 72

[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-propyl-amine

To a solution of [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine (7.00 g, 24.6 mmol) in 100 ml of dry THF was added 1.0 M lithium bis(trimethylsilyl)amide in hexane (32 ml, 32 mmol) at -78°C. After stirring at that temperature for 10 min, the reaction mixture was treated with iodopropane (13 ml, 125 mmol) at -70°C. After stirring at that temperature for 20 min, the dry ice bath was removed and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give an oil. The oil residue was purified through silica gel column chromatography using 1:1 chloroform:hexane to chloroform as eluent to give 5.04 g (62.5%) of [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-propyl-amine as yellow solid; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.41 (s, 1H), 3.11 (q, 2H), 3.03 (dd, 2H), 2.30 (s, 3H), 2.25 (s,

3H), 2.19 (s, 3H), 2.07 (s, 6H), 1.55 (m, 2H), 1.08 (t, 3H), 0.90 (t, 3H) ppm. The corresponding HCl salt, white crystals; mp 167-169°C; <sup>1</sup>H NMR (MeOH-d<sub>4</sub>) δ 7.00 (s, 2H), 6.75 (s, 1H), 3.54(q,2H), 3.43 (t, 2H), 2.35 (s, 3H), 2.31 (s, 3H), 2.27 (s, 3H), 2.08 (s, 6H), 1.69 (m, 2H), 1.25 (t, 3H), 0.94 (t, 3H) ppm;

- 5 The title compounds of Examples 73-79 were prepared by the method analogous to that described in Example 72 starting with an appropriate 2-(substituted phenoxy or thiophenoxy)-pyridin-4-yl-ethyl amine and a base (lithium bis(trimethylsilyl)amide or lithium diisopropylamide), followed by quenching with an appropriate alkyl halide.

Example 73

- 10 [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-diethyl-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.87 (s, 2H), 6.40 (s, 1H), 3.10(q,4H), 2.30 (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 2.06 (s, 6H), 1.08 (t, 6H) ppm. The HCl salt, white crystals, mp 180-181°C; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.01 (s, 2H), 6.78 (s, 1H), 3.58(q,4H), 2.38 (s, 3H), 2.32 (s, 6H), 2.10 (s, 6H), 1.28 (t, 6H) ppm.

- 15 Example 74

[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-methyl-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.86 (s, 2H), 6.38 (s, 1H), 3.05(q,2H), 2.75 (s, 3H), 2.29 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 2.06 (s, 6H), 1.18 (t, 3H) ppm. The HCl salt, mp 173-174°C.

Example 75

- 20 Butyl-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.41 (s, 1H), 3.0-3.3 (m, 4H), 2.31 (s, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 2.08 (s, 6H), 1.3-1.6 (m, 4H), 1.09 (t, 3H), 0.93 (t, 3H) ppm.

Example 76

Butyl-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-amine

- 25 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.03 (s, 2H), 6.39 (s, 1H), 3.09(q,2H), 3.01(dd,2H), 2.21 (s, 3H), 2.16 (s, 3H), 2.05 (s, 6H), 1.4-1.6 (m, 2H), 1.25-1.40 (m, 2H), 1.06 (t, 3H), 0.87 (t, 3H) ppm. The HCl salt, mp 177-178°C; <sup>1</sup>H NMR(DMSO-d<sub>6</sub>) δ 7.20 (s, 2H), 6.74 (s, 1H), 3.1-3.4 (m, 4H), , 2.24 (s, 3H), 2.17 (s, 3H), 2.00 (s, 6H), 1.4-1.6 (m, 2H), 1.25-1.40 (m, 2H), 1.05 (t, 3H), 0.86 (t, 3H) ppm.

Example 77

- 30 [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-propyl-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.04 (s, 2H), 6.41 (s, 1H), 3.11(q,2H), 3.00 (m, 2H), 2.24 (s, 3H), 2.17 (s, 3H), 2.07 (s, 6H), 1.54 (m, 2H), 1.08 (t, 3H), 0.90 (t, 3H) ppm. The HCl salt, white crystals, mp 74-76°C. <sup>1</sup>H NMR(CD<sub>3</sub>OD) δ 7.23 (s, 2H), 6.81 (s, 1H), 3.58(q,2H), 3.46 (m, 2H), 2.38 (s, 3H), 2.31 (s, 3H), 2.13 (s, 6H), 1.6-1.8 (m, 2H), 1.26 (t, 3H), 0.96 (t, 3H) ppm.

- 35 Example 78

[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-diethyl-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.05 (s, 2H), 6.41 (s, 1H), 3.11(q,4H), 2.24 (s, 3H), 2.18 (s, 3H), 2.07 (s, 6H), 1.09 (t, 6H) ppm. The HCl salt, white crystals, mp 184-185°C. <sup>1</sup>H NMR(CD<sub>3</sub>OD) δ 7.23 (s, 2H), 6.81 (s, 1H), 3.56(q,4H), 2.37 (s, 3H), 2.33 (s, 3H), 2.12 (s, 6H), 1.26 (t, 6H) ppm.

Example 79

5 [3,6-Dimethyl-2-(2,4,6-trimethyl-phenylsulfanyl)-pyridin-4-yl]-ethyl-propyl-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.95 (s, 2H), 6.45 (s, 1H), 3.02 (q,2H), 2.97 (dd,2H), 2.35 (s, 6H), 2.31 (s, 3H), 2.21 (s, 3H), 2.20 (s, 3H), 1.49 (m, 2H), 1.02 (t, 3H), 0.86 (t, 3H) ppm. The HCl salt, white crystals, mp 110-112°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.92 (s, 2H), 6.51 (s, 1H), 3.27 (q,2H), 3.19 (dd,2H), 2.84 (s, 3H), 2.32 (s, 6H), 2.28 (s, 3H), 1.82 (s, 3H), 1.52 (m, 2H), 1.15 (t, 3H), 0.84 (t, 3H) ppm.

10 Example 80

N-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-N-ethyl-2,2,2-trifluoro-acetamide

To a solution of [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine (200 mg, 0.7 mmol) in dry methylene chloride was added triethylamine (0.1 ml, 0.73 mmol) and trifluoroacetic anhydride (0.11 ml, 0.74 mmol) and stirred at room temperature for 2 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give the crude material. The crude material was purified through silica gel column chromatography using 25% hexane in chloroform as eluent to give 225 mg (83%) of the title compound as white crystals, mp 110-111°C, <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.91 (s, 2H), 6.57 (s, 1H), 4.16 (m, 1H), 3.39 (m, 1H), 2.32 (s, 3H), 2.27 (s, 3H), 2.24 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 1.26 (t, 3H) ppm.

Example 81

3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-(2,2,2-trifluoro-ethyl)-amine

To a solution of N-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-N-ethyl-2,2,2-trifluoro-acetamide (292 mg, 0.77 mmol) in 15 ml of dry THF was added 2M BH<sub>3</sub>.DMS in THF (0.96 ml, 1.92 mmol) at room temperature. The resulting mixture was heated at reflux overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 300 mg of white solid. The solid was recrystallized from hexane and 2 drops of methanol to give white crystals (298 mg, 96%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 6.47 (s, 1H), 3.70 (q,2H), 3.25 (q,2H), 2.32 (s, 3H), 2.27 (s, 3H), 2.20 (s, 3H), 2.05 (s, 3H), 1.13 (t, 3H) ppm. The HCl salt, white crystals, mp 73-74°C. <sup>1</sup>H NMR(CD<sub>3</sub>OD) δ 6.97 (s, 1H), 6.96 (s, 2H), 4.09 (q,2H), 3.46 (q,2H), 2.34 (s, 3H), 2.30 (s, 3H), 2.28 (s, 3H), 2.05 (s, 6H), 1.17 (t, 3H) ppm.

Example 82

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

35 A mixture of 4-chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester (500 mg, 1.56 mmol) and 1-ethyl-propyl-amine (0.8 ml) in 1 ml of DMSO was heated at reflux for 15 hours. The mixture was quenched with sat. ammonium chloride and extracted with ethyl



acetate. The organic layer was dried and concentrated to give 445.6 mg of yellow solid. The solid was purified through silica gel column chromatography using 1:1 ratio of chloroform:hexane as eluent to give (289 mg, 50%) of the title compound as white crystals, mp 98-102°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.04 (d, 1H), 6.85 (s, 2H), 6.06 (s, 1H), 3.85 (s, 3H), 3.32 (m, 1H), 2.28 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 1.62 (m, 4H), 0.95 (t, 6H) ppm.

Example 83

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-methanol

A mixture of 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester (220 mg, 0.594 mmol) and 1M lithium aluminum hydride in THF (4 ml, 4 mmol) in dry THF (3 ml) was heated at reflux for 10 min, then stirred at rt overnight. The mixture was quenched with 0.3 ml of water, 0.3 ml of 2N NaOH, then 0.8 ml of water and stirred at room temperature for 10 min. White solid formed and was filtered through celite. The filtrate was concentrate to dryness to give 207 mg (100%) of the title compound as white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.83 (s, 2H), 6.06 (s, 1H), 4.96 (d, 1H, NH), 4.88 (d, 2H), 3.28 (m, 1H), 2.26 (s, 3H), 2.11 (s, 3H), 2.04 (s, 6H), 1.4-1.6 (m, 4H), 1.4 (t, 1H, OH), 0.93 (t, 6H) ppm.

Example 84

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid

A mixture of 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester (16 mg, 0.043 mmol) and lithium hydroxide (30 mg) in dioxane (1 ml) and water (1 ml) was stirred at rt over night. The mixture was quenched with water and adjusted to pH 7.0 and extracted with chloroform. The organic layer was dried and concentrated to give the crude material. The crude material was purified through silica gel column chromatography using 10% ethyl acetate in chloroform as eluent to give 7 mg of the title compound as white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.12 (d, 1H), 6.87 (s, 2H), 6.16 (s, 1H), 3.35 (m, 1H), 2.29 (s, 3H), 2.10 (s, 3H), 2.07 (s, 6H), 1.4-1.6 (m, 4H), 0.94 (t, 6H) ppm.

Example 85

[3-Chloromethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine hydrogen chloride

To a solution of 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-methanol (40 mg, 0.117 mmol) in 0.3 ml of dry methylene chloride was added thionyl chloride (0.15 ml) and stirred at rt for 1 hr. The mixture was concentrated to dryness and pumped in vacuo to give white glass form. The glass form was triturated with ether to give the title compound (47 mg, 100%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.92 (s, 2H), 6.24 (s, 1H), 5.50 (d, 1H), 4.72 (s, 2H), 3.50 (m, 1H), 2.73 (s, 3H), 2.27 (s, 3H), 2.15 (s, 6H), 1.5-1.8 (m, 4H), 0.97 (t, 6H) ppm.

Example 86

[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine

To a solution of [3-Chloromethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine (35 mg, 0.088 mmol) in dry THF (0.5 ml) was added 1M lithium aluminum hydride in THF (0.3 ml, 0.3 mmol) and the resulting mixture was stirred at rt for 1.5 hours. The mixture was quenched with 0.1 ml of water, 0.1 ml of 2N NaOH and 0.3 ml of water and stirred for 5 min. The mixture was filtered and washed with THF. The filtrate was concentrated to dryness. The residue was dissolved in chloroform and dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give 28 mg (100%) of oil. The oil was purified through silica gel column chromatography using chloroform as eluent to give 26 mg of the title compound as an oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 6.08 (s, 1H), 3.72 (d, NH, 1H), 3.35 (m, 1H), 2.30 (s, 3H), 2.16 (s, 3H), 2.13 (s, 3H), 2.05 (s, 6H), 1.45-1.75 (m, 4H), 0.98 (t, 6H) ppm. The corresponding HCl salt was prepared and triturated with ether to give 20 mg of white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.19 (s, 1H), 4.98 (brs, 1H), 3.50 (m, 1H), 2.71 (s, 3H), 2.26 (s, 3H), 2.12 (s, 6H), 2.00 (s, 3H), 1.5-1.8 (m, 4H), 0.95 (t, 6H) ppm.

#### Example 87

(1-Ethyl-propyl)-[3-methoxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine

To a solution of 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-methanol (46 mg, 0.134 mmol) in dry THF (0.5 ml) was added 60% sodium hydride in oil (6 mg, 0.134 mmol) and stirred for 2 min. Methyl iodide (0.1 ml) was added and the mixture was stirred at room temperature overnight. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give the title compound as an oil (40 mg, 84%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.84 (s, 2H), 6.06 (s, 1H), 5.13 (d, 1H), 4.78 (s, 2H), 3.33 (s, 3H), 3.29 (m, 1H), 2.27 (s, 3H), 2.12 (s, 3H), 2.04 (s, 6H), 1.3-1.6 (m, 4H), 0.93 (t, 6H) ppm.

#### Example 88

(1-Ethyl-propyl)-[6-methyl-3-nitro-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine

To a mixture of (2-chloro-6-methyl-3-nitro-pyridin-4-yl)-(1-ethyl-propyl)-amine (80 mg, 0.31 mmol) and 2,4,6-trimethylphenol (43 mg, 0.31 mmol) in 2ml of dry THF was added potassium tert-butoxide (35 mg, 0.31 mmol) and the resulting mixture was stirred at rt overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give a yellow solid. The solid was purified through silica gel column chromatography using 6:4 ratio of chloroform:hexane as eluent to give 91 mg (83%) of the title compound as yellow solid, mp 160-162°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.62 (d, 1H), 6.87 (s, 2H), 6.18 (s, 1H), 3.40 (m, 1H), 2.30 (s, 3H), 2.15 (s, 3H), 2.10 (s, 6H), 1.5-1.8 (m, 4H), 0.99 (t, 6H) ppm.

#### Example 89

N4-(1-Ethyl-propyl)-6-methyl-3-nitro-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine

A mixture of (2-chloro-6-methyl-3-nitro-pyridin-4-yl)-(1-ethyl-propyl)-amine (250 mg, 0.97 mmol) and 2,4,6-trimethylaniline (262 mg, 1.94 mmol) in 4 ml of dry DMSO was heated at 130°C overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give a yellow oil. The oil was purified through silica gel column chromatography to give 150 mg (43%) of the title compound as yellow solid, mp 104-107°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.36 (s, 1H), 9.24 (d, 1H), 6.93 (s, 2H), 5.86 (s, 1H), 3.45 (m, 1H), 2.32 (s, 3H), 2.18 (s, 6H), 2.13 (s, 3H), 1.55-1.80 (m, 4H), 0.99 (t, 6H) ppm.

Example 90

N4-(1-Ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine

A mixture of (1-ethyl-propyl)-[6-methyl-3-nitro-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine (40 mg, 0.112 mmol) and 4 mg of 10% Pd /C in 10 ml of ethanol was hydrogenated at 50 psi overnight. The mixture was filtered through Celite™ and the filtrate was concentrated to dryness to give a light brown crystals which were purified through silica gel column chromatography using 1:1 chloroform:hexane as eluent to give the title compound as golden crystals (36 mg, 97%), mp 105-107°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 6.11 (s, 1H), 4.00 (brs, 1H), 3.28 (m, 1H), 3.10 (brs, 2H), 2.31 (s, 3H), 2.16 (s, 3H), 2.10 (s, 6H), 1.45-1.75 (m, 4H), 0.98 (t, 6H) ppm. The corresponding HCl salt was prepared as white solid, mp 174-178°C, <sup>1</sup>H NMR(D<sub>2</sub>O) δ 7.09 (s, 2H), 6.63 (s, 1H), 3.65 (m, 1H), 2.31 (s, 3H), 2.25 (s, 3H), 2.11 (s, 6H), 1.45-1.80 (m, 4H), 0.91 (t, 6H) ppm.

Example 91

[2-(4-Chloro-2,6-dimethyl-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-ethyl-propyl)-amine

To a mixture of (2-chloro-6-methyl-3-nitro-pyridin-4-yl)-(1-ethyl-propyl)-amine (850 mg, 3.30mmol) and 4-chloro-2,6-dimethylphenol (516 mg, 3.30 mmol) in 25ml of dry THF was added potassium tert-butoxide (370 mg, 3.30 mmol) and the resulting mixture was stirred at room temperature overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give a yellow solid (1.31 g). The solid was purified through silica gel column chromatography using 6:4 ratio of chloroform:hexane as eluent to give 1.10 g (88%) of the title compound as yellow solid, mp 152-154°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.65 (d, 1H), 7.05 (s, 2H), 6.21 (s, 1H), 3.41 (m, 1H), 2.15 (s, 3H), 2.11 (s, 6H), 1.5-1.8 (m, 4H), 0.99 (t, 6H) ppm.

Example 92

2-(2,6-Dimethyl-phenoxy)-N4-(1-ethyl-propyl)-6-methyl-pyridine-3,4-diamine

A mixture of (1-ethyl-propyl)-[6-methyl-3-nitro-2-(4-chloro-2,6-dimethyl-phenoxy)-pyridin-4-yl]-amine (800 mg, 2.12 mmol) and 160 mg of 10% Pd /C in 150 ml of ethanol was hydrogenated at 50 psi overnight. The mixture was filtered through Celite™ and the filtrate was concentrated to dryness to give a purple glass form (810 mg) which was purified through silica gel column chromatography using 1:1 chloroform:hexane as eluent to give the title compound as tan

crystals (360 mg), mp 98-100°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.05 (m, 3H), 6.11 (s, 1H), 4.00 (brs, 1H), 3.28 (m, 1H), 3.09 (brs, 2H), 2.14 (s, 9H), 1.45-1.75 (m, 4H), 0.98 (t, 6H) ppm. The corresponding HCl salt was prepared as white solid, mp 158-162°C, <sup>1</sup>H NMR(D<sub>2</sub>O) δ 7.27 (s, 3H), 6.67 (s, 1H), 3.65 (m, 1H), 2.27 (s, 3H), 2.16 (s, 6H), 1.45-1.80 (m, 4H), 0.93 (t, 6H) ppm.

5 Example 93

N4-(1-Ethyl-propyl)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine

A mixture of N4-(1-ethyl-propyl)-6-methyl-3-nitro-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine (40 mg, 0.112 mmol) and 8 mg of 10% palladium/carbon (Pd/C) in 20 ml of ethanol was hydrogenated at 50 psi overnight. The mixture was filtered through celite and the filtrate was concentrated to dryness to give a dark residue (40 mg). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 5.97 (s, 1H), 4.32 (d, 1H), 3.28 (m, 1H), 2.27 (s, 3H), 2.26 (s, 3H), 2.18 (s, 6H), 1.45-1.75 (m, 4H), 0.93 (t, 6H) ppm. The corresponding di-HCl salt was prepared as a tan solid, mp 213-216°C, <sup>1</sup>H NMR(DMSO-d<sub>6</sub>) δ 11.1 (s, 1H), 8.48 (s, 1H), 6.98 (s, 2H), 6.73 (brs, 1H), 6.38 (s, 1H), 3.36 (m, 1H), 2.28 (s, 3H), 2.19 (s, 3H), 2.08 (s, 6H), 1.54 (m, 4H), 0.88 (t, 6H) ppm.

15 Example 94

2-(4-Chloro-2,6-dimethyl-phenoxy)-N4-(1-ethyl-propyl)-6-methyl-pyridine-3,4-diamine

A mixture of (1-ethyl-propyl)-[6-methyl-3-nitro-2-(4-chloro-2,6-dimethyl-phenoxy)-pyridin-4-yl]-amine (100 mg, 0.265 mmol) and iron (73 mg, 1.33 mmol) in 12 ml of AcOH/H<sub>2</sub>O (1:1) was heated at 60°C for 3 hours. The mixture was concentrated to dryness. The residue was diluted with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give the title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.04 (s, 2H), 6.12 (s, 1H), 3.60 (brs, 2H), 3.28 (m, 1H), 2.14 (s, 3H), 2.10 (s, 6H), 1.45-1.80 (m, 4H), 0.97 (t, 6H) ppm.

Example 95

N-(1-Ethyl-propyl)-2-methyl-5-nitro-N'-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,6-diamine

25 To a cooled solution of (6-chloro-2-methyl-5-nitro-pyrimidin-4-yl)-(2,4,6-trimethyl-pyridin-3-yl)-amine (88 mg, 0.29 mmol) in 1 ml of dry THF was added 1-ethyl-propyl-amine (80 mg, 0.92 mmol) at -78°C. The mixture was stirred at that temperature for 3 hrs, then warmed to -10°C for 1 hour. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give the title compound (88 mg, 86%) as an orange solid, mp 151-152°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.16 (d, 1H), 6.92 (s, 1H), 4.35 (m, 1H), 2.50 (s, 3H), 2.39 (s, 3H), 2.18 (s, 3H), 2.16 (s, 3H), 1.5-1.80 (m, 4H), 0.94 (t, 6H) ppm.

Example 96

(1-Ethyl-propyl)-[2-methyl-5-nitro-6-(2,4,6-trimethyl-pyridin-3-yloxy)-pyrimidin-4-yl]-amine

35 A solution of 3-hydroxy-2,4,6-trimethylpyridine (41 mg, 0.3 mmol) in 1 ml of dry THF was treated with 60% sodium hydride in oil (13 mg, 0.3 mmol) at rt. The reaction mixture was cooled to -78°C and a solution of (6-chloro-2-methyl-5-nitro-pyrimidin-4-yl)-(1-ethyl-propyl)-amine (78 mg, 0.3 mmol) in 1 ml of dry THF was added. The reaction was stirred at -78°C for 1 hour, quenched

with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 91 mg (84%) of white solid of the title compound, mp 134-135°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.30 (d, 1H), 6.89 (s, 2H), 4.30 (m, 1H), 2.31 (s, 3H), 2.26 (s, 3H), 2.10 (s, 6H), 1.5-1.8 (m, 4H), 0.97 (t, 6H) ppm.

5      Example 97

2-(4-Chloro-2,6-dimethyl-phenoxy)-N4-(1-ethyl-propyl)-6-methyl-pyridine-3,4-diamine

A mixture of [2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-ethyl-propyl)-amine (810 mg, 2.14 mmol) and iron (Fe) (594 mg, 10.72 mmol) in 96 ml of 1:1 of AcOH:H<sub>2</sub>O was heated at reflux for 2 hours. Additional Fe (600 mg) was added. The mixture was heated for an additional 1.5 hours. The reaction mixture was concentrated to dryness. The residue was quenched with water, basified to pH 9.0 and filtered through celite. The filtrate was extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give the title compound as a yellow oil. The oil was purified through silica gel column chromatography using chloroform as eluent to give 570 mg of 2-(4-chloro-2,6-dimethyl-phenoxy)-N4-(1-ethyl-propyl)-6-methyl-pyridine-3,4-diamine as a tan solid, mp 72-74°C. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.04(s,2H), 6.11(s,1H), 4.03(d,1H), 3.30(m,1H), 3.07(s,1H), 2.14(s,3H), 2.10(s,6H), 1.4-1.75(m,4H), 0.97(t,6H)ppm. The corresponding di-HCl salt was prepared as a white solid, mp 208-210°C.

Example 98

20      N-[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-acetamide

A mixture of 2-(2,4,6-trimethyl-phenoxy)-N4-(1-ethyl-propyl)-6-methyl-pyridine-3,4-diamine (250 mg, 0.763 mmol), acetic anhydride (72 mg, 0.763 mmol) and triethylamine (77 mg, 0.763 mmol) in 5 ml of methylene chloride was stirred at room temperature for 3 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness to give 310 mg of the crude material. The crude material was purified through silica gel column chromatography using 2% methanol in chloroform as eluent to give 250 mg (89% yield) of N-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-acetamide as tan solid, mp 154-156°C. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.97(0.64H), 6.86(s,2H), 6.26(0.36H), 6.14(o.64H), 6.12(s,0.36H), 4.80(d,0.64H), 4.40(d,0.36H), 3.2-3.4(m,1H), 2.29(s,3H), 2.26(s,1.9H), 2.17(s,1.1H), 2.16(s,1.9H), 2.06(s,6H), 1.99(s,1.1H), 1.4-1.75(m,4H), 0.97(t,6H)ppm.

Example 99

N-[2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-acetamide

35      The title compound (35 mg) was isolated as a side product from the reduction experiment described in the Example 97. Compound can be prepared by standard acylation method by reacting 2-(4-chloro-2,6-dimethyl-phenoxy)-N4-(1-ethyl-propyl)-6-methyl-pyridine-3,4-diamine with

acetic anhydride and triethylamine in methylene chloride. A tan solid was prepared, mp 161-164°C.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.04(s,2H), 6.88(s,0.6H), 6.26(s,0.4H), 6.15(s,1H), 4.75(d,0.6H), 4.40(d,0.4H), 3.30(m,1H), 2.27(s,1.8H), 2.15(s,3H), 2.06(s,6H), 1.98(s,1.2H), 1.4-1.8(m,4H), 0.97(t,6H)ppm.

5      Example 100

1-Ethyl-3-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-urea

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.85(s,2H), 6.11(s,1H), 5.38(s,1H), 4.68(s,1H), 4.65(m,1H), 3.2-3.4(m,3H), 2.28(s,3H), 2.16(s,3H), 2.08(s,6H), 1.4-1.7(m,4H), 1.10(t,3H), 0.93(t,6H)ppm.

Example 101

10      N-[4-(1-Ethyl-propyl)-2-methyl-N''-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,5,6-triamine

The title compound was prepared by hydrogenation of N-(1-ethyl-propyl)-2-methyl-5-nitro-N''-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,6-diamine by the method analogous to that described in Example 93.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.9(s,1H), 6.25(brs,1H), 4.7(d,1H), 4.08(m,1H), 2.5(s,3H), 2.45(s,3H), 2.30(s,3H), 2.20(s,3H), 1.45-1.7(m,4H), 0.98(t,6H) ppm.

15      Example 102

N4-(1-Ethyl-propyl)-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine-4,5-diamine

The title compound was prepared by hydrogenation of (1-ethyl-propyl)-[2-methyl-5-nitro-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-4-yl]-amine by the method analogous to that described in Example 93.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.88(s,2H), 4.52(d,1H), 4.10(m,1H), 2.94(brs,2H), 2.30(s,3H), 2.23(s,3H), 2.09(s,6H), 1.4-1.8(m,4H), 0.95(t,6H) ppm. The corresponding HCl salt, mp 248-250°C.  $^1\text{H}$  NMR( $\text{CD}_3\text{OD}$ )  $\delta$  6.91(s,2H), 4.00(m,1H), 2.39(s,3H), 2.28(s,3H), 2.07(s,6H), 1.6-1.8(m,4H), 1.00(t,6H) ppm.

Example 103

[6-(1-Ethyl-propoxy)-2-methyl-5-nitro-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-amine

25      A mixture of 3-pentanol (0.5 ml) and 60% sodium hydride (NaH) in oil (89 mg, 2.22 mmol) in 2 ml of dry THF was stirred for 2 min, then treated with a solution of 6-(chloro-2-methyl-5-nitropyrimidin-4-yl)-(2,4,6-trimethylphenyl)-amine (350 mg, 1.14 mmol) in 3 ml of dry THF at -78°C and stirred at that temperature for 1 hour, then stirred at room temperature overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give the crude material which was purified through silica gel column chromatography using 2:1 of hexane/ $\text{CHCl}_3$  as eluent to give 331 mg (85%) of the title compound as a yellow solid, mp 112-113°C.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  9.48(brs,1H), 6.49(s,2H), 5.37(m,1H), 2.33(s,3H), 2.29(s,3H), 2.18(s,6H), 1.7-1.9(m,4H), 0.99(t,6H) ppm.

Example 104

35      N-(1-Ethyl-propyl)-2-methyl-5-nitro-N'-(2,4,6-trimethyl-phenyl)-pyrimidine-4,6-diamine

The title compound was prepared by the method analogous to that described in Example 5 using 1-ethylpropylamine.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  10.48(s,1H), 9.25(d,1H), 6.94(s,2H), 4.37(m,1H), 2.32(s,3H), 2.21(s,3H), 2.18(s,6H), 1.5-1.8(m,4H), 0.97(t,6H) ppm.

Example 105

5 6-(1-Ethyl-propoxy)-2-methyl-N4-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5-diamine

The title compound was prepared by the method analogous to that described in Example 93 starting from [6-(1-ethyl-propoxy)-2-methyl-5-nitro-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-amine.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.92(s,2H), 5.96(s,1H), 5.12(m,1H), 2.85(brs,1H), 2.31(s,3H), 2.30(s,3H), 2.19(s,6H), 1.70(m,4H), 0.94(t,6H) ppm.

10 Example 106

6-(1-Ethyl-propoxy)-2-methyl-5-nitro-pyrimidin-4-yl]-(2,4,6-trimethyl-pyridin-3-yl)-amine

The title compound was prepared by the method analogous to that described in Example 103 starting from (6-chloro-2-methyl-5-nitropyrimidin-4-yl)-(2,4,6-trimethyl-pyridin-3-yl)-amine and sodium 3-pentanoate.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  9.45(s,1H), 6.95(s,1H), 5.35(m,1H), 2.53(s,3H), 2.41(s,3H), 2.29(s,3H), 2.18(s,3H), 1.7-1.9(m,4H), 0.98(t,6H) ppm.

Example 107

N-(1-Ethyl-propyl)-2-methyl-N''-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5,6-triamine

The title compound was prepared by the method analogous to that described in Example 93 starting from N-(1-ethyl-propyl)-2-methyl-5-nitro-N'-(2,4,6-trimethyl-phenyl)-pyrimidine-4,6-diamine.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.90(s,2H), 6.10(s,1H), 4.78(d,1H), 4.03(m,1H), 2.31(s,3H), 2.29(s,3H), 2.20(s,6H), 1.4-1.6(m,4H), 0.91(t,6H) ppm.

Example 108

6-(1-Ethyl-propoxy)-2-methyl-9-(2,4,6-trimethyl-phenyl)-7,9-dihydro-purin-8-one

A mixture of 6-(1-ethyl-propoxy)-2-methyl-N4-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5-diamine (182 mg, 0.554 mmol), triethylamine (39 mg, 0.388 mmol) and triphosgene (58 mg, 0.196 mmol) in 6 ml of dry THF was stirred at room temperature for 30 min. The mixture was quenched with water and extracted with chloroform. The organic layer was dried and concentrated to give 177 mg (90%) of the title compound as a white solid, mp 159-160°C.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  8.50(s,1H), 6.99(s,2H), 5.30(m,1H), 2.47(s,3H), 2.32(s,3H), 2.08(s,6H), 1.73(m,4H), 0.94(t,6H) ppm.

Example 109

6-(1-Ethyl-propoxy)-2-methyl-N4-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,5-diamine

The title compound was prepared by the method analogous to that described in Example 93 starting from 6-(1-ethyl-propoxy)-2-methyl-5-nitro-pyrimidin-4-yl]-(2,4,6-trimethyl-pyridin-3-yl)-amine.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.89(s,1H), 5.97(s,1H), 5.29(m,1H), 2.90(brs,1H), 2.48(s,3H), 2.41(s,3H), 2.26(s,3H), 2.17(s,3H), 1.68(m,4H), 0.93(t,6H) ppm.

Example 110

6-(1-Ethyl-propylamino)-2-methyl-9-(2,4,6-trimethyl-phenyl)-7,9-dihydro-purin-8-one

The title compound was prepared by the method analogous to that described in Example 108 starting from N-(1-ethyl-propyl)-2-methyl-N'-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5,6-triamine. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.59(s,2H), 5.28(d,1H), 3.92(m,1H), 2.40(s,3H), 2.32(s,3H), 2.08(s,6H), 1.25-1.45(m,4H), 0.80(t,6H)ppm.

Example 111

N4-(1-Ethyl-propyl)-6,N3,N3-trimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine  
and N4-(1-Ethyl-propyl)-6,N3-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine

To a solution of N4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine (0.250 g, 0.763 mmol) in dry THF (6 ml) was treated with 1M LiN(SiMe<sub>3</sub>)<sub>2</sub> in THF (1.0 ml, 1.0 mmol) at -78°C and stirred for 10 min. an excess of methyl iodide was added and the resulting mixture was stirred at room temperature overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give a crude material. The crude material was purified through silica gel column chromatography using 5% ethyl acetate in hexane as eluent to give N4-(1-ethyl-propyl)-6,N3,N3-trimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine and N4-(1-ethyl-propyl)-6,N3-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine.

N4-(1-Ethyl-propyl)-6,N3,N3-trimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine :

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.88(s,2H), 6.02(s,1H), 5.55(d,1H), 3.21(m,1H), 2.79(s,6H), 2.30(s,3H), 2.10(s,3H), 2.09(s,6H), 1.4-1.75(m,4H), 0.95(t,6H) ppm.

N4-(1-Ethyl-propyl)-6,N3-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine :

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.89(s,2H), 6.10(s,1H), 4.84(d,1H), 3.30(m,1H), 2.98(s,1H), 2.72(s,3H), 2.32(s,3H), 2.16(s,3H), 2.12(s,6H), 1.45-1.70(m,4H), 0.99(t,6H) ppm.

Example 112

N4-(1-Ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyrimidine-3-chloro-4-amine

The title compound was prepared by the method analogous to those of Examples 33-39 starting from 3,4-dichloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyrimidine and 1-ethyl-propylamine. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,2H), 4.97(d,1H), 4.12(m,1H), 2.30(s,3H), 2.25(s,3H), 2.10(s,6H), 1.4-1.8(m,4H), 0.96(t,6H) ppm.

Example 113

Butyl-{2,8-dimethyl-9-(2,4,6-trimethyl-phenyl)-9H-purin-6-yl}-ethyl-amine

A mixture of N-butyl-N-ethyl-2-methyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,

5,6-triamine (105 mg, 0.63 mmol) and triethyl orthoacetate (0.204 g, 1.25 mmol) and 10 mg of p-TsOH in toluene was heated reflux overnight. The mixture was concentrated to dryness and the residue was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give yellow oil. The oil was purified through silica gel column chromatography using 1:1 of hexane:chloroform as eluent to give the title compound. <sup>1</sup>H



NMR(CDCl<sub>3</sub>) δ 7.01(s,2H), 3.9-4.1(m,4H), 2.45(s,3H), 2.35(s,3H), 2.20(s,3H), 1.91(s,6H), 1.6-1.8(m,2H), 1.35-1.5(m,2H), 1.29(t,3H), 0.99(t,3H) ppm.

Example 114

The compounds below were prepared by reacting of (2-chloro-6-methyl-3-nitro-pyridin-4-yl)-(alkyl- or dialkyl)-amine with substituted phenol by a method analogous to the following:  
To a mixture of (2-chloro-6-methyl-3-nitro-pyridin-4-yl)-(alkyl- or dialkyl)-amine (1 mmol) and 2,4,6-trimethylphenol (1 mmol) in dry THF was added potassium tert-butoxide (1 mmol) and the resulting mixture was stirred at room temperature until all starting material was consumed. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give the title compound after purification through silica gel column chromatography:

2-[2-(4-Chloro-2,6-dimethyl-phenoxy)-6-methyl-3-nitro-pyridin-4-(S)-ylamino]-butan-1-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.69(1H), 6.289s,1H), 3.65-3.80(m,2H), 3.60m,1H), 2.12(s,3H), 2.08(s,6H), 1.8(1H), 1.5-1.8(m,2H), 1.01(t,3H) ppm.

(1-Methoxymethyl-propyl)-[6-methyl-3-nitro-2-(4-trifluoromethoxy-phenoxy)-pyridin-4-yl]-amine

yellow solid, mp. 75-76 °C, Anal. For C<sub>18</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub>F<sub>3</sub>, calc. C52.05; H, 4.85; N, 10.12; found, C, 52.14; H, 5.04; N, 10.13

2-(2-Amino-4,6-dichloro-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.55(d,1H), 7.23(d,1H), 7.00(d,1H), 6.05(s,1H), 3.69(m,1H), 3.49(m,2H), 3.38(s,3H), 2.35(s,3H), 1.78(m,1H), 1.65(m,1H), 0.99(t,3H) ppm.

3-Methoxy-2-[4-(1-methoxymethyl-propylamino)-6-methyl-3-nitro-pyridin-2-yloxy]-benzaldehyde

yellow solid, mp. 126.5-130.5°C, Anal. For C<sub>19</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>, calc. C58.60; H, 5.95; N, 10.79; found, C, 58.45; H, 6.11; N, 10.32

[2-(2,6-Dibromo-4-trifluoromethoxy-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

yellow solid, <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.00(d,1H), 7.49(2H), 6.35(s,1H), 3.64(m,1H), 3.53(m,2H), 3.43(s,3H), 2.20(s,3H), 1.6-1.9(m,4H), 1.04(t,3H)ppm.

[2-(2-Bromo-4-chloro-6-methoxy-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

yellow solid, mp. 111.8-113.6°C, Anal. For C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>BrCl, calc, C, 45.54; H, 4.46; N, 8.85; found, C, 45.94; H, 4.32; N, 8.68

[2-(2,4-Dichloro-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.83(d,1H), 7.46(d,1H), 7.30(dd,1H), 7.15(dd,1H), 6.33(s,1H), 3.65(m,1H), 3.51(m,2H), 3.42(s,3H), 2.21(s,3H), 1.82(m,1H), 1.66(m,1H), 1.03(t,3H) ppm.

5 [2-(2-Bromo-6-chloro-4-methoxy-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.88(d,1H), 7.04(d,1H), 6.93(d,1H), 6.27(s,1H), 3.79(s,3H), 3.60(m,1H), 3.4-3.5(m,2H), 3.38(s,3H), 2.15(s,3H), 1.78(m,1H), 1.64(m,1H), 0.99(t,3H)

10 (1-Methoxymethyl-propyl)-[6-methyl-3-nitro-2-(2,4,6-trimethoxy-phenoxy)-pyridin-4-yl]-amine

mp. 126.8-129.5°C; Anal. For C<sub>20</sub>H<sub>27</sub>N<sub>3</sub>O<sub>7</sub> calc. C, 57.00; H, 6.46; N, 9.97; found C, 56.94; H, 6.85; N, 9.66.

Example 115

15 2-Chloro-N-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-acetamide

To a solution of N-4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine (250 mg, 0.763 mmol) in dry THF was added chloroacetyl chloride (86 mg, 0.763 mmol) and triethylamine (77 mg, 0.763 mmol) at 0°C. The resulting mixture was warmed to room temperature and stirred for 1 hr. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give the title compound as a solid. The solid was purified through silica gel column chromatography to give 280 mg(91%) of tan crystals, mp. 152-154°C.

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.07(brs,1H), 6.88(s,2H), 6.16(s,1H), 4.75(m,1H), 4.25(s,2H), 3.33(m,1H), 2.30(s,3H), 2.18(s,3H), 2.08(s,6H), 1.4-1.75(m,4H), 0.97(t,6H) ppm.

25 The following compounds were prepared by an analogous method to that in the preceding paragraph:

3-Chloro-N-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-propionamide

30 tan solid, mp. 183-185°C. Anal. For C<sub>23</sub>H<sub>32</sub>ClN<sub>3</sub>O<sub>2</sub> calc. C, 66.09; H, 7.72; N, 10.05; found, C, 66.27; H, 7.87; N, 9.99.

2-Chloro-N-[4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-propionamide

mp. 170-172°C, Anal. For C<sub>23</sub>H<sub>32</sub>ClN<sub>3</sub>O<sub>2</sub> calc. C, 66.09; H, 7.72; N, 10.05; found C, 66.20; H, 7.52; N, 10.09.

35 Example 116

N3-Allyl-N4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine

To a solution of N-4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine (500 mg, 1.52 mmol) in dry THF was added 1M in THF of lithium bis(trimethylsilyl)amide (1.6 ml, 1.6 mmol) at -78°C. After stirring at -78°C for 10 min, allyl bromide (0.13 ml, 1.52 mmol) was added and the resulting mixture was stirred at that temperature for 20 min, then warmed to room temperature overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give the title compound as a green-blue oil. The oil was purified through silica gel column chromatography using 5%ethyl acetate in hexane as eluent to give a yellow crystal, mp. 86-88°C.

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,2H), 6.0(m,2H), 5.2-5.35(m,2H), 4.8(d,1H), 3.54(d,2H), 3.3(m,1H), 3.05(s,1H), 2.30(s,3H), 2.14(s,3H), 2.09(s,6H), 1.4-1.6(m,4H), 0.96(t,6H) ppm.

The following compounds were prepared by an analogous method:

N3-(3-Chloro-propyl)-N4-(1-ethyl-propyl)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.85(s,2H), 6.05(s,1H), 4.9(d,1H), 3.8(m,2H), 3.3(m,1H), 3.1(m,2H), 2.3(s,3H), 2.159s,3H), 2.04(s,6H), 1.79m,2H), 1.5(m,2H), 1.0(m,6H) ppm.

N4-(1-Ethyl-propyl)-6-methyl-N3-propa-1,2-dienyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3,4-diamine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.93(d,1H), 6.86(s,2H), 6.66(m,1H), 6.09(s,1H), 5.4-5.6(m,2H), 5.54(d,1H), 3.27(m,1H), 2.27(s,3H), 2.12(s,3H), 2.05(s,6H), 1.6(m,4H), 0.94(t,6H) ppm.

Example 117

2-[3-Amino-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol

A mixture of 2-[2-(4-Chloro-2,6-dimethyl-phenoxy)-6-methyl-3-nitro-pyridin-4-(S)-ylamino]-butan-1-ol (120 mg) and Fe (73 mg) in 12 ml of 1:1 of AcOH:H<sub>2</sub>O was heated at reflux for 2 hr. The reaction mixture was concentrated to dryness. The residue was quenched with water, basified to pH 12 and filtered through celite. The filtrate was extracted with chloroform. The organic layer was washed with brine, dried and concentrated to give the title compound as a yellow solid. The solid was purified through silica gel column chromatography using 1:1 EtOAc:hexane as eluent to give the title compound as a white solid, mp. 161-162°C.

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.03(s,2H), 6.15(s,1H), 3.75(m,2H), 3.47(m,1H), 2.25(brs,3H), 2.08(s,6H), 1.5-1.8(m,2H), 0.98t,3H) ppm

Example 118

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid methyl ester

A mixture of 4-chloro-6-methyl-2-(4-Chloro-2,6-dimethyl-phenoxy)-nicotinic acid methyl ester (77mg, 0.226 mmol) and 1-ethyl-propyl-amine in DMSO was heated at 120°C for 4 hr. The mixture was quenched with sat. ammonium chloride, water, brine and extracted with ethyl acetate. The organic layer was dried and concentrated to give 140 mg of yellow solid.

5 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.10(d,1H), 7.03(s,2H), 6.09(s,1H), 3.88(s,3H), 3.35(m,1H), 2.10(s,3H), 2.08(s,6H), 1.5-1.7(m,4H), 0.96(t,6H) ppm.

Example 119

2-(4-Bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid methyl ester

10 A mixture of 4-chloro-6-methyl-2-(4-bromo-2,6-dimethyl-phenoxy)-nicotinic acid methyl ester and 1-ethyl-propyl-amine in DMSO was heated at 120°C for 16 hr. The mixture was quenched with water, brine and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness. The residue was purified through silica gel column chromatography using hexane to 3% ethyl acetate in hexane as eluent to give the title compound as a white

15 solid. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.1(d,1H), 7.18(s,2H), 6.08(s,1H), 3.87(s,3H), 3.35(m,1H), 2.10(s,3H), 2.08(s,6H), 1.4-1.7(m,4H), 0.96(t,6H) ppm.

Example 120

4-(1-Ethyl-prop-2-ynylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

20 A mixture of 4-chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester and 1-ethyl-propyl-amine in DMSO was heated at 130°C overnight. The mixture was quenched with water, brine and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness. The residue was purified through silica gel column chromatography to give the title compound. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.26(d,1H), 6.87(s,2H), 6.26(s,1H), 4.11(m,1H),

25 3.87(s,3H), 2.324(m,1H), 2.30(s,3H), 2.17s,3H), 2.08(s,6H), 1.92(q,2H), 1.16(t,3H) ppm.

Example 121

4-(s)-(1-Hydroxymethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

30 A mixture of 4-chloro-2-(2,4,6-trimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester (500 mg, 1.56 mmol) and (S)-2-amino-1-butanol (696 mg, 7.82 mmol) in DMSO was heated in 130°C oil bath for 24hr. The mixture cooled to rt and quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give 610 mg of crude product as an oil. The oil was purified through silica gel column chromatography using 30% ethyl acetate in

35 hexane as eluent to give the title compound. Anal. calc. for C<sub>21</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>. 1/2H<sub>2</sub>O: C, 66.11; H, 7.66; N, 7.34; found: C, 66.27; H, 7.60; N, 7.21.

Example 122

EXPRESS MAIL NO. EL162815459US

4-(1-Ethyl-2-hydroxy-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

A mixture of 4-chloro-2-(2,4,6-trimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester (250 mg, 0.78 mmol) and 3-amino-pentan-2-ol (320 mg, 3.13 mmol) in DMSO was heated in 130°C oil bath for 24hr. The mixture cooled to rt and quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give 280mg of crude product as an oil. The oil was purified through silica gel column chromatography using 20% ethyl acetate in hexane as eluent to give the title compound as a yellow solid, mp 116-120°C.

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.17(m,1H), 6.87(s,2H), 6.21&6.14(two s, 1H), 3.88(s,3H), 3.8-4.0(m,2H), 3.5(m,1H), 3.3(m,1H), 2.30(s,3H), 2.12(s,3H), 2.09(s,6H), 1.8(d,1H), 1.5-1.8(m,2H), 1.26(d,3H), 0.99(t,3H) ppm.

Example 123

2-(4-Bromo-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester

A mixture of 4-chloro-2-(4-bromo-2,6-trimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester (850 mg) and (S)-2-amino-1-butanol in DMSO was heated in 130°C oil bath for 24hr. The mixture cooled to rt and quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give 764mg of crude product as an oil. The oil was purified through silica gel column chromatography to give the title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.15(d,1H), 7.16(s,2H), 6.18(s,1H), 3.86(s,3H), 3.72(m,1H), 3.70(m,1H), 3.54(m,1H), 2.10(s,3H), 2.06(s,6H), 1.5-1.8(m,2H), 1.00(t,3H) ppm.

Example 124

2-(4-Bromo-2,6-dimethyl-phenoxy)-4-(S)-(1-methoxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester

A mixture of 4-chloro-2-(4-bromo-2,6-trimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester and 1-methoxymethyl-propylamine in DMSO was heated in 130°C oil bath for 24hr. The mixture cooled to rt and quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give crude product. The crude compound was purified through silica gel column chromatography to give the title compound.

Example 125

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester

A mixture of 4-chloro-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester (9.000g, 26.45 mmol) and (S)-2-amino-1-butanol (12.7ml) in 1-methyl-2-pyrrolidinone

was heated at 130°C for 2 hr, then at 100°C overnight. The mixture cooled to rt and poured into ice-water and diluted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give 13.6g of crude product as a light yellow oil. The oil was purified through silica gel column chromatography using chloroform to 2%MeOH in chloroform as eluent to give 6.6839 g (64%) of the title compound as a white glass foam. The glass foam was triturated with hexane to give a white solid. The solid was recrystallized from di-iso-propyl ether to give a white crystals, mp 122.5-124°C. Anal. calc. for  $C_{20}H_{25}ClN_2O_4$ : C, 61.14; H, 6.41; N, 7.13; found: C, 60.98; H, 6.43; N, 6.95.

Example 126

2-(4-Chloro-2-methoxy-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester

A mixture of 4-chloro-2-(4-Chloro-2-methoxy-phenoxy)-6-methyl-nicotinic acid methyl ester and (S)-2-amino-1-butanol in 1-methyl-2-pyrrolidinone was heated at 130°C overnight. The mixture cooled to room temperature and poured into ice-water and diluted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified through silica gel column chromatography to give the title compound as a solid mp. 92.8-93.8°C, Anal. For  $C_{19}H_{23}N_2O_5Cl$  calc. C, 57.80; H, 5.87; 7.09; found, C, 57.70; H, 5.89; , 7.02.

Example 127

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-hydroxy-propylamino)-6-methyl-nicotinic acid methyl ester

A mixture of 4-chloro-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester (500 mg, 1.47 mmol) and 3-amino-pentan-2-ol (758mg, 7.35 mmol) in 1-methyl-2-pyrrolidinone was heated in 130°C oil bath for 24hr. The mixture cooled to rt and quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give an oil. The oil was purified through silica gel column chromatography using 20% ethyl acetate in hexane as eluent to give the title compound as a white crystal, mp 133-135°C.

$^1H$  NMR( $CDCl_3$ )  $\delta$  8.19(m,1H), 7.00(s,2H), 6.20&6.14(two sets of s,1H), 3.8-3.9(m,1H), 3.86(s,3H), 3.3&3.5(two sets of m,1H), 2.07(s,3H), 2.06(s,6H), 1.75(m,1H), 1.55(m,1H), 1.24(d,3H), 0.96(t,3H)ppm.

Example 128

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-methoxy-propylamino)-6-methyl-nicotinic acid methyl ester

To a solution of 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-hydroxy-propylamino)-

6-methyl-nicotinic acid methyl ester (50 mg, 0.123 mmol) in dry THF was added NaH and stirred for 20 min. An excess of MeI was added and the resulting mixture was stirred at rt overnight. The mixture cooled to rt and quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give an oil. The oil was purified through silica gel column chromatography using 20% ethyl acetate in hexane as an eluent to give the title compound as a clear oil. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.20(d,1H), 7.00(s,2H), 6.14&6.10(two sets of s,1H), 3.859s,3H), 3.47(m,1H), 3.39&3.37(two sets of s,3H), 2.08(s,3H), 2.06(s,6H), 1.75(m,1H), 1.58(m,1H), 1.14(t,3H), 0.95(t,3H)ppm.

Example 129

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-oxo-propylamino)-6-methyl-nicotinic acid methyl ester

The title compound was prepared by Dess-Martin oxidation of 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-hydroxy-propylamino)-6-methyl-nicotinic acid methyl ester. A white solid was obtained after silica gel column chromatography. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.6(d,1H), 7.01(s,2H), 5.899s,1H), 3.9-4.0(m,1H), 3.90(s,3H), 2.17(s,3H), 2.07(s,3H), 2.05(s,3H), 1.859m,1H), 1.93(m,1H), 1.00(t,3H) ppm.

Example 130

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-formyl-propylamino)-6-methyl-nicotinic acid methyl ester

The title compound was prepared by Dess-Martin oxidation of 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester. The title compound was obtained after column chromatography. <sup>1</sup>H NMR (CDCl<sub>3</sub>) 9.54(d,1H), 8.56(d,1H), 7.01(s,2H), 5.93(s,1H), 3.92(m,1H), 3.89(s,3H), 2.08(s,3H), 2.05(s,6H), 1.05(t,3H) ppm.

Example 131

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S)-(4-ethyl-2-oxo-oxazolidin-3-yl)-6-methyl-nicotinic acid methyl ester

A mixture of 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester (106 mg, 0.27 mmol), triphosgene (27 mg, 0.090 mmol), triethylamine (27 mg, 0.27 mmol) in dry THF was stirred at room temperature for 2 hr. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give 13.6g of crude product as a white glass foam. The foam was triturated with hexane/diethyl ether to give a white solid, mp. 144-145.5°C, Anal. For C<sub>21</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>5</sub> calc.: C, 60.22; H, 5.53; N, 6.69; found: C, 60.10, H, 5.79; N, 6.66.

Example 132

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S)-{1-[(2-hydroxy-ethylamino)-methyl]-propylamino}-6-methyl-nicotinic acid methyl ester

To a solution of 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-formyl-propylamino)-6-methyl-nicotinic acid methyl ester in dichloroethane was added 2-amino-ethanol, sodium cyanoborohydride, acetic acid, anhydrous sodium sulfate. The resulting mixture was heated at reflux and cooled to rt. The mixture was quenched with water and extracted with chloroform. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. After chromatography, the title compound was obtained as a white glass foam. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.3(d,1H), 7.0(s,2H), 6.1(s,1H), 3.9(s,3H), 3.64(m,2H), 3.57(m,1H), 2.90(m,2H), 2.83(m,2H), 2.5(brs,2H), 2.09(s,3H), 2.06(s,6H), 1.65(m,2H), 0.97(t,3H) ppm.

Example 133

4-[Ethyl-(2-hydroxy-ethyl)-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

A mixture of 4-chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester and 1-ethyl-propyl-amine in 1-methyl-2-pyrrolidinone was heated at 130°C until starting material was consumed. The mixture was quenched with water, brine and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness. The residue was purified through silica gel column chromatography to give the title compound. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.85(s,2H), 6.40(s,1H), 3.88(s,3H), 3.73(t,2H), 3.43(t,2H), 3.31(q,2H), 2.27(s,3H), 2.22(s,3H), 2.06(s,6H), 1.15(t,3H) ppm.

Example 134

4-[Ethyl-(2-methanesulfonyloxy-ethyl)-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

A mixture of 4-[ethyl-(2-hydroxy-ethyl)-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester, methanesulfonyl chloride and triethylamine in methylene chloride was stirred at rt until all starting material were consumed. The mixture was quenched with water, brine and extracted with methylene chloride. The organic layer was dried and concentrated to dryness. The residue was purified through silica gel column chromatography to give the title compound. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.83(s,2H), 6.25(s,1H), 4.34(t,2H), 3.86(s,3H), 3.6(t,2H), 3.38(t,2H), 3.09s,3H), 2.25(s,3H), 2.20(s,3H), 2.04(s,6H), 1.18(t,3H) ppm.

Example 135

4-[(2-Hydroxy-ethyl)-thiophen-2-ylmethyl-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

A mixture of 4-chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester and 2-[(thiophen-2-ylmethyl)-amino]-ethanol in 1-methyl-2-pyrrolidinone was heated at 130°C overnight. The mixture was quenched with water, brine and extracted with ethyl acetate. The



organic layer was dried and concentrated to dryness. The residue was purified through silica gel column chromatography to give the title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.22(m,1H), 6.94m,2H), 6.84(s,2H), 6.44(s,1H), 4.52(s,2H), 3.91(s,3H), 3.679t,2H), 3.369t,2H), 2.279s,3H), 2.20(s,3H), 2.07(s,6H) ppm.

5 Example 136

The following compounds were prepared by the method analogous to that in Example 118, starting with an appropriate 4-chloro-6-methyl-2-(substituted-phenoxy)-nicotinic acid alkyl ester with an appropriate alkyl- or dialkyl-amine.

10 4-(2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-ylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester  
<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.71(d,2H), 7.1-7.4(m,5H), 6.82(s,2H), 5.55(s,1H), 5.229s,1H), 4.29(d,1H), 3.97(d,1H), 3.869s,3H), 3.61(d,1H), 2.25(s,3H), 2.01(s,6H), 1.91(s,3H), 1.65(s,3H), 1.61(s,3H) ppm.

15 2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid ethyl ester  
<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.01(d,1H), 7.02(s,2H), 6.17(s,1H), 4.33(q,2H), 3.71(m,1H), 3.66(m,1H), 3.54m,1H), 2.10(s,3H), 2.07(s,6H), 1.5-1.8(m,2H), 1.33(t,3H), 1.00(t,3H) ppm.

20 4-[Ethyl-(2-methoxy-ethyl)-amino]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester  
<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.83(s,2H), 6.19(s,1H), 3.869s,3H), 3.35-3.6(m,4H), 3.35(s,3H), 2.26(s,3H), 2.15(s,3H), 2.06(s,6H), 1.179t,3H) ppm.

25 2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S,R)-&(S,S)-(1-ethyl-2-hydroxy-propylamino)-6-methyl-nicotinic acid methyl ester  
<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.2(d,1H), 7.01(s,2H), 6.20(s, 0.2H), 6.15(s,0.8H), 3.92(m,1H), 3.87(s,3H), 3.48(m,0.2H), 3.31(m,0.8H), 2.08(s,3H), 2.06(s,6H), 1.5-1.8(m,2H), 1.25(d,3H), 0.96(t,3H) ppm.

30 2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(R)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester  
<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.12(d,1H), 7.00(s,2H), 6.16(s,1H), 3.85(s,3H), 3.6-3.8(m,2H), 3.53(m,1H), 2.08(s,3H), 2.05(s,6H), 1.5-1.8(m,2H), 0.98(t,3H) ppm.

35 4-(2-Hydroxy-1-hydroxymethyl-ethylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester  
<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.44(d,1H), 6.84(s,2H), 6.17(s,1H), 3.8-4.0(m,4H), 3.85(s,3H), 3.70(m,1H), 2.60(s,3H), 2.27(s,3H), 2.11(s,2H), 2.05(s,6H) ppm.

4-(2-Methoxy-1-methoxymethyl-ethylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.38(d,1H), 6.88(s,2H), 6.18(s,1H), 3.88(s,3H), 3.78(m,1H), 3.56(m,2H), 3.44(s,6H), 2.31(s,3H), 2.15(s,3H), 2.09(s,6H) ppm.

4-(1-Hydroxymethyl-2-methoxy-ethylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

5 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.44(d,1H), 6.88(s,2H), 6.21(s,1H), 3.89(s,3H), 3.80(m,1H), 3.5-3.7(m,2H), 3.45(s,3H), 2.31(s,3H), 2.16(s,3H), 2.09(s,6H) ppm.

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-hydroxy-butylamino)-6-methyl-nicotinic acid methyl ester

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.34(d,1H), 7.069s,2H), 6.16(s,1H), 3.91(s,3H), 3.70(m,1H), 3.5(m,1H), 2.13(s,3H), 2.11(s,6H), 1.5-1.9(m,4H), 1.01(m,6H) ppm.

Example 137

[2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-methanol

15 A mixture of 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester (130 mg, 0.332 mmol) and an excess of 1M diisobutyl aluminum hydride in THF in dry THF was stirred at -78°C for 10 min, then warmed to rt. The mixture was quenched with methanol and stirred at room temperature for 20 min, filtered through celite and washed with methanol and chloroform. The filtrate was concentrated to dryness. The residue was purified through silica gel column chromatography to give the title compound. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ  
20 7.03(s,2H), 6.11(s,1H), 5.03(d,1H), 4.96(s,2H), 3.32(m,1H), 2.14(s,3H), 2.07(s,6H), 1.4-1.7(m,4H), 0.96(t,6H) ppm.

[2-(4-Bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-methanol

25 The title compound was prepared by the method analogous to that in the preceding paragraph. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.18(s,2H), 6.11(s,1H), 5.05(d,1H), 4.91(d,2H), 3.31(m,1H), 2.14(s,3H), 2.07(s,6H), 1.4-1.7(m,4H), 0.96(t,6H) ppm.

Example 138

2-[3-Hydroxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-(S)-ylamino]-butan-1-ol

30 A mixture of 4-(s)-(1-hydroxymethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester and 1M lithium aluminum hydride and aluminum chloride in THF in dry THF was heated at reflux. The mixture was cooled and quenched with water, 2N NaOH, then of water and stirred at room temperature for 10 min. White solid formed and was filtered through celite, washed with THF. The filtrate was concentrate to dryness to give the title  
35 compound as white solid after column chromatography,

mp. 135-137°C; Anal. For C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub> calc. C, 69.74; H, 8.19; N, 8.13; found C, 69.42; H, 8.34; N, 7.95

The following compounds were prepared by the method analogous to that in the preceding paragraph, starting with the corresponding ester with lithium aluminum hydride and aluminum chloride.

- 5        3-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-pentan-2-ol

mp. 180-182°C. <sup>1</sup>H NMR(CDCl<sub>3</sub>) 7.0(s,2H), 6.18&6.15(two sets of s,1H), 5.1 and 5.22(m,1H), 4.92(m,2H), 3.80-4.0(m,1H), 3.20-3.5(m,1H), 2.11(s,3H), 2.04(s,6H), 1.4-1.8(m,2H), 1.23(m,3H), 0.98(m,3H) ppm.

- 10        2-[2-(2,6-Dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-butan-1-ol  
<sup>1</sup>H (CDCl<sub>3</sub>) d 7.05(m,3H), 6.20(s,1H), 4.8-5.0(m,2H), 3.74(m,1H), 3.66(m,1H), 3.50(m,1H), 2.0-2.29m,9H), 1.55-1.75(m,2H), 0.99(t,3H) ppm.

- 15        3-[3-Hydroxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-pentan-2-ol  
<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 6.86(s,2H), 6.17(s, 1H), 4.0(d,1H), 3.9(m,1H), 3.3(m,1H), 2.29(s,3H), 2.14(s,3H), 2.13(s,3H), 2.07(s,6H), 1.8(d,1H), 1.4-1.8(m,2H), 1.25(d,3H), 0.99(t,3H) ppm.

- 20        2-[2-(4-Chloro-2-methoxy-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-butan-1-ol  
<sup>1</sup>H NMR(CDCl<sub>3</sub>) 6.8-7.0(m,3H), 6.2(s,1H), 5.02(d,1H), 4.7(ABq,2H), 3.74(m,5H), 3.350-3.5(m,2H), 2.9(brs,2H), 2.18(s,3H), 1.4-1.7(m,2H), 1.23(m,3H), 0.95(t,3H) ppm.

Example 139

- 25        2-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-butan-1-ol  
A mixture of 4-(s)-(1-hydroxymethyl-propylamino)-6-methyl-2-(4-chloro-2,6-dimethyl-phenoxy)-nicotinic acid methyl ester and 1M lithium aluminum hydride in THF was stirred at rt for 2 hr. The mixture was cooled and quenched with water, 2N NaOH, then of water and stirred at room temperature for 10 min. White solid formed and was filtered through celite, washed with THF. The filtrate was concentrate to dryness to give the title compound as white solid after  
30        column chromatography, mp 133-135°C, <sup>1</sup>H NMR(CDCl<sub>3</sub>) 7.00(s,2H), 6.17(s,1H), 5.12(d,1H), 4.90(m,2H), 3.4-3.8(m,3H), 2.12(s,3H), 2.04(s,6H), 1.4-1.6(m,2H), 0.99(t,3H) ppm.

The following compounds were prepared by the method analogous to that in the preceding paragraph, starting with the corresponding methyl ester with lithium aluminum hydride:

- 35        2-[Ethyl-[3-hydroxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amino]-ethanol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 1H NMR(CDCl<sub>3</sub>) 6.86(s,2H), 6.53(s,1H), 4.94(s,2H), 3.67(m,2H), 3.1-3.3 (m,4H), 2.28(s,3H), 2.20(s,3H), 2.04(s,6H), 1.09(t,3H) ppm.

4-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-hexan-3-ol

5 mp. 145-148°C. <sup>1</sup>H NMR(CDCl<sub>3</sub>) d 1H NMR(CDCl<sub>3</sub>) 7.05(s,2H), 6.16(s,1H), 5.3(d,1H), 4.94(s,2H), 3.67(m,1H), 3.40 (m,1H), 2.151(s,3H), 2.09(s,6H), 1.4-1.8(m,4H), 1.23(m,3H), 1.02(m,6H) ppm.

2-[2-(4-Chloro-2-methoxy-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>) d 7.8-7.95(m,2H), 5.02(d,1H), 4.74(ABq,2H), 3.74(s,3H), 3.72(m,2H), 3.45m,1H), 2.98(brs,1H), 2.18(s,3H), 1.4-1.7(m,2H), 0.95(t,3H) ppm.

4-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-hexan-3-ol

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>) d 7.05(s,2H), 6.16(s,1H), 5.30(d,1H), 4.94(s,2H), 3.67(m,1H), 3.4(m,1H), 2.15(s,3H), 2.09(s,6H), 1.5-1.9(m,4H), 1.01(m,6H) ppm.

[2-(2,4-Dimethoxy-phenylamino)-4-(1-methoxymethyl-propoxy)-6-methyl-pyridin-3-yl]-methanol

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) d 6.90(d,1H), 6.42(s,1H), 6.40(d,1H), 5.91(s,1H), 4.42(m,1H), 4.28(s,2H), 3.79(s,3H), 3.76(s,3H), 3.56(m,2H), 3.40(s,3H), 2.33(s,3H), 1.5-1.85(m,2H), 1.02(t,3H) ppm.

Example 140

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid

25 A mixture of 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester (113 mg) and lithium hydroxide in dioxane/THF/water was stirred at room temperature over night. The mixture was quenched with ammonium chloride and extracted with chloroform. The organic layer was dried and concentrated to give 78mg of the title compound as a white solid. <sup>1</sup>H NMR(CDCl<sub>3</sub>) d 10.55(brs,1H), 9.2(d,1H), 7.06(s,2H), 6.3(s,1H), 3.5-3.8(m,3H), 2.11(s,3H), 2.09(s,3H), 2.08(s,3H), 1.78(m,1H), 1.62(m,1H), 1.00(t,3H) ppm.

4-(1-Ethyl-prop-2-ynylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid

mp. 131-133°C, <sup>1</sup>H NMR(CDCl<sub>3</sub>) d 11.29(brs,1H), 9.35(d,1H), 6.91(s,2H), 6.38(s,1H), 4.12(m,1H), 2.88(m,1H), 2.32(s,3H), 2.19(s,3H), 2.09(s,6H), 1.96(m,2H), 1.17(t,6H) ppm.

35 2-(4-Bromo-2,6-dimethyl-phenoxy)-4-(S)-(1-methoxymethyl-propylamino)-6-methyl-nicotinic acid

<sup>1</sup>H NMR (CDCl<sub>3</sub>) d 10.5(brs, 1H), 8.6(d,1H), 7.15(d,2H), 6.25(s,1H), 3.3-3.6(m,3H), 3.38(s,3H), 2.11(s,3H), 2.09(s,3H), 2.08(s,3H), 1.5-1.85(m,2H), 0.91(t,3H) ppm.

4-(2-Methoxy-1-methoxymethyl-ethylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.44(d,1H), 6.92(s,2H), 6.30(s,1H), 3.80(m,1H), 3.58(m,2H), 3.44(s,6H), 2.33(s,3H), 2.16(s,3H), 2.10(s,6H) ppm.

5      Example 141

The following compounds were prepared by reacting the corresponding [2-(substituted-phenoxy)-3-chloromethyl-6-methyl-pyridin-4-yl]-(alkyl)-amine with an appropriate amine.

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-isobutoxymethyl-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

10      <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.94(s,2H), 6.0(s,1H), 5.13(d,1H), 4.7(s,2H), 3.2(m,1H), 3.16(d,2H), 2.02(s,3H), 1.96(s,6H), 1.8(m,1H), 1.3-1.6(m,4H), 0.82(t,6H), 0.8(d,6H) ppm.

[3-Ethoxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine

15      <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.86(s,2H), 6.03(s,1H), 5.30(d,1H), 4.83(s,2H), 3.58(q,2H), 3.35(m,1H), 2.29(s,3H), 2.15(s,3H), 2.06(s,6H), 1.5-1.78(m,4H), 1.23(t,3H), 0.967(t,6H)ppm.

2-[3-Butoxymethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-butan-1-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.85(s,2H), 6.179s,1H), 5.3(d,1H), 4.82(Abq,2H), 3.5-3.8(m,2H), 3.5(t,2H), 2.3(s,3H), 2.15(s,3H), 2.02(s,6H),1.75(brs,1H), 1.5-1.8(m,4H), 1.3-1.5(m,2H), 1.02(t,3H), 0.9(t,3H) ppm.

20      Example 142

1-[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-ethanol

The title compound was prepared by reacting 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3-carbaldehyde with methyllithium lithium in THF at -78°C. The desired product was isolated after silica gel column chromatography to give 60.1%of  
25      colorless oil. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,2H), 6.06(s,1H), 5.7(q,1H), 3.3(m,1H), 2.29(s,3H), 2.12(s,6H), 2.069s,3H), 1.4-1.7(m,4H), 1.59(d,3H), 0.8-1.0(m,6H) ppm.

Example 143

Acetic acid 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl ester

30      The title compound was obtained by acetylation of [2-(2,4,6-trimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine.

<sup>1</sup>H NMR(CCl<sub>3</sub>) δ 6.84(s,2H), 6.04(s,1H), 5.35(s,2H), 5.23(d,1H), 3.32(m,1H), 2.28(s,3H), 2.12(s,3H), 2.08(s,3H), 2.07(s,6H), 1.4-1.7(m,4H), 0.93(t,6H) ppm.

Example 144

35      2-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-(1-hydroxy-1-methyl-ethyl)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol

The title compound was prepared by reacting 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester with an excess of 1M methyl magnesium bromide in THF at room temperature overnight. Standard work-up procedure to give the title compound after silica gel chromatography.

5             $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.4(brs,1H), 7.01(s,2H), 6.13(s,1H), 3.7(m,1H), 3.6(m,1H), 3.45(m,1H), 2.04(s,3H), 2.03(s,3H), 2.02(s,3H), 1.5-1.7(m,2H), 0.98(t,3H) ppm.

Example 145

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

To a solution of [2-(4-Chloro-2,6-dimethyl-phenoxy)-3-chloromethyl-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine (75 mg, 0.196 mmol) in dry THF was added 1.0M  $\text{BH}_3$  in THF (0.59 ml, 0.59 mmol) and stirred for 2 hr. The mixture was quenched with dilute HCl and stirred for 5 min. The reaction mixture was neutralized with 2N NaOH, water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to dryness. The residue was purified through silica gel column chromatography to give the title compound as a colorless oil.

15             $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.03(s,2H), 6.08(s,1H), 3.73(d,1H), 3.3(m,1H), 2.15(s,3H), 2.12(s,3H), 2.08(s,6H), 1.4-1.6(m,4H), 0.96(t,6H) ppm.

Example 146

[2-(2,6-Dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

To a solution of [2-(4-bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-methanol (43 mg, 0.106 mmol) in dry THF was added 1.0M lithium aluminium hydride in diethyl ether (0.25 ml) and aluminum chloride (28 mg). The resulting mixture was stirred at room temperature overnight. The mixture was quenched with water, 2NaOH, then water. Solid formed and filtered through celite, washed with THF, then chloroform. The filtrate was concentrated to dryness. The residue was diluted with water and ethyl acetate. The organic layer was separated, dried and concentrated to give the crude material. The title compound was isolated after silica gel chromatography.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.9-7.1(m,3H), 6.07(s,1H), 3.35(d,1H), 3.33(m,1H), 2.14(s,3H), 2.13(s,3H), 2.12(s,6H), 1.5-1.8(m,4H), 0.97(t,6H) ppm.

30            Example 147

[2-(4-Bromo-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

The title compound was prepared by the method analogous to that in Example 145 as a white solid.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.19(s,2H), 6.09(s,1H), 3.36(d,1H), 3.33(m,1H), 2.15(s,3H), 2.12(s,3H), 2.09(s,6H), 1.4-1.8(m,4H), 0.97(t,6H) ppm.

35            Example 148

4-[4-(1-Ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-benzaldehyde

To a solution of [2-(4-bromo-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine in dry THF was added n-butyllithium at  $-78^{\circ}\text{C}$ . After stirring at  $-78^{\circ}\text{C}$  for 10 min, n,N-dimethylformamide was added and the resulting mixture was stirred at  $-78^{\circ}\text{C}$  for 20 min, the dry-ice bath was removed. After stirring for 5 min, the mixture was quenched with diluted HCl, water and adjusted to pH7.5 and extracted with ethyl acetate. The organic layer was separated, dried, and concentrated to dryness. The residue was purified through silica gel chromatography to give the title compound.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  9.93(s,1H), 7.60(s,2H), 6.10(s,1H), 3.75(d,1H), 3.35(m,1H), 2.17(s,6H), 2.13(s,3H), 2.12(s,3H), 1.4-1.8(m,4H), 0.97(t,6H) ppm.

Example 149

{4-[4-(1-Ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl}-methanol

A mixture of 4-[4-(1-Ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-benzaldehyde and sodium borohydride in methanol was stirred at room temperature. After standard work-up procedure and purification, the title compound was obtained as a solid.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.06(s,2H), 6.08(s,1H), 4.64(s,2H), 3.74(d,1H), 3.33(m,1H), 2.14(s,3H), 2.13(s,3H), 2.11(s,6H) ppm.

Example 150

(1-Ethyl-propyl)-[2-(4-methoxymethyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine

To a solution of {4-[4-(1-Ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl}-methanol in dry THF was added 60% NaOH in oil and stirred for 5 min. Excess of MeI was added and stirred at room temperature for 2hr. After standard worked up procedure and purification, the title compound was obtained as a clear golden oil.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.02(s,2H), 6.06(s,1H), 4.40(s,3H), 3.72(d,1H), 3.39(s,3H), 3.36(m,1H), 2.12(s,3H), 2.11(s,3H), 2.10(s,6H), 1.4-1.7(m,4H), 0.95(t,6H) ppm.

Example 151

[2-(4-Ethyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

To a solution of [2-(4-bromo-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine in dry THF was added n-butyllithium at  $-78^{\circ}\text{C}$ . After stirring at  $-78^{\circ}\text{C}$  for 10 min, ethyl iodide was added and the resulting mixture was stirred at  $-78^{\circ}\text{C}$  for 30 min, the dry-ice bath was removed. After stirring for 5 min, the mixture was quenched with brine and extracted with ethyl acetate. The organic layer was separated, dried, and concentrated to dryness. The residue was purified through silica gel chromatography to give the title compound.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.89(s,2H), 6.07(s,1H), 3.72(d,1H), 3.34(m,1H), 2.58(q,2H), 2.16(s,3H), 2.12(s,3H), 2.09(s,6H), 1.4-1.7(m,4H), 1.25(t,3H), 0.96(t,6H) ppm.

Example 152

2-[4-[4-(1-Ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl]-propan-2-ol

To a solution of [2-(4-bromo-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine in dry THF was added n-butyllithium at  $-78^{\circ}\text{C}$ . After stirring at  $-78^{\circ}\text{C}$  for 10 min, acetone was added and the resulting mixture was stirred at  $-78^{\circ}\text{C}$  for 30 min, the dry-ice bath was removed. After stirring for 5 min, the mixture was quenched with brine and extracted with ethyl acetate. The organic layer was separated, dried, and concentrated to dryness. The residue was purified through silica gel chromatography to give the title compound.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.17(s,2H), 6.08(s,1H), 3.73(d,1H), 3.33(m,1H), 2.19(s,3H), 2.15(s,3H), 2.12(s,6H), 1.4-1.7(m,4H), 1.26(s,6H), 0.96(t,6H) ppm.

Example 153

1-[4-[4-(1-Ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl]-ethanol

To a solution of [2-(4-bromo-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine in dry THF was added n-butyllithium at  $-78^{\circ}\text{C}$ . After stirring at  $-78^{\circ}\text{C}$  for 10 min, acetaldehyde was added and the resulting mixture was stirred at  $-78^{\circ}\text{C}$  for 30 min, the dry-ice bath was removed. After stirring for 5 min, the mixture was quenched with brine and extracted with ethyl acetate. The organic layer was separated, dried, and concentrated to dryness. The residue was purified through silica gel chromatography to give the title compound.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.06(s,2H), 4.84(m,1H), 6.08(s,1H), 3.73(d,1H), 3.35(m,1H), 2.14(s,3H), 2.12(s,3H), 2.11(s,6H), 1.4-1.7(m,4H), 1.51(d,3H), 0.96(t,6H) ppm.

Example 154

(1-Ethyl-propyl)-[2-(4-isopropenyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine

The title compound was prepared by reacting of 2-[4-[4-(1-Ethyl-propylamino)-3,6-dimethyl-pyridin-2-yloxy]-3,5-dimethyl-phenyl]-propan-2-ol with Burgess Inner salt ( $\text{Et}_3\text{NS}(\text{O})_2\text{NCOOMe}$ ) in benzene at reflux for 30 min.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.17(s,2H), 6.08(s,1H), 5.34(s,1H), 5.02(s,1H), 3.72(d,1H), 3.32(m,1H), 2.12 and 2.15 (two sets of s, 12H), 1.4-1.6(m,4H), 0.97(t,6H) ppm.

Example 155

(1-Ethyl-propyl)-[2-(4-isopropyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine

The title compound was prepared by hydrogenation of (1-ethyl-propyl)-[2-(4-isopropenyl-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine using 10% Pd/C as catalyst in ethyl acetate at 55 psi until all starting material were consumed. The title compound was obtained as an oil after purification.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.93(s,2H), 6.10(s,1H), 3.73(brs,1H), 3.36(m,1H), 2.18(s,3H), 2.14(s,3H), 2.12(s,6H), 1.4-1.8(m,4H), 1.27(d,6H), 0.98(t,6H) ppm.



Example 156

[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl- allyl)-amine

The title compound was prepared as a clear oil by reduction of 4-(1-Ethyl-prop-2-ynylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid with lithium aluminum hydride and aluminum chloride. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,2H), 6.08(s,1H), 5.7-5.9(m,1H), 5.1-5.3(m,2H), 3.75-4.0(m,2H), 2.30(s,3H), 2.16(s,3H), 2.15(s,3H), 2.08(s,6H), 1.70(m,2H), 1.03(t,3H)ppm.

Example 157

(1-Ethyl-propyl)-[2-(4-fluoro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine

To a solution of [2-(4-bromo-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine in dry THF was added n-butyllithium at -78°C. After stirring at -78°C for 10 min, (PhSO<sub>2</sub>)<sub>2</sub>NF was added and the resulting mixture was stirred at -78°C for 30 min, the dry-ice bath was removed. After stirring for 5 min, the mixture was quenched with brine and extracted with ethyl acetate. The organic layer was separated, dried, and concentrated to dryness. The residue was purified through silica gel chromatography to give the title compound. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.77(s,1H), 6.73(s,1H), 6.08(s,1H), 3.3(m,1H), 2.12(s,3H), 2.09(s,6H), 2.08(s,3H), 1.4-1.8(m,4H), 0.97(t,6H)ppm.

Example 158

2-[2-(2,6-Dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-butan-1-ol

The title compound was prepared by the method analogous to that in Example 146. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.05(m,3H), 6.24(s,1H), 3.4-3.8(m,3H), 2.24(s,3H), 2.16(s,3H), 2.10(s,6H), 1.5-1.8(m,2H), 0.99(t,3H)ppm.

Example 159

2-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-(S)-ylamino]-butan-1-ol

To a solution of 2-(2,4,6-trimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid methyl ester in dry THF was added 1.0M lithium aluminium hydride in diethyl ether (0.25 ml) and aluminum chloride. The resulting mixture was heated at reflux for 2 hr. The mixture was quenched with of water, 2NaOH, then water and stirred. Solid formed and was filtered through celite, washed with water and ethyl acetate. The organic layer was separated, dried, concentrated, and purification to give the title compound as a white solid. Anal. For C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub>·1/2H<sub>2</sub>O calc. C, 70.90; H, 8.52; N, 8.01; found C, 71.18; H, 8.66; N, 8.30

The following compounds were prepared by the method analogous to that in the preceding paragraph, using the corresponding 2-(substituted phenoxy)-4-(alkyl-amino)-6-methyl-nicotinic acid methyl ester with lithium aluminum hydride and aluminum chloride.

3-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-pentan-2-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.86(s,2H), 6.17&6.13(two sets of s, 1H), 5.0-5.2(m,1H), 4.9(s,2H), 3.9-4.1(m,1H), 3.5(m,1H), 3.3(m,1H), 2.29(s,3H), 2.14(s,3H), 2.08(s,6H), 1.4-1.8(m,2H), 1.27(m,3H), 0.98(m,3H) ppm.

3-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-pentan-2-ol

5 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.01(s,2H), 6.14&6.11(two sets of s,1H), 4.04&3.82(two sets of d,1H), 3.92(m,1H), 3.4&3.2(m,1H), 2.13(s,3H), 2.11(s,3H), 2.05(s,6H), 1.4-1.8(m,2H), 1.25(two sets of d, 3H), 0.98&0.96(two sets of t,3H) ppm.

Example 160

Benzyl-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine

10 A mixture of 4-bromo-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine (250 mg, 0.78 mmol), benzylethylamine (127 mg, 0.937 mmol), Pd(OAc)<sub>2</sub> (3.6 mg, 0.0156 mmol), (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (9.7 mg, 0.0156 mmol), potassium t-butoxide (105 mg, 0.781 mmol) in 25 ml of toluene was heated at reflux for 2 hr. The mixture was cooled to rt, quenched with water and extracted with ethyl acetate. The organic layer was separated,  
15 dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to give a brown oil. The crude material was purified through silica gel column chromatography to give the title compound. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.2-7.4(m,5H), 6.86(s,2H), 6.41(s,1H), 4.23(s,2H), 3.07(q,2H), 2.31(s,3H), 2.29(s,3H), 2.16(s,3H), 2.06(s,6H), 1.05(t,3H) ppm.

The following compounds were prepared by the method analogous to that in the preceding paragraph, using an appropriate 4-bromo-2-(substituted phenoxy)-3-methyl-6-alkyl or alkoxy-pyridine with an appropriate amine.

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.06(s,2H), 6.13(s,1H), 4.14(d,1H), 3.3-3.6(m,3H), 3.42(s,3H), 2.16(s,3H), 2.14(s,3H), 2.09(s,6H), 1.5-1.8(m,2H), 1.03(t,3H) ppm.

2-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-3-phenyl-propan-1-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.6(d,1H), 7.2-7.4(m,5H), 6.84(s,2H), 6.169s,1H), 4.099d,1H), 3.82(m,1H), 3.5-3.7(m,2H), 2.95(d,2H), 2.96(s,3H), 2.27(s,3H), 2.14(s,3H), 2.05(s,6H) ppm.

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

30 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.06(s,2H), 6.13(s,1H), 4.2(m,1H), 3.53(m,2H), 3.42(s,3H), 2.19(s,3H), 2.14(s,3H), 2.10(s,6H), 1.5-1.8(m,2H), 1.03(t,3H) ppm.

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethoxymethyl-propyl)-amine

35 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.06(s,2H), 6.14(s,1H), 4.24(d,1H), 4.4-4.65(m,5H), 2.19(s,3H), 2.14(s,3H), 2.10(s,6H), 1.8(m,1H), 1.65(m,1H), 1.25(t,3H), 1.03(t,3H) ppm.

[3,6-Dimethyl-2-(2,4,6-trimethoxy-phenoxy)-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.20(s,2H), 6.08(s,1H), 3.80(s,3H), 3.73(s,6H), 3.8(m,2H), 3.39(m,1H), 3.36(s,3H), 2.23(brs,3H), 2.10(s,3H), 1.74(m,1H), 1.59(m,1H), 0.969(t,3H) ppm.

5 [2-(4-Bromo-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.18(s,2H), 6.09(s,1H), 4.43(d,1H), 3.89(s,3H), 3.25(m,1H), 2.10(s,9H), 1.4-1.8(m,4H), 0.95(t,6H) ppm.

10 (1-Ethyl-propyl)-[3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.85(s,2H), 6.07(s,1H), 4.44(m,1H), 3.89(s,3H), 3.23(m,1H), 2.27(s,3H), 2.09(s,6H), 2.08(s,3H), 1.65(m,2H), 1.45(m,2H), 0.93(m,6H) ppm.

[2-(4-Chloro-2,6-dimethyl-phenoxy)-6-methyl-3-propyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

15 [2-(4-Bromo-2,6-dimethyl-phenoxy)-6-methyl-3-propyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.03(s,2H), 6.13(s,1H), 3.8(m,1H), 3.74(s,2H), 3.38(m,1H), 2.15(s,3H), 2.05(s,6H), 1.50-1.7(m,4H), 0.97(t,6H) ppm.

20 (1-Ethyl-propyl)-[6-methyl-3-propyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine  
[2-(2,4-Dichloro-6-methyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.24(d,1H), 7.1(d,1H), 6.1(s,1H), 4.47(d,1H), 3.9(s,3H), 3.22(m,1H), 2.12(s,3H), 2.08(s,3H), 1.4-1.7(m,4H), 0.9(t,6H) ppm.

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-ethyl-propyl)-amine

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.02(s,2H), 6.07(s,1H), 4.44(brs,1H), 3.8-3.95(m,3H), 3.23(m,1H), 2.09(s,6H), 2.08(s,3H), 1.4-1.7(m,4H), 0.93(t,6H) ppm.

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine  
<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.02(s,2H), 6.11(s,1H), 4.71(d,1H), 3.88(s,3H), 3.45(m,2H), 3.37(s,3H), 2.10(s,3H), 2.09(s,6H), 1.73(m,1H), 1.59(m,1H), 0.98(m,3H) ppm.

30 [2-(2,4-Dichloro-6-methyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.1-7.25(m,2H), 6.13(s,1H), 4.74(d,1H), 3.91(s,3H), 3.47(m,1H), 3.39(m,2H), 3.37(s,3H), 2.14(s,3H), 2.10(s,3H), 1.78(m,1H), 1.59(m,1H), 0.98(t,3H) ppm.

35 [2-(4-Chloro-2-methoxy-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.8-7.0(m,3H), 6.17(s,1H), 4.76(d,1H), 3.82(s,3H), 3.75(s,3H), 3.3-3.5(m,3H), 3.35(s,3H), 2.19(s,3H), 1.73(m,1H), 1.56(m,1H), 0.96(t,3H) ppm.

[2-(3-Chloro-2,6-dimethoxy-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

5 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.12(d,1H), 6.64(d,1H), 6.12(s,1H), 4.73(d,1H), 3.88(s,3H), 3.78(s,3H), 3.70(s,3H), 3.3-3.5(m,3H), 3.35(s,3H), 2.11(s,3H), 1.5-1.8(m,2H), 0.96(t,3H) ppm.

(1-Methoxymethyl-propyl)-[3-methoxy-6-methyl-2-(2,4,6-trimethoxy-phenoxy)-pyridin-4-yl]-amine

10 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.19(s,2H), 6.10(s,1H), 4.75(m,1H), 3.87(s,3H), 3.80(s,3H), 3.73(s,6H), 3.3-3.5(m,2H), 3.35(s,3H), 2.17(s,3H), 1.78(m,1H), 1.5(m,1H), 0.96(t,3H) ppm.

[3-Methoxy-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-yl]-(1-ethoxymethyl-propyl)-amine

15 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.59(s,2H), 6.10(s,1H), 4.70(d,1H), 3.89s,3H), 3.77(s,3H), 3.48(m,1H), 3.39(m,2H), 3.37(s,3H), 2.11(s,3H), 2.10(s,6H), 1.74(m,1H), 1.57(m,1H), 0.98(t,3H) ppm.

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-ethoxy-6-methyl-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.07(s,2H), 6.16(s,1H), 4.82(d,1H), 4.20(q,2H), 3.54(m,1H), 3.43(m,2H), 3.42(s,3H), 2.15(s,3H), 2.13(s,6H), 1.5-1.9(m,2H), 1.439t,3H), 1.02(t,3H) ppm.

#### Example 161

2-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-(S)-ylamino]-butan-1-ol

To a solution of [1-(tert-butyl-dimethyl-silanyloxymethyl)-propyl]-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine in dry THF was added 1M tetrabutylammonium fluoride in THF at room temperature. The mixture was stirred at room temperature for 2 hr, quenched with water, extracted with ethyl acetate. The organic layer was separated, dried and concentrated to dryness. The residue was purified by Biotage using 15% ethyl acetate in hexane as eluent to give the title compound as a white solid. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.06(s,2H), 6.18(s,1H), 4.04(d,1H), 3.74(m,1H), 3.69(m,1H), 3.53(m,1H), 2.18(s,3H), 2.16(s,3H), 2.10(s,6H), 1.6-1.8(m,2H), 1.04(t,3H) ppm.

30 The following compounds were prepared by the method analogous to that in the preceding paragraph, starting with the corresponding tert-butyl-dimethyl-silanyloxymethyl derivative with tetrabutylammonium fluoride.

2-[3-Methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-(S)-ylamino]-butan-1-ol

35 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85(s,2H), 6.15(s,1H), 4.57(d,1H), 3.91(s,3H), 3.72(m,1H), 3.61(m,1H), 3.41(m,1H), 2.27(s,3H), 2.10(s,3H), 2.07(s,6H), 1.5-1.8(m,3H), 0.98(t,3H) ppm.

2-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-ylamino]-butan-1-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.02(s,2H), 6.16(s,1H), 4.60(d,1H), 3.91(s,3H), 3.71(m,1H), 3.61(m,1H), 3.40(m,1H), 2.10(s,3H), 2.08(s,6H), 1.8(brs,1H), 1.71(m,1H), 1.68(m,1H), 0.99(t,3H) ppm.

5 4-[4-(1-Hydroxymethyl-propylamino)-3-methoxy-6-methyl-pyridin-2-yloxy]-3,5-dimethyl-benzonitrile

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.35(s,2H), 6.19(s,1H), 4.7(brs,1H), 3.88(s,3H), 3.731(m,1H), 3.64(m,1H), 3.43(m,1H), 2.14(m,9H), 1.8(brs,1H), 1.71(m,1H), 1.58(m,1H), 0.99(t,3H) ppm.

Example 162

10 3-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-pentan-2-ol

The title compound was prepared by Dess Martin oxidation of 2-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-(S)-ylamino]-butan-1-ol methylene chloride at room temperature, followed by Grignard reaction using methyl magnesium bromide in THF. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.07(s,2H), 6.18(s,1H), 4.3(brs,1H), 4.0(m,1H), 3.32(m,1H), 2.22(s,3H), 2.17(s,3H), 2.11(s,6H), 1.6-1.8(m,2H), 1.30(d,3H), 1.01(t,3H) ppm.

15 Example 163

2-[2-Methyl-6-(2,4,6-trimethyl-phenoxy)-pyridin-4-ylamino]-butan-1-ol

The title compound was prepared as an oil by heating 2-(2,4,6-trimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid in 160°C until all starting material were consumed. Anal. For C<sub>19</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub> · H<sub>2</sub>O calc. C, 68.65; H, 8.49; N, 8.42; found C, 69.04; H, 8.14; N, 8.91

Example 164

(1-Ethyl-prop-2-ynyl)-[2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine

The title compound was prepared by the method analogous to that in Example 163. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.89(s,2H), 6.12(d,1H), 5.41(d,1H), 3.9-4.2(m,2H), 2.37(s,3H), 2.30(s,3H), 2.27(m,1H), 1.76(m,2H), 1.05(t,3H) ppm.

Example 165

2-(4-Bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-ol

To a solution of [2-(4-bromo-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(1-ethy-propyl)-amine in methylene chloride was added BBr<sub>3</sub> at 0°C and stirred for hr. The mixture was quenched with water and extracted with chloroform. The organic layer was separated, dried, and concentrated to give the title compound. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.20(s,2H), 6.12(s,1H), 4.77(d,1H), 3.27(m,1H), 2.13(s,3H), 2.10(s,6H), 1.4-1.8(m, 4H), 0.97(t,6H) ppm.

The following compounds were prepared by the method analogous to that in the preceding paragraph, starting with an appropriate [2-(substituted phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-(alkyl)-amine with BBr<sub>3</sub> or BCl<sub>3</sub>.

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.85(s,2H), 6.10(s,1H), 5.12(brs,1H), 4.21(m,1H), 3.27(m,1H), 2.28(s,3H), 2.09(s,9H), 1.5-1.8(m,4H), 0.96(m,6H) ppm.

4-(S)-(1-Hydroxymethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ol

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85(s,2H), 6.17(s,1H), 5.13(brs,1H), 4.28(d,1H), 3.73(m,1H), 3.60(m,1H), 3.50(m,1H), 2.27(s,3H), 2.12(s,3H), 2.07(s,6H), 1.75(brs,1H), 1.5-1.7(m,2H), 0.99(t,3H) ppm.

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-pyridin-3-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.032(s,2H), 6.10(s,1H), 5.2(brs,1H), 4.35(brs,1H), 3.71(m,1H), 3.61(m,1H), 3.40(m,1H), 2.07(s,9H), 1.8(brs,1H), 1.71(m,1H), 1.60(m,1H), 0.99(m,3H) ppm.

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.02(s,2H), 6.10(s,1H), 5.02(brs,1H), 4.22(brs,1H), 3.25(brs,1H), 2.08(brs,9H), 1.62(m,2H), 1.52(m,2H), 0.95(brs,6H) ppm.

Example 166

Chloro-acetic acid 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl ester

The title compound was prepared by reacting 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ol with chloroacetyl chloride /triethylamine in THF at 0°C to rt. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.84(s,2H), 6.15(s,1H), 4.3(s,2H), 4.0(d,1H), 3.3(m,1H), 2.28(s,3H), 2.17(s,3H), 2.08(s,6H), 1/6-1.7(m,4H), 0.9(t,6H) ppm.

Example 167

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-[(1-ethyl-propyl)-methyl-amino]-6-methyl-pyridin-3-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.03(s,2H), 6.25(s,1H), 5.4(brs,1H), 3.93(m,1H), 2.70(s,3H), 2.12(s,3H), 2.08(s,6H), 1.55(m,4H), 0.89(t,6H) ppm.

Example 168

[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-acetonitrile

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,2H), 6.13(s,1H), 3.83(d,1H), 3.79(s,2H), 3.38(m,1H), 2.30(s,3H), 2.27(s,3H), 2.21(s,6H), 1.4-1.8(m,4H), 1.00(t,6H) ppm.

Example 169

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3-carbaldehyde

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 10.52(s,1H), 9.26(d,1H), 6.89(s,2H), 6.11(s,1H), 3.42(m,1H), 2.31(s,3H), 2.15(s,3H), 2.11(s,6H), 1.45-1.75(m,4H), 0.97(t,6H) ppm.

Example 170

(1-Ethyl-propyl)-[3-[(1-ethyl-propylamino)-methyl]-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 10.33(d,1H), 8.94(s,1H), 6.89(s,2H), 6.10(s,1H), 3.41(m,1H), 2.86(m,1H), 2.99(s,3H), 2.14(s,3H), 2.10(s,6H), 1.4-1.89m,8H), 0.94(t,6H), 0.87(t,6H) ppm.

Example 171

2-[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl]-

5 malonic acid dimethyl ester

To a solution of dimethylmalonate (60 mg, 0.44 mmol) and 60% NaH in oil (20 mg, 0.44 mmol) in dry THF was added the title compound of Example 85 (50 mg, 0.146 mmol) at room temperature for 1 hr. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to dryness. The residue was purified  
10 through silica gel column chromatography to give the title compound as a clear oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88(s,2H), 6.03(s,1H), 4.85(m,1H), 4.03(t,1H), 3.73(s,6H), 3.26(m,1H), 3.18(d,2H), 2.30(s,3H), 2.13s,3H), 2.07(s,6H), 1.5-1.8(m,4H), 0.97(t,6H)ppm.

Example 172

2-[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl]-

15 malonic acid diisopropyl ester

The title was prepared by the method analogous to that in Example 171. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.87(s,2H), 6.03(s,1H), 5.10(m,2H), 4.90(d,1H), 3.94(t,1H), 3.31(m,1H), 3.16(d,2H), 2.30(s,3H), 2.13s,3H), 2.08(s,6H), 1.5-1.8(m,4H), 1.1-1.3(two sets of d, 6H), 0.97(t,6H)ppm.

Example 173

20 4-(1-Ethyl-propoxy)-6-methyl-3-nitro-2-(2,4,6-trimethyl-phenoxy)-pyridine

To a mixture of 2-chloro-4-(1-ethyl-propoxy)-6-methyl-3-nitro-pyridine (500 mg, 1.93 mmol) and 2,4,6-trimethylphenol (289 mg, 2.13 mmol) in dry THF was added potassium t-butoxide. The resulting mixture was stirred at rt. overnight. The mixture was quenched with water, brine and extracted 3 times with ethyl acetate. The organic layer was separated, dried  
25 (MgSO<sub>4</sub>) and concentrated to dryness. After silica gel column chromatography purification, the title compound was obtained as a light yellow crystal, mp 106-109°C. Anal. For C<sub>20</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub> calc. C, 67.02; H, 7.31; N, 7.82; found, C, 67.34; H, 7.40; N, 7.42.

Example 174

4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylamine

A mixture of 4-(1-ethyl-propoxy)-6-methyl-3-nitro-2-(2,4,6-trimethyl-phenoxy)-pyridine (150 mg, 0.418 mmol) and 10%Pd/C (23 mg) in ethanol was hydrogenated at 50 psi for 15 hours. An additional 10Pd/C was added and the resulting mixture was hydrogenated for an additional 24 hr. The mixture was filtered through celite and the filtrate was concentrated to dryness to give 200 mg of the crude material. After column chromatography, the title  
30 compound was prepared as a the corresponding HCl salt as a white solid, mp 96-98°C.

Example 175

[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin- 3-yl]-dimethyl-amine

To a solution of 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylamine in dry THF was added lithium bis(trimethylsilyl)amide at  $-78^{\circ}\text{C}$ . After stirring at  $-78^{\circ}\text{C}$  for 10 minutes, an excess of methyl iodide was added. The title compound was isolated after quenching with water and extracting with ethyl acetate. The crude material was purified by silica gel column chromatography to give the title compound as a tan foam.

Example 176

N-[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-succinamic acid

A mixture of 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylamine (100mg, 0.304 mmol), succinic anhydride 31mg, 0.304 mmol) and triethylamine in methylene chloride was stirred at rt. overnight. The mixture was quenched with water, and extracted with methylene chloride. The organic layer was separated, dried and concentrated to give a solid. The title compound was isolated as a white crystal after silica gel column chromatography.

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.90(brs,1H), 6.84(s,2H), 6.37(s,1H), 4.2(m,1H), 2.6-2.8(m,4H), 2.28(s,3H), 2.22(s,3H), 2.03(s,6H), 1.69(m,4H), 0.94(t,6H) ppm.

Example 177

4-(1-Ethyl-propoxy)-3,6-dimethyl-2-[3-(2,4,6-trimethyl-pyridinoxy)]-pyridine

To a solution of 3-pentanol (0.11 ml) in dry THF was added sodium hydride (60% in oil, 20 mg). After stirring for 5 min, a solution of 4-chloro-2,5-dimethyl-6-[3-(2,4,6-trimethyl-pyridinoxy)]-pyridine (92 mg, 0.332 mmol) in THF was added. DMSO was added and the resulting mixture was heated at  $130^{\circ}\text{C}$  oil bath overnight. The mixture was quenched with water, brine and extracted 3 times with ethyl acetate. The organic layer was separated, dried ( $\text{MgSO}_4$ ) and concentrated to dryness. After silica gel column chromatography purification, the title compound was obtained as a clear oil.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.88 (s,1H), 6.37(s,1H), 4.21(m,1H), 2.5(s,3H), 2.29(s,3H), 2.19(s,3H), 2.18(s,3H), 2.07(s,3H), 1.70(m,4H), 0.98(t,6H) ppm. The oil was prepared as the corresponding HCl salt to give a white solid (63 mg).

The title compounds of the following Examples 178 and 179 were prepared by the methods analogous to that in Example 177, starting with an appropriate 6-alkyl-4-chloro-or bromo-3-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine with 3-pentanol/NaH:

Example 178

6-Ethyl-4-(1-ethyl-propoxy)-3-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.87(s,2H), 6.28(s,1H), 4.20(m,1H), 2.46(q,2H), 2.30(s,3H), 2.20(s,3H), 2.07(s,6H), 1.72(m,4H), 1.05(t,3H), 0.99(t,6H) ppm.

Example 179

4-(1-Ethyl-propoxy)-2-(4-fluoro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine

colorless oil. Anal. For  $\text{C}_{20}\text{H}_{26}\text{FNO}_2$  calc. C, 72.48; H, 7.91; N, 4.23; found C, 72.39; H, 7.77; N, 4.10.



Example 180

[4-(1-Ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine

To a solution of 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid (240 mg, 0.673 mmol) in dry THF was added lithium aluminum hydride and aluminum chloride. The resulting mixture was heated at reflux for 3 hours. The mixture was quenched with 0.1ml water and 0.1ml 2N NaOH, then quenched with water and ethyl acetate. The organic layer was separated, dried and concentrated to give 250 mg of brown oil. After silica gel column chromatography, 170 mg(78%) of the title compound was obtained which was prepared as a HCl salt as a white solid, mp. 132-133°C. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,2H), 6.09(s,1H), 5.399brs,1H), 4.13(m,1H), 2.27(s,3H), 2.22(s,3H), 2.15(s,6H), 1.98(s,3H), 1.67(m,4H), 0.94(t,6H) ppm.

Example 181

[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-methanol

To a solution of 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid (100 mg, 0.281 mmol) in dry THF was added BH<sub>3</sub>.DMS. The resulting mixture was heated at reflux overnight. The mixture was quenched with dilute HCl and stirred for 30 minutes, adjusted pH to 7.5-8.5, then extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give 100 mg of brown oil. After silica gel column chromatography, 91 mg(95%) of the title compound was obtained as a white foam. Anal. For C<sub>21</sub>H<sub>30</sub>N<sub>2</sub>O<sub>2</sub>.1/2H<sub>2</sub>O cal. C, 71.76; H, 8.89; N, 7.97; found: C, 71.97; H, 8.90; N, 7.69.

Example 182

[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-oxo-acetonitrile

The title compound was prepared by reacting [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-methanol with thionyl chloride in benzene, concentrated to dryness, followed by reacting with diethylaluminum cyanide. After standard workup procedure and silica gel column chromatography, the title compound was obtained as a yellow crystal, mp. 108-110°C.

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.57(s,1H), 6.97(s,2H), 6.37(s,1H), 4.46(m,1H), 2.35(s,3H), 2.34(s,3H), 2.09(s,6H), 1.6-1.8(m,4H), 0.99(t,6H) ppm.

Example 183

[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-imidazol-1-yl-methanone

To a solution of 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid (250 mg, 0.701 mmol) in 2ml of DMF was added carbonyldiimidazole (190 mg, 1.19 mmol) and the resulting mixture was stirred at room temperature overnight. After standard workup procedure and silica gel column chromatography, 260 mg(91.2%) of the title compound was

obtained as a golden crystal, mp. 120-122°C, Anal. For  $C_{24}H_{30}N_4O_2 \cdot 1/4H_2O$  calc: C, 70.13; H, 7.48; N, 13.63; Found: C, 70.06; H, 7.69; N, 13.37.

Example 184

2-[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-propan-2-

5 ol

The title compound was prepared by reacting [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-imidazol-1-yl-methanone with an excess MeMgBr in THF at rt. After standard workup procedure and silica gel column chromatography, the title compound was obtained as a tan solid, mp. 81-83°C; Anal. For  $C_{22}H_{30}N_2O_2 \cdot 1.5 H_2O$  calc.: C, 69.49; H, 9.38; N, 7.04; found: C, 69.49; H, 9.27; N, 6.86

Example 185

2-[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-ylmethyl]-malonic acid dimethyl ester

15 The title compound was prepared by reacting [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-methanol with thionyl chloride in benzene, concentrated to dryness, followed by reacting with methyl malonate/NaH in DMSO. After standard workup procedure and silica gel column chromatography, the title compound was obtained as a solid, mp. 96-98°C; Anal. For  $C_{26}H_{36}N_2O_5 \cdot 1/3 H_2O$  calc.: C, 67.51; H, 7.99; N, 6.04; found: C, 67.48; H, 7.99; N, 6.02.

20 Example 186

3-[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-propionic acid

25 Hydrolysis of 2-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-ylmethyl]-malonic acid dimethyl ester with phosphoric/water at reflux to give the title compound as a white foam. Anal. For  $C_{23}H_{32}N_2O_3 \cdot 3/4 H_2O$  calc.: C, 69.40; H, 8.48; N, 7.04; found: C, 69.17; H, 8.62; N, 6.90.

Example 187

[3-Aminomethyl-4-(1-ethyl-propoxy)-6-methyl-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine

30 The title compound was prepared by reacting [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-methanol with thionyl chloride in benzene, concentrated to dryness, followed by reacting with  $NH_3(g)$  at room temperature. After standard workup procedure and silica gel column chromatography, the title compound was obtained as a golden oil (80%), Anal. For  $C_{21}H_{31}N_3O$  calc.: C, 73.86; H, 9.15; N, 12.3; found: C, 73.50; H, 9.25; N, 11.39.

Example 188

2-Chloro-N-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-ylmethyl]-acetamide

The title compound was prepared by acylation of 3-aminomethyl-4-(1-ethyl-propoxy)-6-methyl-pyridin-2-yl-(2,4,6-trimethyl-phenyl)-amine with chloroacetyl chloride. After standard workup procedure and silica gel column chromatography, the title compound was obtained as an off-white crystal, mp. 142-144°C; Anal. For  $C_{23}H_{32}ClN_3O_2$ . calc.: C, 66.09; H, 7.72; N, 10.05; found: C, 65.81; H, 7.64; N, 9.86.

Example 189

[3-Dimethylaminomethyl-4-(1-ethyl-propoxy)-6-methyl-pyridin-2-yl-(2,4,6-trimethyl-phenyl)-amine hydrochloride salt

The title compound was prepared by reacting [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-methanol with thionyl chloride in benzene, concentrated to dryness, followed by reacting with dimethylamine at room temperature. After standard work-up procedure and silica gel column chromatography, the title compound was obtained as an oil. The corresponding HCl salt was prepared as a white solid, mp. 85-88°C; Anal. For  $C_{23}H_{35}N_3O.2HCl.1.5H_2O$  calc.: C, 58.83; H, 8.588; N, 8.94; found: C, 58.32; H, 8.5327; N, 8.64.

Example 190

Dithiocarbonic acid O-ethyl ester S-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-ylmethyl] ester

The title compound was prepared by reacting [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-methanol with thionyl chloride in benzene, concentrated to dryness, followed by reacting with  $NaSCSOEt$  at room temperature. After standard work-up procedure and silica gel column chromatography, the title compound was obtained as a white solid, mp. 55-57°C; Anal. For  $C_{24}H_{34}N_2O_2S_2$ . calc.: C, 64.54; H, 7.67; N, 6.27; found: C, 64.67; H, 7.78; N, 6.26.

Example 191

4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinamide

The title compound was prepared by reacting 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid with thionyl chloride in benzene, concentrated to dryness, followed by reacting with  $NH_3(g)$  at room temperature. After standard work-up procedure and silica gel column chromatography, the title compound was obtained an oil. The corresponding HCl salt was prepared as an off-white solid, mp 185-187°C; Anal. For  $C_{21}H_{29}N_3O_2$ . calc.: C, 70.96; H, 8.22; N, 11.82; found: C, 71.30; H, 8.33; N, 11.78.

Example 192

4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinonitrile

The title compound was prepared by reacting 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinamide with triphosgen/triethylamine in THF. mp 105-107°C, <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.90(s,2H), 6.26(brs,1H), 6.05(s,1H), 4.24(m,1H), 2.28(s,3H), 2.25(s,3H), 2.17(s,6H), 1.72(m,4H), 0.97(t,6H) ppm.

5      Example 193

4-(1-Ethyl-propoxy)-6,N,N-trimethyl-2-(2,4,6-trimethyl-phenylamino)-nicotinamide

The title compound was prepared by reacting 4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid with thionyl chloride in benzene, concentrated to dryness, followed by reacting with dimethylamine at room temperature. After standard work-up  
10      procedure and silica gel column chromatography, the title compound was obtained an oil. . The corresponding HCl salt was prepared as a white solid, mp. 197-200°C; Anal. For C<sub>23</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub>·H<sub>2</sub>O. calc.: C,63.07; H, 8.28; N, 9.59; found: C, 63.24; H, 8.07; N, 9.61.

Example 194

[4-(1-Ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-acetonitrile

The title compound was prepared by reacting [4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-methanol with thionyl chloride in benzene, concentrated to dryness, followed by reacting with potassium cyanide in DMSO at room temperature. After standard work-up procedure and silica gel column chromatography, the title compound was  
15      obtained as a pale orange solid, mp. 112-115°C, <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.9(s,2H), 6.14(s,1H),  
20      5.6(brs,1H), 4.22(m,1H), 3.49(s,2H), 2.28(s,3H), 2.22(s,3H), 2.16(s,6H), 1.71(m,4H), 0.95(t,6H) ppm.

Example 195

[2-(4-Bromo-2,6-dimethyl-phenylamino)-4-(1-ethyl-propoxy)-6-methyl-pyridin-3-yl]-methanol

To a solution of 4-(1-ethyl-propoxy)-6-methyl-2-(4-bromo-2,6-dimethyl-phenylamino)-nicotinic acid (130 mg, 0.309 mmol) in dry THF was added BH<sub>3</sub>.DMS. The resulting mixture was heated at reflux overnight. The mixture was quenched with dilute HCl and stirred for 30 min, adjusted pH to 7.5-8.5, then extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give 100 mg of brown oil. After silica gel column  
25      chromatography, 110mg(87.3%) of the title compound was obtained as a white semi-solid. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.25(s,2H), 6.85(brs,1H), 4.8(brs,2H), 4.18(m,1H), 2.2(s,3H), 2.07(s,6H), 1.7(m,4H), 0.95(t,6H) ppm.

Example 196

35      [2-(4-chloro-2,6-dimethyl-phenylamino)-4-(1-ethyl-propoxy)-6-methyl-pyridin-3-yl]-methanol

To a solution of 4-(1-ethyl-propoxy)-6-methyl-2-(4-chloro-2,6-dimethyl-phenylamino)-nicotinic acid in dry THF was added BH<sub>3</sub>.DMS. The resulting mixture was heated at reflux

overnight. The mixture was quenched with dilute HCl and stirred for 30 minutes, adjusted pH to 7.5-8.5, then extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give a brown oil. After silica gel column chromatography, the title compound was obtained as a green oil. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.02(s,2H), 6.83(brs,1H), 4.78(s,2H), 4.14(m,1H), 2.2(s,3H), 2.13(s,6H), 1.66(m,4H), 0.93(9t,6H) ppm.

Example 197

[2-(2,4-Dichloro-phenylamino)-4-(1-ethyl-propoxy)-6-methyl-pyridin-3-yl]-methanol

To a solution of 4-(1-ethyl-propoxy)-6-methyl-2-(2,4-dichloro-phenylamino)-nicotinic acid in dry THF was added BH<sub>3</sub>.DMS. The resulting mixture was heated at reflux overnight. The mixture was quenched with dilute HCl and stirred for 30 min, adjusted pH to 7.5-8.5, then extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give a golden oil. After silica gel column chromatography, the title compound was obtained as a golden oil. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.44(d,1H), 8.18(s,1H), 7.32(d,1H), 7.179d,1H), 6.28(s,1H), 4.82(s,2H), 4.21(m,1H), 2.42(s,3H), 1.6-1.8(m,4H), 0.94(t,6H) ppm.

Example 198

[2-(2,4-Dimethoxy-phenylamino)-4-(1-methoxymethyl-propoxy)-6-methyl-pyridin-3-yl]-methanol

The title compound was prepared by a method analogous to that described for Example 197, starting with the corresponding nicotinic acid with BH<sub>3</sub>.DMS. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.91(d,1H), 6.50(m,2H), 5.91(s,1H), 4.42(m,1H), 4.281(s,2H), 3.79(s,3H), 3.76(s,3H), 3.56(m,2H), 3.40(s,3H), 2.33(s,3H), 1.6-1.8(m,2H), 1.02(t,3H) ppm.

Example 199

[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-imidazol-1-yl-methanone

The title compound was prepared by a method analogous to that described for Example 183, starting with the corresponding nicotinic acid with carbonyldiimidazole. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.1(s,1H), 7.52(s,1H), 7.05(s,1H), 6.78(s,2H), 6.17(s,1H), 5.97(d,1H), 3.3(m,1H), 2.23(s,3H), 2.18(s,3H), 2.00(s,6H), 1.4-1.7(m,4H), 0.93(t,6H) ppm.

Example 200

1-[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-ethanone

The title compound was prepared by reacting [4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl]-imidazol-1-yl-methanone with methylmagnesium bromide/ethyl ether in methylene chloride. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.7(d,1H), 6.88(s,2H), 6.10(s,1H), 3.32(m,1H), 2.73(s,3H), 2.31(s,3H), 2.10(s,3H), 2.09(s,6H), 1.5-1.7(m,4H), 0.95(t,6H) ppm.

Example 201

(1-Ethyl-propyl)-[6-methyl-3-propyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.84(s,2H), 6.04(s,1H), 3.81(d,1H), 3.31(m,1H), 2.56(t,2H), 2.27(s,3H), 2.12(s,3H), 2.04(s,6H), 1.4-1.7(6H), 1.02(t,3H), 0.93(t,6H) ppm.

Example 202

5 2-[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl]-2-methyl-malonic acid dimethyl ester

The title compound was prepared by a method analogous to that described for Example 185. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,2H), 6.01(s,1H), 5.05(m,1H), 3.70(s,6H), 3.4(s,2H), 3.3(m,1H), 2.27(s,3H), 2.12(s,3H), 2.07(s,6H), 1.4-1.7(m,4H), 1.48(s,3H), 0.949t,6H) ppm.

Example 203

10 [4-(1-Ethyl-propoxy)-6-methyl-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine

The title compound was prepared by decarboxylation of the corresponding nicotinic acid at 160°C oil bath. mp. 98-100°C; Anal. For C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O calc. C, 76.88; H, 9.03; N, 8.97; found: C, 76.97; H, 9.21; N, 8.99.

15 The following title compounds of Examples 204 and 205 were prepared by reacting of 3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-4-carbaldehyde with alkyl-magnesium bromide in THF:

Example 204

2-Ethyl-1-[3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-butan-1-ol

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,2H), 6.72(s,1H), 4.90(t,1H), 4.00(s,3H), 2.29(s,3H), 2.19(s,3H), 2.06(s,6H), 1.2-1.6(m,5H), 0.92(t,3H), 0.88(t,3H) ppm.

Example 205

1-[3-Methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-2-methyl-butan-1-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.88(s,2H), 6.74(s,1H), 5.00(m,1H), 4.00(s,3H), 2.29(s,3H), 2.19(s,3H), 2.06(s,6H), 1.4-1.9(m,3H), 0.992(t,3H), 0.989(d,3H) ppm.

25 Example 206

1-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-propan-1-ol

30 To a -78°C solution of 4-bromo-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine in dry THF was added nBuLi and stirred at that temperature for 20 minutes. Excess propionaldehyde was added and stirred for 2 hours at -78°C. The mixture was quenched with water, extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated. After column chromatography, an off-white solid was obtained, mp. 119-120°C. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.86(s,3H), 4.90(m,1H), 2.281(s,3H), 2.28(s,3H), 2.21(s,3H), 2.02(s,6H), 1.65-1.8(m,2H), 1.00(t,3H) ppm.

Example 207

35 4-(1-Methoxy-propyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

The title compound was prepared by reaction of 1-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-propan-1-ol with sodium hydride, followed by quenching with methyl

iodide.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.87(s,2H), 6.74(s,1H), 4.33(m,1H), 3.25(s,3H), 2.28(s,3H), 2.27(s,3H), 2.21(s,3H), 2.03(s,6H), 1.6-1.8(m,2H), 0.94(t,3H) ppm.

Example 208

4-(1-Ethoxy-propyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

The title compound was prepared by reaction of 1-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-propan-1-ol with sodium hydride, followed by quenching with ethyl iodide.

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.86(s,2H), 6.77(s,1H), 4.41(m,1H), 3.22-3.45(m,2H), 2.28(s,3H), 2.27(s,3H), 2.21(s,3H), 2.03(s,6H), 1.6-1.8(m,2H), 1.20(t,3H), 0.95(t,3H) ppm.

Example 209

4-(1-Allyloxy-propyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

The title compound was prepared by reaction of 1-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-propan-1-ol with sodium hydride, followed by quenching with allyl bromide.

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.87(s,2H), 6.78(s,1H), 5.93(m,1H), 5.1-5.3(m,2H), 4.48(m,1H), 3.95(m,1H), 3.76(m,1H), 2.29(s,3H), 2.26(s,3H), 2.21(s,3H), 2.03(s,6H), 1.6-1.8(m,2H), 0.96(t,3H) ppm.

Example 210

4-(1-Butoxy-propyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

The title compound was prepared by reacting of 1-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-propan-1-ol with sodium hydride, followed by quenching with butyl iodide.

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  6.86(s,2H), 6.76(s,1H), 4.37(m,1H), 3.35(m,1H), 3.25(m,1H), 2.28(s,3H), 2.26(s,3H), 2.20(s,3H), 2.03(s,6H), 1.6-1.8(m,2H), 1.5-1.65(m,2H), 1.3-1.5(m,2H), 0.96(t,3H), 0.89(t,3H) ppm.

The title compounds of the following Examples 211 through 215 were prepared by a method analogous to that described in Example 206 starting with an appropriate 4-bromo-2-(substituted-phenoxy)-pyridine derivative with nBuLi, followed by quenching with an appropriate aldehyde.

Example 211

1-[2-(2,4-Dichloro-6-methyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-ol

one racemate  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.28(d,1H), 7.14(d,1H), 6.80(s,1H), 4.92(d,1H), 4.00(s,3H), 2.21(s,3H), 2.13(s,3H), 1.3-1.65(m,5H), 0.93(t,3H), 0.87(t,3H) ppm.

The other racemate  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.18(s,1H), 7.08(d,1H), 6.74(d,1H), 5.17(m,1H), 3.93(s,3H), 2.75(m,1H), 2.1-2.25(m,1H), 2.16(s,3H), 2.13(s,3H), 1.6-1.8(m,2H), 1.0-1.3(m,2H), 0.93(t,3H), 0.72(t,3H) ppm.

Example 212

1-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-2,2,2-trifluoro-ethanol

mp. 134-139°C, Anal. For  $C_{18}H_{20}F_3NO_2$  calc.: C, 63.71; H, 5.94; N, 4.13; found: C, 63.59; H, 6.00; N, 4.02.

5

Example 213

1-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-2,2,2-trifluoro-ethanol

$^1H$  NMR( $CDCl_3$ ) d 6.979s, 2H), 6.19(s, 1H), 2.14(s, 6H), 2.06(s, 6H) ppm.

Example 214

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-pyridin-2-yl-methanol

10  $^1H$  NMR( $CDCl_3$ ) d 8.61(d, 1H), 7.71(m, 1H), 7.30(m, 1H), 7.10(m, 1H), 7.03(s, 2H), 6.70(s, 1H), 6.03(s, 1H), 2.37(s, 3H), 2.16(s, 3H), 2.03(s, 6H), ppm.

Example 215

1-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-

ol

15  $^1H$  NMR( $CDCl_3$ ) d 7.05(s, 2H), 6.759s, 1H), 4.90(t, 1H), 3.98(s, 3H), 2.19(s, 3H), 2.06(s, 6H), 2.13(d, 1H), 1.25-1.65(m, 5H), 0.92(t, 3H), 0.87(t, 3H) ppm.

The title compounds of the following Examples 216 through 219 were prepared by oxidation of the corresponding alcohol with Dess Martin reagent in DMSO/methylene chloride or pyridinium chlorochromate in methylene chloride.

20

Example 216

1-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-propan-1-one

mp. 82-85.5°C, Anal. For  $C_{19}H_{25}NO_2$  calc.: C, 76.74; H, 7.80; N, 4.71; Found: C, 76.61; H, 7.94; N, 4.66.

Example 217

25

1-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-2,2,2-trifluoro-ethanone

$^1H$  NMR( $CDCl_3$ ) d 7.06(s, 2H), 6.99(s, 1H), 2.42(s, 3H), 2.30(s, 3H), 2.03(s, 6H) ppm.

Example 218

[2-(4-Chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-pyridin-2-yl-methanone

30  $^1H$  NMR( $CDCl_3$ ) d 8.72(d, 1H), 8.17(d, 1H), 7.95(m, 1H), 7.52(m, 1H), 7.05(s, 2H), 6.75(s, 1H), 2.25(s, 3H), 2.22(s, 3H), 2.07(s, 6H) ppm.

Example 219

1-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-

one

35  $^1H$  NMR( $CDCl_3$ ) d 7.05(s, 2H), 6.67(s, 1H), 3.98(s, 3H), 3.09(m, 1H), 2.61(s, 3H), 2.06(s, 6H), 1.76(m, 2H), 1.51(m, 2H), 0.92(t, 6H) ppm.

Example 220

4-(1-Ethoxy-2,2,2-trifluoro-ethyl)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine



The title compound was prepared by reacting the corresponding alcohol with NaH, followed by quenching with ethyl iodide.

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.92(s,1H), 6.87(s,2H), 4.92(m,1H), 3.60(m,2H), 2.349s,3H), 2.29(s,3H), 2.26(s,3H), 2.03(s,6H), 1.26(t,3H) ppm.

5 The title compounds of the following Examples 221 through 222 were prepared by reacting of the corresponding ketone with alkyl lithium or alkyl magnesium.

Example 221

2-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-butan-2-ol

10 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.86(m,3H), 2.48(s,3H), 2.28(s,3H), 2.21(s,3H), 2.02(s,6H), 1.8-2.1(m,2H), 1.61(s,3H), 0.84(t,3H) ppm.

Example 222

3-[3,6-Dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-pentan-3-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.87(s,1H), 6.86(s,2H), 2.43(s,3H), 2.28(s,3H), 2.21(s,3H), 2.0-2.2(m,2H), 2.02(s,6H), 1.7-1.9(m,2H), 1.69(brs,1H), 0.8(t,6H) ppm.

15 Example 223

1-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-hydroxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-one

20 The title compound was prepared by reacting 1-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-2-ethyl-butan-1-one with BBr<sub>3</sub> or BCl<sub>3</sub> in THF or methylene chloride.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.04(s,2H), 7.01(s,1H), 3.26(m,1H), 2.24(s,3H), 2.08(s,6H), 1.80(m,2H), 1.63(m,2H), 0.91(t,6H) ppm.

Example 224

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinamide

25 To a solution of 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)nicotinic acid in anhydrous methylene chloride was added thionyl chloride. After stirring for 1 hr, the reaction mixture was concentrated to dryness. The residue was dissolved in dry THF and NH<sub>3</sub>(g) was bubbled in. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give a light yellow  
30 solid. The solid was purified through silica gel column chromatography using 1% methanol in chloroform as eluent to give the title compound as a white solid, mp. 85-88°C. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.69(brs,1H), 8.01(brs,1H), 6.87(s,2H), 6.11(s,1H), 5.48(brs,1H), 3.31(m,1H), 2.29(s,3H), 2.10(s,3H), 2.07(s,6H), 1.60(m,4H), 0.95(t,6H) ppm.

35 The title compounds of the following Examples 225 through 231 were prepared by a method analogous to that described in the preceding paragraph, starting with the corresponding nicotinic acid or pyrimidine-5-carboxylic derivative and quenching with an appropriate nucleophile.

Example 225

4-(1-Ethyl-propylamino)-6,N-dimethyl-2-(2,4,6-trimethyl-phenoxy)-nicotinamide

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.8(bris,1H), 8.21(bris,1H), 6.88(s,2H), 6.11(s,1H), 3.31(m,1H), 2.92(d,3H), 2.30(s,3H), 2.10(s,3H), 2.07(s,6H), 1.60(m,4H), 0.95(t,6H) ppm.

5 Example 226

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinamide

10 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.7(d,1H), 7.9(bris,1H), 7.0(s,2H), 6.2(s,1H), 5.6(bris,1H), 3.7(m,1H), 3.66(m,1H), 3.54(m,1H), 2.07(s,3H), 2.068(s,3H), 2.06(s,3H), 1.7(m,1H), 1.6(m,1H), 0.99(t,3H) ppm.

Example 227

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid hydrazide

15 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.15(s,1H), 7.04(s,2H), 6.23(s,1H), 3.6-3.8(m,2H), 3.53(m,1H), 2.08(s,6H), 2.05(s,3H), 2.04(s,3H), 1.5-1.8(m,2H), 1.01(t,3H) ppm.

Example 228

2-(4-Chloro-2,6-dimethyl-phenoxy)-N-ethyl-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinamide

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.74(d,1H), 8.12(s,1H), 7.05(s,2H), 6.23(s,1H), 3.5-3.8(m,3H), 3.43(m,2H), 2.06(s,9H), 1.8(bris,1H), 1.5-1.7(m,2H), 1.19(t,3H), 1.00(t,3H) ppm.

Example 229

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S)-(1-hydroxymethyl-propylamino)-6,N-dimethyl-nicotinamide

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.80(d,1H), 8.12(s,1H), 7.04(s,2H), 6.22(s,1H), 3.5-3.8(m,3H), 2.93(d,3H), 2.06(s,9H), 1.8(bris,1H), 1.5-1.7(m,2H), 0.99(t,3H) ppm.

Example 230

2-(4-Chloro-2,6-dimethyl-phenoxy)-N-cyclopentyl-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinamide

30 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.69(d,1H), 8.13(d,1H), 7.04(s,2H), 6.22(s,1H), 4.35(m,1H), 3.4-3.8(m,3H), 2.056(s,9H), 1.4-2.0(m, 10H), 0.99(t,3H) ppm.

Example 231

2-(4-Chloro-2,6-dimethyl-phenoxy)-N-cyclopropylmethyl-4-(S)-(1-hydroxymethyl-propylamino)-6-methyl-nicotinamide

35 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.71(d,1H), 8.24(s,1H), 7.05(s,2H), 6.23(s,1H), 3.5-3.8(m,3H), 3.27(t,2H), 2.08(s,6H), 2.07(s,3H), 1.8(bris,1H), 1.5-1.75(m,2H), 0.99(t,3H), 0.46(m,2H), 0.21(m,2H) ppm.

The title compounds of the following Examples 232 through 236 were prepared by a method analogous to that described for Example 224.

Example 232

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinamide

5 A brown solid, mp. 204-206°C.

Example 233

4-(1-Ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carboxylic acid amide

10 Mp. 174-176°C; Anal. For  $C_{20}H_{28}N_4O_2$  calc.: C, 67.39; H, 7.92; N, 15.72; found: C, 67.90; H, 8.19; N, 14.66.  $^1H$  NMR( $CDCl_3$ ) d 7.95(s,1H), 6.89(s,2H), 5.58(s,1H), 5.4(m,1H), 2.28(s,3H), 2.25(s,3H), 2.15(s,6H), 1.75(m,4H), 0.96(t,6H) ppm.

Example 234

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinonitrile

15  $^1H$  NMR( $CDCl_3$ ) d 6.85(s,2H), 6.06(s,1H), 4.72(d,1H), 3.36(m,1H), 2.28(s,3H), 2.17(s,3H), 2.09(s,6H), 1.5-1.8(m,4H), 0.96(t,6H) ppm.

Example 235

[4-(1-Ethyl-propoxy)-6-methyl-3-nitro-pyridin-2-yl]-(2,4,6-trimethyl-phenyl)-amine

20 The title compound was prepared by heating 2-bromo (or chloro)-4-(1-ethyl-propoxy)-6-methyl-3-nitro-pyridine with 2,4,6-trimethylaniline in DMSO at 130°C. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give crude material. The material was purified through silica gel column chromatography to give the title compound as a yellow solid.  $^1H$  NMR( $CDCl_3$ ) d 8.52(s,1H), 6.92(s,2H), 6.12(s,1H), 4.31(m,1H), 2.32(s,3H), 2.24(s,3H), 2.18(s,6H), 1.77(m,4H), 1.01(t,6H) ppm.

25 Example 236

4-(1-Ethyl-propoxy)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3-diamine

30 The title compound was prepared by hydrogenation of the corresponding 3-nitro derivative with 10%Pd/C in ethanol at 50 psi. A pale gray solid was obtained in 97% yield, mp. 73-75°C.  $^1H$  NMR( $CDCl_3$ ) d 6.89(s,2H), 6.18(s,1H), 4.22(m,1H), 3.2(brs,2H), 2.29(s,3H), 2.19(s,6H), 1.7(m,4H), 0.97(t,6H) ppm.

Example 237

2-Chloro-N-[4-(1-ethyl-propoxy)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-yl]-acetamide

35 The title compound was prepared by acylation of 4-(1-ethyl-propoxy)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3-diamine with chloroacetyl chloride,  $NEt_3$  in THF at room temperature. A tan solid was isolated, mp. 79-82°C. Anal. For  $C_{22}H_{30}ClN_3O_2$  calc. C, 65.41; H, 7.49; N, 10.40; found: C, 65.56; H, 7.62; N, 10.98.

Example 238

N-Butyl-N-ethyl-6-methyl-3-nitro-N-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine

A mixture of butyl-(2-chloro-6-methyl-3-nitro-pyridin-4-yl)-ethyl-amine (700 mg, 2.58 mmol) and 2,4,6-trimethylaniline in DMSO was heated in 140°C oil bath for overnight. An additional 0.75 ml of 2,4,6-trimethylaniline was added and the resulting mixture was heated for an additional 48 hours. The mixture was quenched with water, brine and extracted 3 times with ethyl acetate. The organic layer was separated, dried (MgSO<sub>4</sub>) and concentrated to dryness. After silica gel column chromatography purification, the title compound was obtained as an oil.

Example 239

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid

The title compound was prepared by heating 2-chloro-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid and trimethylaniline in the presence of potassium carbonate and copper in DMF. The desired product was isolated by silica gel column chromatography using 5% methanol in chloroform as solvent to give a tan solid, mp. 130-135°C.

Example 240

4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid methyl ester

A mixture of 2-chloro-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid methyl ester, trimethylaniline, potassium carbonate, copper in DMF was heated at reflux. The mixture was quenched with ammonium chloride and stirred for 20 min, filtered through celite and washed with ethyl acetate. The filtrate was extracted with ethyl acetate. The organic layer was separated, dried and concentrated to dryness. The residue was purified through silica gel column chromatography using 2% methanol in chloroform as eluent to give the title compound as a solid.

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.9(s,1H), 8.0(d,1H), 6.91(s,2H), 5.79s,1H), 3.92(s,3H), 3.37(m,1H), 2.30(s,3H), 2.17(s,3H), 2.10(s,6H), 1.5-1.7(m,4H), 0.96(t,6H) ppm.

Example 241

N4-(1-Ethyl-propyl)-3,6-dimethyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine

The title compound was prepared by reduction of 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-nicotinic acid with 1M of lithium aluminium hydride in diethyl ether and aluminium trichloride at reflux. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.9(s,2H), 6.0(s,1H), 5.4(brs,1H), 3.6(d,1H), 3.3(m,1H), 2.32(s,3H), 2.2(s,3H), 2.15(s,6H), 1.4-1.7(m,4H), 1.0(t,6H) ppm.

Example 242

2-[4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyridin-3-ylmethyl]-malonic acid dimethyl ester

Mp. 136-138°C; Anal. For C<sub>26</sub>H<sub>37</sub>N<sub>3</sub>O<sub>4</sub>. 3/4 H<sub>2</sub>O calc.: C, 66.57; H, 8.27; N, 8.96; found: C, 66.67; H, 7.95; N, 8.88.

EXPRESS MAIL NO. EL162815459WS

Example 243

[2-(4-Bromo-2,6-dimethyl-phenylamino)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-methanol

5 The title compound was prepared by reduction of the corresponding nicotinic acid derivative with  $\text{BH}_3$ .DMS in THF at reflux. Standard work-up procedure to give the title compound as a white foam.  $^1\text{H}$  NMR( $\text{CDCl}_3$ ) 7.15(s,2H), 6.2(brs,1H), 5.92(s,1H), 4.47m,1H), 4.43(s,2H), 3.25(m,1H), 2.17(s,3H), 2.10(s,6H), 1.58(m,2H), 1.47(m,2H), 0.90(t,6H) ppm.

Example 244

N2-(2,4-Dichloro-phenyl)-N4-(1-ethyl-propyl)-3,6-dimethyl-pyridine-2,4-diamine

10 The title compound was prepared by a method analogous to that described for Example 146.  $^1\text{H}$  NMR( $\text{CDCl}_3$ ) d 7.79(dd,1H), 7.30(d,1H), 7.10(dd,1H), 6.53(brs,1H), 6.13(s,1H), 3.79(d,1H), 3.2-3.4(m,1H), 2.36(s,3H), 1.92(s,3H), 1.4-1.6(m,4H), 0.93(t,6H) ppm.

Example 245

[2-(2,4-Dichloro-phenylamino)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-methanol

15 The title compound was prepared by reduction of the corresponding nicotinic acid derivative with  $\text{BH}_3$ .DMS in THF at reflux.  $^1\text{H}$  NMR( $\text{CDCl}_3$ ) d 7.22(d,1H), 7.07(d,1H), 7.00(d,1H), 6.10(s,1H), 5.7(brs,1H), 4.4(s,2H), 3.3 (m,1H), 2.35(s,3H), 2.02(s,3H), 1.4-1.6(m,4H), 0.92&0.91(two sets of t,6H) ppm.

Example 246

20 2-[6-Methyl-3-nitro-2-(2,4,6-trimethyl-phenylamino)-pyridin-4-ylamino]-butan-1-ol

The title compound was prepared by heating 2-[6-methyl-3-nitro-2-chloro-pyridin-4-ylamino]-butan-1-ol with trimethylaniline in DMSO at  $130^\circ\text{C}$ .  $^1\text{H}$  NMR( $\text{CDCl}_3$ ) d 9.38(brs,1H), 6.93(s,3H), 3.7-3.8(m,3H), 2.30(s,3H), 2.12(s,6H), 1.8(m,1H), 1.65(m,1H), 1.02(t,3H) ppm

Example 247

25 2-[4-(1-Ethyl-propylamino)-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-5-yl]-propionic acid ethyl ester

$^1\text{H}$  NMR( $\text{CDCl}_3$ ) d 6.85(s,2H), 5.16(d,1H), 4.49(q,1H), 4.0-4.2(m,3H), 2.289s,3H0, 2.20(s,3H), 2.06(s,6H), 1.4-1.7(m,4H), 1.44(d,3H), 1.21(t,3H), 0.93(t,3H), 0.87(t,3H) ppm.

Example 248

30 [3-Aminomethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine

The title compound was prepared by a method analogous to that described for Example 188. mp.  $117-119^\circ\text{C}$ ; Anal. For  $\text{C}_{21}\text{H}_{31}\text{N}_3\text{O}$ .  $1/3 \text{ H}_2\text{O}$  calc.: C, 72.58; H, 9.18; N, 12.09; found: C, 72.93; H, 9.28; N, 12.02.

35 The following title compounds of Examples 249-251 were prepared by reacting [4-(1-ethyl-propylamino)-6-methyl-2-(4-halo-2,6-dimethyl-phenoxy)-pyridin-3-yl]-methanol with thionyl

chloride in benzene, concentrated to dryness, followed by reacting with potassium cyanide in DMSO at room temperature.

Example 249

[2-(4-Bromo-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-

5 acetonitrile

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.2(s,2H), 6.1(s,1H), 3.82(d,1H), 3.7(s,2H), 3.34(m,1H), 2.1(s,3H), 2.03(s,6H), 1.45-1.7(m,4H), 0.99(t,6H) ppm.

Example 250

[2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-propylamino)-6-methyl-pyridin-3-yl]-

10 acetonitrile hydrogen chloride

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.08(s,2H), 6.2(s,1H), 4.92(d,1H), 3.45(m,1H), 2.71(s,3H), 2.549m,2H), 2.14(s,6H), 1.7(m,2H), 1.40-1.6(m,4H), 0.95(t,6H) ppm.

Example 251

[6-(1-Ethyl-propoxy)-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-amine

15 MP. 149-151°C, Anal. For C<sub>20</sub>H<sub>26</sub>N<sub>4</sub>O calc.: C, 72.81; H, 8.68; N, 13.41; found: C, 72.70; H, 8.86; N, 13.14

Example 252

2-[2-(4-Chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol

20 The title compound was prepared by heating the corresponding nicotinic acid derivative at 160-170°C oil bath. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.05(s,2H), 6.09(s,1H), 5.35(s,1H), 4.43(s,1H), 3.68(m,1H), 3.64(m,1H), 3.29(m,1H), 2.30(s,3H), 2.09(s,6H), 1.60(m,1H), 1.47(m,1H), 0.89(t,3H) ppm.

Example 253

[3-Aminomethyl-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-yl]-(1-

25 chloromethyl-propyl)-amine

The title compound was prepared by reacting [2-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-pyridin-4-(S)-ylamino]-butan-1-ol with thionyl chloride in benzene, concentrated to dryness, followed by reacting with NH<sub>3</sub>(g) at room temperature. After standard workup procedure and silica gel column chromatography, the title compound was obtained. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.00(s,2H), 6.3(brs,1H), 6.07(s,1H), 4.0-4.2(m,2H), 3.9(brs,2H), 3.5-3.8(m,3H), 2.12(s,3H), 2.03(s,6H), 1.6-1.9(m,2H), 1.00(t,3H) ppm

35 The following title compounds of Examples 254 and 255 were prepared by reacting [2-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-pyridin-4-(S)-ylamino]-butan-1-ol with thionyl chloride in benzene, concentrated to dryness, followed by reacting with an appropriate amine in THF at room temperature. After standard workup procedure and silica gel column chromatography, the title compound was obtained.

Example 254

2-[2-(4-Chloro-2,6-dimethyl-phenoxy)-6-methyl-3-methylaminomethyl-pyridin-4-(S)-ylamino]-butan-1-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.01(s,2H), 6.14(s,1H), 4.55(brs,1H), 3.6-3.8(m,2H), 3.4(m,1H), 2.6(s,3H), 2.11(s,3H), 2.02(brs,6H), 1.65(m,2H), 0.97(t,3H)ppm.

5      Example 255

2-[3-Aminomethyl-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.999s,2H), 6.10(s,1H), 4.4.00(Abq,2H), 3.5-3.75(m,2H), 3.4(m,1H), 2.73(brs,4H), 2.08(s,3H), 2.00(s,6H), 1.58(m,4H), 0.94(t,3H) ppm.

10      The title compounds of the following Examples 256 through 262 were prepared by bromination or chlorination of 2-[2-(substituted-phenoxy)-6-methyl-pyridin-4-alkylamine with NBS or NCS in methylene chloride or chloroform at room temperature.

Example 256

[3-Bromo-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine

15      <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.85(s,2H), 6.04(s,1H), 4.62(d,1H), 3.33(m,1H), 2.27(s,3H), 2.13(s,3H), 2.08(s,6H), 1.5-1.7(m,2H), 0.95(t,3H) ppm.

Example 257

2-[3,5-Dibromo-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-ylamino]-butan-1-ol

20      <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.02(s,2H), 4.34(m,1H), 3.6-3.8(m,2H), 2.30(s,3H), 2.05(s,6H), 1.5-1.8(m,2H), 0.98(t,3H) ppm.

Example 258

2-[3-Bromo-6-(4-chloro-2,6-dimethyl-phenoxy)-2-methyl-pyridin-4-(S)-ylamino]-butan-1-ol

25      <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.05(s,2H), 5.62(s,1H), 4.86(d,1H), 3.55-3.7(m,2H), 3.3(m,1H), 2.428(s,3H), 2.09(s,6H), 1.4-1.7(m,3H), 0.91(t,3H) ppm.

Example 259

2-[3-Bromo-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol

30      <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.02(s,2H), 6.14(s,1H), 4.81(d,1H), 3.6-3.8(m,2H), 3.45(m,1H), 2.12(s,3H), 2.08(s,6H), 1.5-1.8(m,2H), 1.00(t,3H) ppm.

Example 260

2-[3-Chloro-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-(S)-ylamino]-butan-1-ol

35      <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.02(s,2H), 6.18(s,1H), 4.76(d,1H), 3.6-3.8(m,2H), 3.45(m,1H), 2.13(s,3H), 2.07(s,6H), 1.5-1.8(m,2H), 0.99(t,3H) ppm.

Example 261

2-[3,5-Dichloro-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-ylamino]-butan-1-

ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.03(s,2H), 4.34(m,1H), 3.6-3.8(m,2H), 2.40(s,3H), 2.05(s,6H), 1.5-1.8(m,2H), 0.99(t,3H) ppm.

5

Example 262

2-[3-Chloro-6-(4-chloro-2,6-dimethyl-phenoxy)-2-methyl-pyridin-4-(S)-ylamino]-butan-1-

ol

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.05(s,2H), 5.66(s,1H), 4.86(brs,1H), 3.5-3.8(m,2H), 3.3(m,1H), 2.38(s,3H), 2.09(s,6H), 1.4-1.7(m,3H), 0.91(t,3H) ppm.

10

Example 263

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(S)-(4-ethyl-2-oxo-oxazolidin-3-yl)-6-methyl-nicotinonitrile

The title compound was prepared by reacting with 2-(4-chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-propylamino)-6-methyl-nicotinic acid with triphosgene/NEt<sub>3</sub> in THF. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.18(s,1H), 7.06(s,2H), 5.00(m,1H), 4.64(t,1H), 4.23(dd,1H), 2.339s,3H), 2.08(s,6H), 1.5-1.8(m,2H), 0.949t,3H) ppm.

15

Example 264

2-(2,4-Dimethoxy-phenylamino)-4-(1-methoxymethyl-propoxy)-6-methyl-nicotinic acid

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.3(brs,1H), 6.5(m,3H), 6.26(s,1H), 4.66(m,1H), 3.92(s,3H), 3.85(s,3H), 3.66(m,2H), 3.43(s,3H), 2.52(s,3H), 1.91(m,2H), 1.07(t,3H) ppm.

20

Example 265

4-(1-Ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carbonitrile

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.92(s,2H), 6.45(s,1H), 5.22(m,1H), 2.29(s,6H), 2.16(s,6H), 1.70(m,4H), 0.93(t,6H) ppm.

25

Example 266

N-(1-Ethyl-propyl)-2,5-dimethyl-N'-(2,4,6-trimethyl-phenyl)-pyrimidine-4,6-diamine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.9(s,1H), 6.85(s,2H), 4.95(d,1H), 4.21(m,1H), 2.5(s,3H), 2.25(s,3H), 2.13(s,6H), 1.4-1.7(m,4H), 1.3(s,3H), 0.85(t,6H) ppm

Example 267

5-Chloro-N4-(1-ethyl-propyl)-2-methyl-N6-(2,4,6-trimethyl-phenyl)-pyrimidine-4,6-diamine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.85(s,2H), 6.0(s,1H), 4.4(m,1H), 4.2(m,1H), 2.3(s,3H), 2.22(s,3H), 2.17(s,6H), 1.4-1.70(m,4H), 0.97(t,6H) ppm.

30

Example 268

5-Bromo-N-(1-ethyl-propyl)-2-methyl-N'-(2,4,6-trimethyl-phenyl)-pyrimidine-4,6-diamine

MP. 117-119°C, Anal. For C<sub>19</sub>H<sub>21</sub>BrN<sub>4</sub> calc.: C, 58.31; H, 6.95; N, 14.32; found: C, 58.43; H, 7.08; N, 14.23.

35

EXPRESS MAIL NO. EL162815459US

000000-130950



Example 269

4-(1-Ethyl-propylamino)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carboxylic acid

1H NMR(CDCl<sub>3</sub>) d 12.2(brs,1H), 11.1(brs,1H), 6.84(s,2H), 4.18(m,1H), 2.38(s,3H),  
5 2.18(s,3H), 2.15(s,6H), 1.56(m,4H), 0.90(t,6H) ppm.

Example 270

[4-(Cyclopropylmethyl-propyl-amino)-2-methyl-6-(2,4,6-trichloro-phenylamino)-pyrimidin-5-yl]-methanol

1H NMR(CDCl<sub>3</sub>) d 7.49s,2H), 4.95(s,2H), 4.92(s,1H), 3.28(brs,4H), 2.359s,3H),  
10 1.54(m,2H), 0.95(m,1H), 0.81(t,3H), 0.44(m,2H), 0.19(m,2H) ppm.

Example 271

6-(1-Ethyl-propoxy)-2,N5,N5-trimethyl-N4-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5-diamine

The title compound was prepared by methylation of 6-(1-ethyl-propoxy)-2-methyl-N4-  
15 (2,4,6-trimethyl-phenyl)-pyrimidine-4,5-diamine with lithium bis(trimethylsilyl)amide in THF, followed by quenching with methyl iodide. 1H NMR(CDCl<sub>3</sub>) d 7.35(s,1H), 6.90(s,2H), 5.16(m,1H), 2.73(s,6H), 2.29(s,3H), 2.27(s,3H), 2.18(s,6H), 1.6-1.8(m,4H), 0.96(t,6H) ppm.

Example 272

[5-Bromo-6-(1-ethyl-propoxy)-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-amine

20 The title compound was prepared by reacting [5-bromo-6-(1-ethyl-propoxy)-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-amine with 3-pentanol/NaH in THF at reflux overnight. After standard work-up and purification, the title compound was obtained as a white solid, mp. 94-96°C. 1H NMR(CDCl<sub>3</sub>) d 6.91(s,2H), 6.41(s,1H), 5.13(m,1H), 2.29(s,3H), 2.26(s,3H), 2.17(s,6H), 1.70(m,4H), 0.95(t,6H) ppm.

25 Example 273

4-(1-Ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carboxylic acid

To a solution of n-BuLi in THF was added a solution of [5-bromo-6-(1-ethyl-propoxy)-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-amine in THF at -78°C. After stirring for 10  
30 minutes, CO<sub>2</sub>(g) was added at -78°C and stirred at that temperature for 1 hour, then gradually warmed to room temperature. The resulting mixture was quenched with water and adjusted to pH 2 to 3 and extracted with chloroform. The organic layer was separated, dried and concentrated to dryness. The residue was purified through silica gel column chromatography to give the title compound as a solid, mp. 118-120°C, Anal. For C<sub>20</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> calc.: C, 67.20; H, 7.61; N, 11.76; found: C, 67.25; H, 7.87; N, 11.48.  
35

Example 274

[4-(1-Ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidin-5-yl]-methanol

To a solution of 4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidine-5-carboxylic acid in dry THF was added  $\text{BH}_3\cdot\text{DMS}$ . The resulting mixture was heated at reflux. The mixture was quenched with dilute HCl and stirred for 30 minutes, adjusted pH to 7.5-8.5, then extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give a crude material. The crude material was purified through silica gel column chromatography to give the title compound as a solid, mp. 121-123°C, Anal. For  $\text{C}_{20}\text{H}_{29}\text{N}_3\text{O}_2$  calc. C, 69.94; H, 8.51; N, 12.23; found: C, 69.73; H, 8.47; N, 11.99.

Example 275

[6-(1-Ethyl-propoxy)-5-methoxymethyl-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-

amine

The title compound was prepared by reacting [4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidin-5-yl]-methanol with NaH, followed by quenching with MeI.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.0(s,1H), 6.89(s,2H), 5.12(m,1H), 4.62(s,2H), 3.33(s,3H), 2.28(s,3H), 2.27(s,3H), 2.14(s,6H), 1.66(m,4H), 0.91(t,6H) ppm.

Example 276

[5-Aminomethyl-6-(1-ethyl-propoxy)-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethyl-phenyl)-

amine

To a solution of [4-(1-ethyl-propoxy)-2-methyl-6-(2,4,6-trimethyl-phenylamino)-pyrimidin-5-yl]-methanol in anhydrous methylene chloride was added thionyl chloride. After stirring for 1 hour, the reaction mixture was concentrated to dryness. The residue was dissolved in dry THF and  $\text{NH}_3(\text{g})$  was bubbled in. The reaction mixture was quenched with water and extracted with ethyl acetate. The reaction was worked-up and purified by standard procedure to give the title compound.

$^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  8.50(s,1H), 6.88(s,2H), 5.08(m,1H), 3.97(s,2H), 2.279s,3H), 2.25(s,3H), 2.159s,6H), 1.74(brs,2H), 1.65(m,4H), 0.91(t,6H) ppm.

Example 277

7-(1-Ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-

ylamine

The title compound was prepared by reacting 4-(1-ethyl-propoxy)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3-diamine with BrCN in acetonitrile at room temperature overnight. The mixture was quenched with water and adjusted to pH 8.0 with saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give crude material. The material was purified through silica gel column chromatography to give the title compound as a white solid, mp. 159-161°C.  $^1\text{H}$  NMR( $\text{CDCl}_3$ )  $\delta$  7.05(s,2H), 6.5(s,1H), 4.6(m,1H), 4.3(m,2H), 2.45(s,3H), 2.35(s,3H), 2.0(s,6H), 1.7(m,4H), 1.0(t,6H) ppm.

Example 278

7-(1-Ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridine

A mixture of 4-(1-ethyl-propoxy)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3-diamine, trimethyl orthoformate, p-toluenesulfonic acid monohydrate in toluene was heated at reflux using Dean-Stark apparatus for 24 hours. The mixture was heated at reflux overnight. The mixture was quenched with water, sat. NaHCO<sub>3</sub>, extracted with ethyl acetate. The organic layer was separated, dried (MgSO<sub>4</sub>) and concentrated to dryness. After purification, the title compound was isolated. Anal. For C<sub>21</sub>H<sub>29</sub>N<sub>3</sub>O.1/4H<sub>2</sub>O calc. C, 73.76; H, 8.10; N, 12.29; found: C, 73.22; H, 7.96; N, 12.42.

Example 279

7-(1-Ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-one

The title compound was prepared by reacting 4-(1-ethyl-propoxy)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3-diamine with triphosgene, NEt<sub>3</sub> in THF at room temperature. A white solid was isolated, mp. 184-186°C. Anal. For C<sub>21</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub> calc. C, 71.36; H, 7.70; N, 11.89; found: C, 71.09; H, 7.75; N, 11.63.

Example 280

7-(1-Ethyl-propoxy)-1,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-one

The title compound was prepared by reacting 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-one with lithium bis(trimethylsilyl)amide, followed by quenching with methyl iodide. Mp. 151-153°C. Anal. For C<sub>22</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>. 1/4H<sub>2</sub>O calc. C, 71.03; H, 7.99; N, 11.30; found: C, 71.29; H, 8.01; N, 11.03.

Example 281

(1-Ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-amine

A mixture of N-4-(1-ethyl-propyl)-6-methyl-N-2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine (250 mg, 0.77 mmol), trimethyl orthoformate (0.081 g, 0.766 mmol), p-toluenesulfonic acid monohydrate (0.01 g) in benzene was heated at reflux using Dean-Stark apparatus for 24 hours. Benzene was removed and toluene was added and an excess of trimethyl orthoformate (0.084 ml) was added to the reaction mixture. The mixture was heated at reflux overnight. The mixture was quenched with water, sat. NaHCO<sub>3</sub>, extracted with ethyl acetate. The organic layer was separated, dried (MgSO<sub>4</sub>) and concentrated to dryness. After purification, the title compound was isolated as a white crystal, mp 78-80°C.

Example 282

[2,5-Dimethyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-amine

A mixture of N-4-(1-ethyl-propyl)-6-methyl-N-2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine (250 mg, 0.77 mmol), trimethyl orthoacetate (0.184 g, 1.532 mmol), p-toluenesulfonic acid monohydrate (0.01 g) in toluene was heated at reflux using Dean-Stark apparatus for 3 hours. The mixture was quenched with water, brine, extracted with ethyl acetate. The organic layer was separated, dried (MgSO<sub>4</sub>) and concentrated to dryness. After purification, the title compound was obtained as a white crystal, mp 101-103°C. Anal. For C<sub>22</sub>H<sub>30</sub>N<sub>4</sub> calc. C, 75.39; H, 8.63; N, 15.98; found, C, 75.44; H, 8.95; N, 15.95.

Example 283

N7-(1-Ethyl-propyl)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridine-2,7-diamine

The title compound was prepared by reacting N4-(1-ethyl-propyl)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine with BrCN in acetonitrile at room temperature overnight. The mixture was quenched with water and adjusted to pH 8.0 with saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give crude material. The material was purified through silica gel column chromatography to give the title compound as a brown solid, mp. 158-160°C; Anal. For C<sub>21</sub>H<sub>29</sub>N<sub>5</sub> 1/4H<sub>2</sub>O calc. C, 70.85; H, 8.35; N, 19.67; found: C, 71.07; H, 8.30; N, 19.63.

Example 284

6-(1-Ethyl-propylamino)-2,7-dimethyl-9-(2,4,6-trimethyl-phenyl)-7,9-dihydro-purin-8-one

The title compound was prepared by methylation of 6-(1-ethyl-propylamino)-2-methyl-9-(2,4,6-trimethyl-phenyl)-7,9-dihydro-purin-8-one with lithium bis(trimethylsilyl)amide in THF, followed by quenching with methyl iodide. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.98(s,2H), 4.45(d,1H), 4.3(m,1H), 3.7(s,3H), 2.4(s,3H), 2.3(s,3H), 2.1(s,6H), 1.5-1.8(m,4H), 1.0(t,6H) ppm.

Example 285

6-(1-Ethyl-propoxy)-2,7-dimethyl-9-(2,4,6-trimethyl-phenyl)-7,9-dihydro-purin-8-one

The title compound was prepared by methylation of 6-(1-Ethyl-propoxy)-2-methyl-9-(2,4,6-trimethyl-phenyl)-7,9-dihydro-purin-8-one with lithium bis(trimethylsilyl)amide in THF, followed by quenching with methyl iodide. <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.00(s,2H), 5.31(m,1H), 3.66(s,3H), 2.479s,3H), 2.33(s,3H), 2.06(s,6H), 1.79(m,4H), 1.01(t,6H) ppm.

Example 286

[2-(4-Methoxy-2,6-dimethyl-phenoxy)-6-methyl-3-nitro-pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.71(d,1H), 6.57(s,2H), 6.21(s,1H), 3.76(s,3H), 3.59(m,1H), 3.48(m,1H), 3.45(m,1H), 3.37(s,3H), 2.13(s,3H), 2.08(s,6H), 1.6-1.8(m,4H), 0.86(t,3H) ppm.

Example 287

(1-Ethyl-propyl)-[2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.64(s,2H), 6.12(s,1H), 3.82(s,3H), 3.36(m,1H), 2.26(s,3H), 2.13(s,6H), 2.10(s,3H), 1.5-1.8m,4H), 0.99(t,6H).

Example 288

2-[2-(4-Methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-butan-1-ol

5 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.64(s,2H), 6.13(s,1H), 4.10(m,1H), 3.76(s,3H), 3.7-3.8(m,21H), 3.57(m,1H), 2.21(s,3H), 2.19(s,6H), 2.12(s,3H), 1.6-1.8(m,2H), 1.04(t,3H) ppm.

Example 289

sec-Butyl-[3-methoxy-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-pyridin-4-yl]-amine

10 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.64(s,2H), 6.13(s,1H), 4.51(d,1H), 3.92(s,3H), 3.82(s,3H), 3.469m,1H), 2.18(s,3H), 2.15(s,6H), 1.60(m,2H), 1.26(d,3H), 1.00(t,3H) ppm.

Example 290

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(4-ethyl-oxazolidin-3-yl)-3,6-dimethyl-pyridine

15 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.07(s,2H), 6.36(s,1H), 4.98(m,1H), 4.78(m,1H), 4.23(m,1H), 3.83(m,1H), 3.71(m,1H), 2.28(s,3H), 2.20(s,3H), 2.09(s,6H), 1.81(m,1H), 1.58(m,1H), 0.98(t,3H) ppm.

Example 291

4-(4-Ethyl-oxazolidin-3-yl)-2-(4-methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.65(s,2H), 6.36(s,1H), 4.98(m,1H), 4.77(m,1H), 4.23(m,1H), 3.83(s,3H), 3.71(m,1H), ), 2.29(s,3H), 2.22(s,3H), 2.119(s,6H), 1.82(m,1H), 1.56(m,1H), 0.99(t,3H) ppm

Example 293

2-(4-Methoxy-2,6-dimethyl-phenoxy)-N%4&-(1-methoxymethyl-propyl)-6-methyl-pyridine-3,4-diamine

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.64(s,2H), 6.16(s,1H), 4.3(m,1H), 3.82(s,3H), 3.6-3.8(m,2H), 3.42(s,3H), 3.2(bris,2H), 2.18(s,3H), 2.13(s,6H), 1.6-1.8(m,2H), 1.03(t,3H) ppm.

Example 294

3-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-hydroxymethyl-6-methyl-pyridin-4-ylamino]-pentan-2-ol

30 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.01(s,2H), 6.16(s,1H), 5.19(d,1H), 4.94(m,2H), 3.88(m,1H), 3.27(m,1H), 2.11(s,3H), 2.05(s,6H), 1.73(m,1H), 1.57(m,1H), 1.24(d,3H), 0.97(t,3H)ppm.

Example 295

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-oxo-propylamino)-6-methyl-nicotinic acid methyl ester

35 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.63(d,1H), 7.01(s,2H), 5.90(s,1H), 3.95(m,1H), 3.90(s,3H), 2.08(s,3H), 2.05(s,3H), 2.03(s,6H), 1.8-2.0(m,2H), 1.00(t,3H) ppm.

Example 296

3-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-methoxymethyl-6-methyl-pyridin-4-ylamino]-pentan-2-ol

1H NMR(CDCI<sub>3</sub>) d 7.08(s,2H), 6.21(s,1H), 5.40(brs,1H), 4.83(q,2H), 3.91(m,1H), 3.40(s,3H), 3.33(m,1H), 2.20(s,3H), 2.10(s,6H), 1.78(m,1H), 1.58(m,1H), 1.29(d,3H), 1.01(t,3H) ppm.

Example 297

3-[2-(4-Methoxy-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-ylamino]-pentan-2-ol

1H NMR(CDCI<sub>3</sub>) d 6.66(s,2H), 6.27(s,1H), 4.05(m,1H), 3.82(s,3H), 3.38(m,1H), 2.35(s,3H), 2.21(s,3H), 2.14(s,6H), 1.6-1.9(m,2H), 1.30(m,3H), 1.01(t,3H)ppm.

Example 298

4-sec-Butylamino-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester

1H NMR(CDCI<sub>3</sub>) d 8.01(d,1H), 6.58(s,2H), 6.06(s,1H), 3.85(s,3H), 3.77(s,3H), 2.10(s,3H), 2.07(s,6H), 1.21(d,3H), 0.97(t,3H) ppm.

Example 299

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-ethyl-2-hydroxy-2-methyl-propylamino)-6-methyl-nicotinic acid methyl ester

1H NMR(CDCI<sub>3</sub>) d 8.28(d,1H), 7.06(s,2H), 6.32(s,1H), 3.92(s,3H), 3.41(m,1H), 2.14(s,3H), 2.12(s,6H), 1.91(m,1H), 1.44(m,1H), 1.33(s,3H), 1.30(s,3H), 0.99(s,3H) ppm.

Example 300

4-(1-Hydroxymethyl-propylamino)-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester

1H NMR(CDCI<sub>3</sub>) d 8.13(d,1H), 6.63(s,2H), 6.21(s,1H), 3.91(s,3H), 3.82(s,3H), 3.81(m,2H), 3.59(m,1H), 2.16(s,3H), 2.12(s,6H), 1.6-1.859m,2H), 1.05(t,3H) ppm.

Example 301

2-(4-Chloro-2,6-dimethyl-phenoxy)-4-(1-hydroxymethyl-3-methylsulfanyl-propylamino)-6-methyl-nicotinic acid methyl ester

1H NMR(CDCI<sub>3</sub>) d 8.25(d,1H), 7.02(s,2H), 6.30(s,1H), 3.85(s,3H), 3.6-3.9(m,3H), 2.5-2.7(m,2H), 2.14(s,3H), 2.10(s,3H), 2.06(s,6H), 1.8-2.1(m,2H)ppm.

Example 301

2-(4-Chloro-2,6-dimethyl-phenoxy)-6-methyl-4-(tetrahydro-furan-3-ylamino)-nicotinic acid methyl ester

1H NMR(CDCI<sub>3</sub>) d 8.25(d,1H), 7.01(s,2H), 6.05(s,1H), 4.11(m,1H), 3.9-4.1(m,2H), 3.8-3.9(m,1H), 3.86(s,3H), 3.73(m,1H), 2.2-2.4(m,1H), 2.11(s,3H), 2.05(s,6H), 1.95(m,1H) ppm.

Example 302

{3-[2-(4-Chloro-2,6-dimethyl-phenoxy)-3-methoxycarbonyl-6-methyl-pyridin-4-ylamino]-4-hydroxy-butyl}-dimethyl-sulfonium iodide

<sup>1</sup>H NMR(CD<sub>3</sub>OD) δ 7.11(s,2H), 6.61(s,1H), 4.00(m,1H), 3.86(s,3H), 3.6-3.9(m,3H), 2.95(d,6H), 2.5-2.7(m,2H), 2.22(s,3H), 2.07(s,6H), 1.8-2.1(m,2H)ppm.

Example 303

5 4-(1-Hydroxymethyl-3-methylsulfonyl-propylamino)-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.15(d,1H), 6.58(s,2H), 6.28(s,1H), 3.85(s,3H), 3.76(s,3H), 3.6-3.9(m,3H), 2.5-2.7(m,2H), 2.12(s,3H), 2.09(s,3H), 2.07(s,6H), 1.8-2.1(m,2H)ppm.

Example 304

10 4-(1-Hydroxymethyl-propylamino)-2-(4-methoxy-2,6-dimethyl-phenoxy)-6,N-dimethyl-nicotinamide

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.84(d,1H), 8.31(m,1H), 6.66(s,2H), 6.29(s,1H), 3.81(s,3H), 3.5-3.9(m,3H), 2.98(d,3H), 2.15(s,3H), 2.12(s,6H), 1.6-1.8(m,2H), 1.05(t,3H)ppm.

Example 305

15 4-sec-Butylamino-2-(4-methoxy-2,6-dimethyl-phenoxy)-6,N-dimethyl-nicotinamide

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.77(brs,1H), 8.22(brs,1H), 6.61(s,2H), 6.11(s,1H), 3.78(s,3H), 3.45(m,1H), 2.93(d,3H), 2.10(s,3H), 2.07(s,6H), 1.5-1.7(m,2H), 1.23(m,3H), 0.98(t,3H)ppm.

Example 306

20 2-(4-Methoxy-2,6-dimethyl-phenoxy)-6-methyl-4-(tetrahydro-furan-3-ylamino)-nicotinic acid methyl ester

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 8.28(d,1H), 6.63(s,2H), 6.09(s,1H), 4.15(m,1H), 3.98-4.1(m,2H), 3.8-3.98(m,1H), 3.90(s,3H), 3.81(s,3H), 3.76(m,1H), 2.32-2.36(m,1H), 2.19(s,3H), 2.11(s,6H), 1.95(m,1H) ppm.

Example 307

25 4-sec-Butylamino-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-nicotinamide

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 9.74(ds,1H), 8.05(brs,1H), 6.65(s,2H), 6.16(s,1H), 5.55(brs,1H), 3.83(s,3H), 3.51(m,1H), 2.16(s,3H), 2.12(s,6H), 1.5-1.7(m,2H), 1.26(d,3H), 1.02(t,3H)ppm.

Preparation A

(6-Chloro-2,5-dimethylpyrimidin-4-yl)-(2,4,6-trimethylphenyl)-amine

30 A mixture of 2,5-dimethyl-4,6-dichloropyrimidine (1.77 g, 10 mmol) and trimethylaniline (2.70 g, 20 mmol) in 5 ml of DMSO was heated in an oil bath of 160°C for 4 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give the crude material. After silica gel column purification, and titration with hexane, white crystals (790 mg) were obtained; high MS calc, 275.1185, found 275.11667;  
35 IR(KBr) 3290, 3240, 2900, 1540 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.91 (s, 2H), 5.85 (s, 1H), 2.33 (s, 3H), 2.87 (s, 3H), 2.24 (s, 3H), 2.12 (s, 6H) ppm.

Preparation B

(6-Chloro-2,5-dimethylpyrimidin-4-yl)-methyl-(2,4,6-trimethylphenyl)-amine

A solution of (6-chloro-2,5-dimethylpyrimidin-4-yl)-(2,4,6-trimethylphenyl)-amine (276 mg, 1 mmol) in dry THF (2 ml) was treated with sodium hydride (60% in oil, 60 mg, 1.5 mmol) at room temperature. After stirring for 2 minutes, an excess of methyl iodide (0.5 ml) was added and the resulting mixture was stirred at room temperature for 20 minutes. The mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give a pale yellow solid (255 mg). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 3.26 (s, 3H), 2.50 (s, 3H), 2.27 (s, 3H), 2.03 (s, 6H), 1.39 (s, 3H) ppm.

Preparation C

4-Chloro-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine

A solution of 2,4,6-trimethylphenol (2.720 g, 20 mmol) in 60 ml of dry THF was treated with NaH (60% in oil, 1.200 g, 30 mmol) at room temperature. After stirring at room temperature for 15 minutes, 2,5-dimethyl-4,6-dichloropyrimidine (3.34 g, 20 mmol) was added and the resulting mixture was heated at reflux for 15 hours. The mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was dried and concentrated to give 5.4528 g of beige solid. The solid was recrystallized from isopropanol to give 5.1345 g of pale yellow solid, mp 86-87°C; high MS (C<sub>15</sub>H<sub>17</sub>ClN<sub>2</sub>O) calc. 276.1025, found 276.10359. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.87 (s, 2H), 2.37 (s, 6H), 2.28 (s, 3H), 2.01 (s, 6H) ppm.

Preparation D

2,4-Dichloro-3,6-dimethylpyridine

A mixture of 2,4-dihydroxy-3,6-dimethylpyridine (2.86 g, 20.58 mmol), POCl<sub>3</sub> (15 ml) and N,N-diethylaniline (3.6 ml, 22.64 mmol) was heated at reflux for 3 hours. The mixture was cooled, poured into ice water and extracted with diethyl ether. The organic layer was dried and concentrated to give 3.02 g of the crude material. After silica gel column chromatography using chloroform as eluent, 1.3102 g of the title compound was obtained as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.07 (s, 1H), 2.43 (s, 3H), 2.39 (s, 3H) ppm.

Preparation E

4-Chloro-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

A solution of 2,4,6-trimethylphenol (450 mg, 3.31 mmol) in 2 ml of DMSO was treated with NaH (60% in oil, 180 mg, 4.5 mmol). After 5min, 2,4-Dichloro-3,6-dimethyl-pyridine (528 mg, 3 mmol) was added. The mixture was heated in the oil bath of 130°C for 6 hours. The mixture was quenched with water and extracted with EtOAc. The organic layer was dried and concentrated to give 812.5 mg of crude material with two regioisomers. After silica gel column chromatography using 1:1 of CHCl<sub>3</sub>:hexane as eluent, the title compound was isolated as white crystals (141 mg), mp 57-62°C; high MS for C<sub>16</sub>H<sub>18</sub>ClNO: calc, 275.1072, found 275.70172; IR(KBr) 2951, 2920, 1592, 1564 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.87 (s, 2H), 6.77 (s, 1H), 2.39 (s, 3H), 2.29 (s, 3H), 2.18 (s, 3H), 2.03 (s, 6H) ppm. The regiochemistry was determined by X-ray



structural analysis of the undesired regioisomer, 2-chloro-3,6-dimethyl-4-(2,4,6-trimethylphenoxy)-pyridine.

To a solution of 4-chloro-2,5-dimethyl-6-(2,4,6-trimethyl-phenoxy)-pyridine 1-oxide (34 mg) in 1 ml dry methylene chloride was added 2M  $\text{PCl}_3$  in methylene chloride (0.022 ml). After addition, the mixture was heated at reflux for 0.5 hours, cooled and concentrated to dryness. The residue was poured into ice-water and extracted with methylene chloride. The organic layer was washed with brine, neutralized with sat. sodium carbonate, dried and concentrated to give 47 mg of the crude material. The crude material was crystallized out upon standing to give 31 mg (95%) of white crystals of the title compound.

#### Preparation F

##### (6-Chloro-2,5-dimethylpyrimidin-4-yl)-(2,4,6-trimethylphenyl)-acetonitrile

To a solution of mesitylacetonitrile (0.900 g, 5.65 mmol) in 8 ml dry THF was added sodium hydride (60% in oil, 0.250 g, 6.21 mmol) and the mixture was stirred at room temperature for 40 minutes. 2,5-Dimethyl-4,6-dichloropyrimidine (1.000 g, 5.65 mmol) was added and the resulting mixture was heated at reflux for 5 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 1.800 g of a yellow oil. The oil residue was purified through silica gel column chromatography using 10% ethyl acetate in hexane as eluent to give 0.986 g (58.3%) of the title compound as a white solid, mp 100-102°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.86 (s, 2H), 5.60 (s, 1H), 2.69 (s, 3H), 2.25 (s, 3H), 2.18 (s, 6H), 1.92 (s, 3H) ppm.

#### Preparation G

##### 2-(6-Chloro-2,5-dimethylpyrimidin-4-yl)-2-(2,4,6-trimethylphenyl)-propionitrile

A solution of (6-chloro-2,5-dimethylpyrimidin-4-yl)-(2,4,6-trimethylphenyl)-acetonitrile (0.250 g, 0.834 mmol) in 4 ml of dry THF was cooled to -78°C and treated with lithium bistrimethylsilylamide (1.0 M in THF, 0.92 ml) and stirred at that temperature for 45 minutes. Methyl iodide (0.426 g, 3.00 mmol) was added. The reaction mixture was gradually warmed to room temperature and stirred for 1 hour. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give a yellow oil. The oil residue was purified through silica gel chromatotron using ethyl acetate/hexane (4:6) as eluent to give 161 mg (62%) of yellow solid, mp 181-183°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.980 (s, 2H), 3.45 (s, 3H), 2.40 (s, 3H), 2.24 (s, 3H), 2.21 (s, 6H), 1.25 (s, 3H) ppm.

#### Preparation H

##### 4-Hydroxy-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine

A mixture of 6-chloro-2,5-dimethylpyrimidin-4-yl)-(2,4,6-trimethylphenyl)-acetonitrile (1.5 g, 5.0 mmol) and 60ml of 85% phosphoric acid was heated at reflux for 2 hours. The mixture was cooled at rt and diluted with water and extracted with chloroform. The organic layer was washed

with brine, dried and concentrated to give 1.21 g (95%) of the title compound as a white solid, mp 260-262°C.

Preparation I

4-Chloro-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine

5 A mixture of 4-hydroxy-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine (1.2 g, 4.68 mmol) and POCl<sub>3</sub> (25 ml) was heated at reflux for 1 hour. The mixture was cooled and evaporated to dryness. The residue was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to dryness to give 1.24 g (97%) of golden crystals, mp 82-84°C.

10 Preparation J

The following compounds were prepared by the methods analogous to that in Preparation C starting with 5-substituted-4,6-dichloro-2-methyl-pyrimidine and substituted phenol in tetrahydrofuran in the presence of a base (sodium hydride) at the temperature indicated below.

5-tert-Butyl-4-chloro-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine

15 The reaction was carried out at reflux in THF to give white crystals, mp 70-72°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.82 (s, 2H), 2.28 (s, 3H), 2.24 (s, 3H), 1.96 (s, 6H), 1.60 (s, 9H) ppm.

4-Chloro-5-isopropyl-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine

20 The reaction was carried at reflux in THF to give white crystals, mp 68-70°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 3.60 (m, 1H), 2.36 (s, 3H), 2.29 (s, 3H), 2.00 (s, 6H), 1.43 (s, 3H), 1.41 (s, 3H) ppm.

4,5-Dichloro-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine

The reaction run at room temperature to give white crystals, mp 68-70°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 2.41 (s, 3H), 2.29 (s, 3H), 2.04 (s, 6H) ppm.

4-Chloro-5-bromo-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine

25 The reaction was run at 0°C to room temperature. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (s, 2H), 2.41 (s, 3H), 2.29 (s, 3H), 2.03 (s, 6H) ppm.

4-Chloro-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidine-5-carbonitrile

The reaction was run at -40°C to give yellow crystals, mp 89-91°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.89 (s, 2H), 2.51 (s, 3H), 2.29 (s, 3H), 2.04 (s, 6H) ppm.

30 Preparation K

2,4-Dichloro-3,6-dimethyl-pyridine 1-oxide

A mixture of 2,4-dichloro-3,6-dimethyl-pyridine (790 mg, 4.49 mmol) and 50% m-chloro-perbenzoic acid (1.544 g, 4.49 mmol) in 10 ml of chloroform was stirred at room temperature for 20 hours. The mixture was quenched with water, washed with saturated sodium thiosulfate and saturated sodium carbonate, brine and extracted with chloroform. The organic layer was dried and concentrated to give 954 mg of crude material. The material was purified through silica gel to

give 662 mg of the title compound as a white crystals, mp 131-132°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.22 (s, 1H), 2.51 (s, 3H), 2.47 (s, 3H) ppm.

Preparation L

The following compounds were prepared by the method analogous to that described in

- 5 Preparation K starting with an appropriate 2,4-dichloro-pyridine and an oxidizing agent.

2,4-Dichloro-6-methyl-1-oxy-nicotinic acid methyl ester

M.p. 90-91.5°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.26 (s, 1H), 3.98 (s, 3H), 2.54 (s, 3H) ppm.

(2,4-Dichloro-6-methyl-1-oxy-pyridin-3-yl)methanol

- 10 M.p. 188-191°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.13 (s, 1H), 4.87 (d, 2H), 2.47 (s, 3H), 2.38 (t, 1H, OH) ppm.

2,4-Dichloro-3,5,6-trimethyl-pyridine 1-oxide

M.p. 146-148°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  2.57 (s, 3H), 2.49 (s, 3H), 2.38 (s, 3H) ppm.

2,4-Dichloro-6-methyl-pyridine 1-oxide

M.p. 100-102°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.42 (d, 1H), 7.22 (d, 1H), 2.55 (s, 3H) ppm.

- 15 Preparation M

4-Chloro-2,5-dimethyl-6-(2,4,6-trimethyl-phenoxy)-pyridine-1-oxide

- 20 To a solution of 2,4,6-trimethylphenol (415 mg, 3.05 mmol) in dry THF (20 ml) was treated with 60% sodium hydride in oil (122 mg, 3.05 mmol) at room temperature. After all  $\text{H}_2$  was evolved, 2,4-dichloro-3,6-dimethyl-pyridine 1-oxide (585.4 mg, 3.05 mmol) was added and the resulting mixture was heated at reflux for 2 hours. The mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness to give solid. The solid was recrystallized from pet ether to give 802 mg (90%) of the title compound as white crystals, mp 106-107°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.04 (s, 1H), 6.78 (s, 2H), 2.41 (s, 3H), 2.36 (s, 3H), 2.22 (s, 3H), 2.06 (s, 6H) ppm.

- 25 Preparation N

The following compounds were prepared by the method analogous to that described in Preparation M starting with an appropriate 2,4-dichloro-pyridine-1-oxide with an appropriate phenol or thiophenol in the presence of a base (potassium tert-buoxide, sodium hydride, or potassium hydride) at temperature between room temperature to reflux in dry THF.

- 30 2-(4-Bromo-2,6-dimethyl-phenoxy)-4-chloro-3,6-dimethyl-pyridine 1-oxide

White crystals, mp 137-139°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.12 (s, 2H), 7.08 (s, 1H), 2.42 (s, 6H), 2.09 (s, 6H) ppm.

4-Chloro-2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine 1-oxide

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.08 (s, 1H), 6.97 (s, 2H), 2.42 (s, 6H), 2.09 (s, 6H) ppm,

- 35 4-Chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-1-oxy-nicotinic acid methyl ester

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.04 (s, 1H), 6.78 (s, 2H), 3.48 (s, 3H), 2.52 (s, 3H), 2.22 (s, 3H), 2.08 (s, 6H) ppm.

4-Chloro-2,3,5-trimethyl-6-(2,4,6-trimethyl-phenoxy)-pyridine 1-oxide

White crystals, mp 132-134°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.75 (s, 2H), 2.47 (s, 3H), 2.38 (s, 3H), 2.35 (s, 3H), 2.20 (s, 3H), 2.04 (s, 6H) ppm.

4-Chloro-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyridine 1-oxide

5 White crystals, mp 191-193°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.96 (s, 1H), 6.95 (s, 2H), 2.62 (s, 3H), 2.32 (s, 3H), 2.13 (s, 6H) ppm.

4-Chloro-2-(2,4-dimethyl-phenylsulfanyl)-3,6-dimethyl-pyridine 1-oxide

white crystals, mp 148-151°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.23 (s, 1H), 7.02 (s, 1H), 6.88 (s, 2H), 2.46 (s, 3H), 2.41 (s, 3H), 2.39 (s, 3H), 2.27 (s, 3H) ppm.

10 4-Chloro-2-(2,4,6-trimethyl-phenylsulfanyl)-3,6-dimethyl-pyridine 1-oxide

White crystals, mp 132-134°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.13 (s, 1H), 6.91 (s, 2H), 2.46 (s, 3H), 2.31 (s, 6H), 2.27 (s, 3H), 2.10 (s, 3H) ppm.

Preparation O

The following compounds were prepared by the method analogous to that described in  
15 Preparation E, second paragraph, starting with an appropriate 4-chloro-6-substituted phenoxy-pyridine 1-oxide and phosphorous trichloride.

2-(4-Bromo-2,6-dimethyl-phenoxy)-4-chloro-3,6-dimethyl-pyridine

White crystals. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.22 (s, 2H), 6.81 (s, 1H), 2.40 (s, 3H), 2.20 (s, 3H), 2.05 (s, 6H) ppm.

20 4-Chloro-2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine

White crystals. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.07 (s, 2H), 6.81 (s, 1H), 2.41 (s, 3H), 2.20 (s, 3H), 2.06 (s, 6H) ppm.

4-Chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester

25 Yellow crystals, mp 122-125°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.84 (s, 2H), 6.82 (s, 1H), 3.94 (s, 3H), 2.27 (s, 3H), 2.25 (s, 3H), 2.04 (s, 6H) ppm.

4-Chloro-2,3,5-trimethyl-6-(2,4,6-trimethyl-phenoxy)-pyridine

White crystals, mp 101-103°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.85 (s, 2H), 2.39 (s, 3H), 2.28 (s, 3H), 2.22 (s, 3H), 2.20 (s, 3H), 2.01 (s, 6H) ppm.

4-Chloro-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyridine

30 White crystals, mp 46-48°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.92 (s, 2H), 6.84 (s, 1H), 2.62 (s, 3H), 2.32 (s, 3H), 2.13 (s, 6H) ppm.

4-Chloro-2-(2,4-dimethyl-phenylsulfanyl)-3,6-dimethyl-pyridine

White crystals, mp 148-151°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.23 (s, 1H), 7.02 (s, 1H), 6.88 (s, 2H), 2.46 (s, 3H), 2.41 (s, 3H), 2.39 (s, 3H), 2.27 (s, 3H) ppm.

35 4-Chloro-2-(2,4,6-trimethyl-phenylsulfanyl)-3,6-dimethyl-pyridine

White crystals, mp 132-134°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.13 (s, 1H), 6.91 (s, 2H), 2.46 (s, 3H), 2.31 (s, 6H), 2.27 (s, 3H), 2.10 (s, 3H) ppm.

Preparation P

2-Chloro-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid methyl ester

A mixture of 2,4-dichloro-6-methyl-nicotinic acid methyl ester (2.228 g, 10.13 mmol) and 1-ethyl-propyl amine (1.762 g, 20.26 mmol) in DMSO (4 ml) was heated at 110°C for 5 hours, then at room temperature overnight. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 1.796 g of crude material. The crude material was purified through silica gel column chromatography using chloroform to 5% methanol in chloroform as eluent to give 1.167 g (43%) of the title compound as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.14 (brs, 1H), 6.27 (s, 1H), 3.86 (s, 3H), 3.27 (m, 1H), 2.33 (s, 3H), 1.3-1.6 (m, 4H), 0.88 (t, 6H) ppm.

Preparation Q

(2-Chloro-6-methyl-3-nitro-pyridin-4-yl)-(1-ethyl-propyl)-amine

A mixture of 2,4-dichloro-6-methyl-3-nitro-pyridine (250 mg, 1.21 mmol) and 1-ethyl-propyl amine (105 mg, 1.21 mmol) in DMSO (4 ml) was stirred at room temperature for 15 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated to give 280 mg of yellow oil. The oil was purified through silica gel column chromatography using 65% chloroform in hexane as eluent to give 110 mg (35%) of the title compound as a yellow crystal, mp 82-84°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.57 (d, 1H), 6.46 (s, 1H), 3.39 (m, 1H), 2.42 (s, 3H), 1.4-1.8 (m, 4H), 0.94 (t, 6H) ppm.

Preparation R

(6-Chloro-2-methyl-5-nitro-pyrimidin-4-yl)-(1-ethyl-propyl)-amine

A mixture of 2-methyl-5-nitro-4,6-dichloro-pyrimidine (208 mg, 1.00 mmol) and 1-ethyl-propyl-amine (87 mg, 1.03 mmol) in 2 ml of dry THF was stirred at -78°C for 4 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give a green oil. The oil was purified through silica gel column chromatography using chloroform to 1:1 hexane/chloroform as eluent to give the title compound (93 mg, 35%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.50 (brs, 1H), 4.29 (m, 1H), 2.51 (s, 3H), 1.4-1.8 (m, 4H), 0.92 (t, 6H) ppm.

Preparation S

(6-Chloro-2-methyl-5-nitro-pyrimidin-4-yl)-(2,4,6-trimethyl-pyridin-3-yl)-amine

A solution of 2-methyl-5-nitro-4,6-dichloro-pyrimidine (208 mg, 1.00 mmol) in 2.5 ml of acetonitrile was treated with 2,4,6-trimethyl-3-amino-pyridine (273 mg, 2 mmol) stirred at room temperature 2 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated to give red residue. The residue was purified through silica gel column chromatography using chloroform to 6% methanol in chloroform as eluent to give the title compound (110 mg, 36%) as an orange oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.78 (brs, 1H), 6.97 (s, 1H), 2.54 (s, 3H), 2.43 (s, 3H), 2.40 (s, 3H), 2.17 (s, 3H) ppm.

Preparation T

2-Chloro-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid

The title compound was prepared by reaction of 2-chloro-4-(1-ethyl-propylamino)-6-methyl-nicotinic acid methyl ester with LiOH.H<sub>2</sub>O in a mixture of water and dioxane at room temperature. The desired product was acidified to pH 3 and extracted with ethyl acetate. The organic layer was dried and concentrated to dryness. The title compound was obtained as white crystals after titration with ethyl acetate. mp. 164-165°C; anal. For C<sub>12</sub>H<sub>17</sub>Cl<sub>2</sub>O<sub>2</sub> calcd. C, 56.14; H, 6.67; N, 10.91; found: C, 56.40; H, 6.53; N, 10.93.

Preparation U

4-Chloro-6-ethyl-3-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine 1-oxide

To a solution of 2,4,6-trimethylphenol in dry THF was added NaH and stirred at room temperature for 20 minutes. A solution of 2,4-dichloro-6-ethyl-3-methyl-pyridine 1-oxide was added and the resulting mixture was heated at reflux for 1.5 hour. The mixture was cooled to room temperature, quenched with water, extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give the title compound which was used directly for the next step reaction.

Preparation V

4-Chloro-6-ethyl-3-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

To a solution of 4-Chloro-6-ethyl-3-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine 1-oxide in methylene chloride was added PCl<sub>3</sub> and the resulting mixture was heated at reflux for 20 min, cooled to rt. The mixture was concentrated to dryness. The residue was worked-up using standard procedure to give the title compound. After silica gel purification, the title compound was prepared as a white solid, mp. 42-44°C. Anal. For C<sub>17</sub>H<sub>20</sub>ClNO calc. C, 70.46; H, 6.96; N, 4.83; found, C, 70.35; H, 7.13; N, 4.58.

Preparation W

2-[4-Chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-ylmethyl]-malonic acid dimethyl ester

The title compound was prepared by reacting 4-chloro-3-chloromethyl-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine with dimethyl malonate/NaH in methanol. The title compound was isolated as a colorless oil.

Preparation X

4-Chloro-3,6-dimethyl-2-(2,4,6-trimethyl-3-pyridyl)-pyridine

Preparation Y

2-Chloro-4-(1-methoxymethyl-propoxy)-6-methyl-nicotinic acid ethyl ester

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.72(s,1H), 4.5(m,1H), 4.4(q,2H), 3.49(d,2H), 3.31(s,3H), 2.46(s,3H), 1.68(m,2H), 1.34(t,3H), 0.93(t,3H) ppm.

EXPRESS MAIL NO. EL16281545908

Preparation Z

2-Chloro-4-(1-methoxymethyl-propoxy)-6-methyl-nicotinic acid

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.81(s,2H), 4.51(m,1H), 3.60(m,2H), 3.40(s,3H), 2.55(s,3H), 1.77(m,2H), 1.02(t,3H)ppm.

5 Preparation AA

(2-Chloro-6-methyl-3-nitro-pyridin-4-yl)-(1-methoxymethyl-propyl)-amine

mp. 63-65°C, Anal. For C<sub>11</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub>Cl calc. C, 48.27; H, 5.89, N, 15.35; found C, 48.65; H, 6.03, N, 15.11.

Preparation BB

10 (5-Bromo-6-chloro-2-methyl-pyrimidin-4-yl)-(2,4-dichloro-phenyl)-amine

Mp. 165-167°C; Anal. For C<sub>11</sub>H<sub>7</sub>BrCl<sub>3</sub> calc.: C, 35.95; H, 1.92; N, 11.43; found: C, 36.41; H, 1.91; N, 11.05.

Preparation CC

(6-Chloro-2-methyl-pyrimidin-4-yl)-(2,4-dichloro-phenyl)-amine

15 Mp. 134-136°C; Anal. For C<sub>11</sub>H<sub>8</sub>Cl<sub>3</sub>N<sub>3</sub> calc.: C, 45.79; H, 2.79; N, 14.56; found: C, 45.91; H, 2.69; N, 14.50.

Preparation DD

[4-Chloro-6-(1-ethyl-propylamino)-2-methyl-pyrimidin-5-yl]-acetic acid ethyl ester

20 Mp. 78-80°C, anal. For C<sub>14</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>2</sub> calc.: C, 56.09; H, 7.40; N, 14.02; found: C, 56.31; H, 7.60; N, 13.94.

Preparation EE

2-[4-Bromo-2-methyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-5-yl]-propionic acid ethyl ester

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 6.86(s,2H), 4.2-4.359m,2H), 4.0-4.15(m,1H), 2.4(s,3H), 2.28(s,3H), 1.99(s,3H), 1.97(s,3H), 1.58(d,3H), 1.22(t,3H) ppm.

Preparation FF

2-(4,6-Dibromo-2-methyl-pyrimidin-5-yl)-propionic acid ethyl ester

<sup>1</sup>H NMR(CDCl<sub>3</sub>) 4.36(m,1H), 4.19(m,2H), 2.68(s,3H), 1.549d,3H), 1.22(t,3H) ppm.

Preparation GG

4-Bromo-3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 6.92(s,1H), 6.87(s,2H), 4.00(s,3H), 2.299s,3H), 2.18(s,3H), 2.059s,6H) ppm.

Preparation HH

5 4-Bromo-2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 7.04(s,2H), 6.97(s,1H), 2.42(s,3H), 2.17(s,3H), 2.03(s,6H) ppm.

Preparation II

4-Bromo-2-(2,4-dichloro-6-methyl-phenoxy)-3-methoxy-6-methyl-pyridine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 7.3(d,1H), 7.18(d,1H), 4.0(s,3H), 2.2(s,3H), 2.15(s,3H) ppm.

10 Preparation JJ

4-Bromo-2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridine

Anal. For C<sub>15</sub>H<sub>15</sub>BrClNO<sub>2</sub> calc.: C, 50.52; H, 4.24; N, 3.93; found: C, 50.52; H, 4.37; N, 3.91.

Preparation KK

15 4-Bromo-2-(4-chloro-2-methoxy-phenoxy)-3-methoxy-6-methyl-pyridine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 6.9-7.1(m,4H), 3.94(s,3H), 3.71(s,3H), 2.21s,3H) ppm.

Preparation LL

4-Bromo-2-(3-chloro-2,6-dimethoxy-phenoxy)-3-methoxy-6-methyl-pyridine

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) d 7.17(d,1H), 6.96(s,1H), 6.66(d,1H), 3.97(s,3H), 3.79(s,3H), 3.70(s,3H), 2.18(s,3H) ppm.

Preparation MM

4-Bromo-3-methoxy-6-methyl-2-(2,4,6-trimethoxy-phenoxy)-pyridine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 6.90(s,1H), 6.19(s,2H), 3.968(s,3H), 3.80(s,3H), 3.71(s,6H), 2.18(s,3H) ppm.

25 Preparation NN

4-Bromo-3-methoxy-2-(4-methoxy-2,6-dimethyl-phenoxy)-6-methyl-pyridine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 6.92(s,1H), 6.60(s,2H), 3.98(s,3H), 3.78(s,3H), 2.18(s,3H), 2.07(s,6H) ppm.

Preparation OO

30 4-Bromo-2-(4-chloro-2,6-dimethyl-phenoxy)-3-ethoxy-6-methyl-pyridine

<sup>1</sup>H NMR(CDCl<sub>3</sub>) d 7.099s,2H), 7.00(s,1H), 4.28(q,2H), 2.22(s,3H), 2.10(s,6H), 1.51(t,3H) ppm.

Preparation PP

4-Bromo-3,6-dimethyl-2-(2,4,6-trimethoxy-phenoxy)-pyridine

35 <sup>1</sup>H NMR(CDCl<sub>3</sub>) d 6.99(s,1H), 6.25(s,2H), 3.86(s,3H), 3.77(s,6H), 2.47(s,3H), 2.25(s,3H) ppm.

Preparation QQ



4-Chloro-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-1-oxy-nicotinic acid methyl ester

Preparation RR

4-Chloro-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-nicotinic acid methyl ester

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.03(s,2H), 6.869s,1H), 3.969s,3H), 2.259s,3H), 2.05(s,6H) ppm.

5

Preparation SS

4-Chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridine-3-carbaldehyde

The title compound was prepared by oxidation of 4-chloro-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-3-yl-methanol with pyridinium chlorochromate in methylene chloride at room temperature. The desired product was isolated after column chromatography to give a green solid (80% yield). <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 10.66(s,1H), 6.91(s,3H), 2.31(s,3H), 2.07(s,3H) ppm.

10

Preparation TT

2-(4-Bromo-2,6-dimethyl-phenoxy)-4-chloro-6-methyl-nicotinic acid methyl ester

mp. 108-110°C; Anal. For C<sub>16</sub>H<sub>15</sub>BrClNO<sub>3</sub> calc., 49.96; H, 3.93; N, 3.64; found: C, 50.07; H, 4.10; N, 3.57.

15

Preparation UU

4-Chloro-2-(4-chloro-2-methoxy-phenoxy)-6-methyl-1-oxy-nicotinic acid methyl ester

mp. 117-120°C, Anal. For C<sub>15</sub>H<sub>13</sub>NO<sub>5</sub>Cl<sub>2</sub> calc.: C, 50.30; H, 3.66; N, 3.91; Found: C, 50.41; H, 3.55; N, 4.00.

Preparation VV

4-Chloro-2-(4-chloro-2-methoxy-phenoxy)-6-methyl-nicotinic acid methyl ester

mp. 92-93°C, Anal. For C<sub>15</sub>H<sub>13</sub>NO<sub>4</sub>Cl<sub>2</sub> calc.: C, 52.65; H, 3.83; N, 4.09; found: C, 52.34; H, 3.85; N, 4.13.

20

Preparation WW

[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propyl]-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-amine

25

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ 7.06(s,2H), 6.12(s,1H), 4.3(d,1H), 3.6-3.8(m,2H), 3.4(m,1H), 2.16(s,3H), 2.14(s,3H), 2.10(s,6H), 1.5-1.8(m,2H), 1.03(t,3H), 0.95(s,9H), 0.09(m,6H) ppm.

The following compounds were prepared by a method analogous to that described in Example 160, using an appropriate 4-bromo-2-(substituted phenoxy)-6-alkyl or alkoxy-pyridine with 1-(tert-Butyl-dimethyl-silanyloxymethyl)-propylamine.

30

Preparation XX

[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propyl]-[3-methoxy-6-methyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-(S)-yl]-amine

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.84(s,2H), 6.08(s,1H), 4.8(d,1H), 3.88(s,3H), 3.5-3.7(m,2H), 3.3(m,1H), 2.27(s,3H), 2.099s,3H), 2.07(s,6H), 1.75(m,1H), 1.55(m,1H), 0.97(t,3h), 0.89(s,9H), 0.04(s,6H) ppm.

35

Preparation YY

[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propyl]-[2-(4-chloro-2,6-dimethyl-phenoxy)-3-methoxy-6-methyl-pyridin-4-yl]-amine

1H NMR(CDCl<sub>3</sub>) d 7.02(s,2H), 6.10(s,1H), 4.80(d,1H), 3.87(s,3H), 3.6-3.7(m,2H), 3.30(m,1H), 2.09(s,3H), 2.08(s,6H), 1.75(m,1H), 1.55(m,1H), 0.97(t,3H), 0.89(s,9H),  
5 0.03(s,6H) ppm.

Preparation ZZ

4-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propylamino]-2-(4-chloro-2,6-dimethyl-phenoxy)-6-methyl-pyridin-3-ol

1H NMR(CDCl<sub>3</sub>) d 7.01 (s,2H), 6.15(s,1H), 4.46(d,1H), 3.7(m,1H), 3.6(m,1H),  
10 3.4(m,1H), 2.09(s,3H), 2.08(s,6H), 1.5-1.8(m,2H), 1.06(s,9H), 0.98(t,3H), 0.24(s,6H) ppm.

Preparation AAA

[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propyl]-[3-methoxy-6-methyl-2-(2,4,6-trimethoxy-phenoxy)-pyridin-4-yl]-amine

1H NMR(CDCl<sub>3</sub>) d 6.19(s,2H), 6.09(s,1H), 3.86(s,3H), 3.80(s,3H), 3.73(s,6H),  
15 3.3(m,1H), 2.16(s,3H), 1.75(m,1H), 1.5(m,1H), 0.95(t,3H), 0.89(s,9H), 0.04(s,6H) ppm.


Preparation BBB

4-{4-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propylamino]-3-methoxy-6-methyl-pyridin-2-yloxy}-3,5-dimethyl-benzonitrile

1H NMR(CDCl<sub>3</sub>) d 7.40(s,2H), 6.19(s,1H), 4.90(brs,1H), 3.87(s,3H), 3.70(m,2H),  
20 3.3(m,1H), 2.19(m,9H), 1.5-1.8(m,2H), 1.02(t,3H), 0.93(s,9H), 0.09(s,6H) ppm.

CLAIMS

1. A compound of the formula



I

5

or a pharmaceutically acceptable salt thereof, wherein

A is N;

- 10 B is  $-NR_1R_2$ ,  $-CR_1R_2R_{11}$ ,  $-C(=CR_2R_{12})R_1$ ,  $-NHCHR_1R_2$ ,  $-OCHR_1R_2$ ,  $-SCHR_1R_2$ ,  $-CHR_2OR_1$ ,  $-CHR_1OR_2$ ,  $-CHR_2SR_1$ ,  $-C(S)R_2$ ,  $-C(O)R_2$ ,  $-CHR_2NR_1R_2$ ,  $-CHR_1NHR_2$ ,  $-CHR_1N(CH_3)R_2$ , or  $-NR_{12}NR_1R_2$ ;

- 15 Z is NH, O, S,  $-N(C_1-C_2 \text{ alkyl})$ ,  $-NC(O)CF_3$ , or  $-C(R_{13}R_{14})$ , wherein  $R_{13}$  and  $R_{14}$  are each, independently, hydrogen, trifluoromethyl or methyl, or one of  $R_{13}$  and  $R_{14}$  is cyano and the other is hydrogen or methyl, or  $-C(R_{13}R_{14})$  is a cyclopropyl group, or Z is nitrogen or CH and forms a five or six membered heterocyclic ring fused with  $R_5$ , which ring optionally comprises two or three further hetero members selected independently from oxygen, nitrogen,  $NR_{12}$ , and  $S(O)_m$ , and optionally comprises from one to three double bonds, and is optionally substituted with halo,  $C_1-C_4$  alkyl,  $-O(C_1-C_4 \text{ alkyl})$ ,  $NH_2$ ,  $NHCH_3$ ,  $N(CH_3)_2$ ,  $CF_3$ , or  $OCF_3$ , with the proviso that said ring does not contain any  $-S-S-$ ,  $-S-O-$ ,  $-N-S-$ , or  $-O-O-$  bonds, and does not comprise more than two oxygen or  $S(O)_m$  heterologous members;

- 20  $R_1$  is  $C(O)H$ ,  $C(O)(C_1-C_6 \text{ alkyl})$ ,  $C(O)(C_1-C_6 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $C(O)(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $C(O)(C_1-C_6 \text{ alkylene})(C_4-C_8 \text{ heterocycloalkyl})$ ,  $-C(O)(C_3-C_8 \text{ cycloalkylene})(C_4-C_8 \text{ heterocycloalkyl})$ ,  $C_1-C_6 \text{ alkyl}$ ,  $C_3-C_8 \text{ cycloalkyl}$ ,  $C_4-C_8 \text{ heterocycloalkyl}$ ,  $-(C_1-C_6 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_1-C_6 \text{ alkylene})(C_4-C_8 \text{ heterocycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkylene})(C_4-C_8 \text{ heterocycloalkyl})$ , or  $-O\text{-aryl}$ , or  $-O-(C_1-C_6 \text{ alkylene})\text{-aryl}$ ; wherein said aryl,  $C_4-C_8 \text{ heterocycloalkyl}$ ,  $C_1-C_6 \text{ alkyl}$ ,  $C_3-C_8 \text{ cycloalkyl}$ ,  $C_3-C_8 \text{ cycloalkylene}$ , and  $C_1-C_6 \text{ alkylene}$  groups may each independently be optionally substituted with from one to six fluoro and may each independently be optionally substituted with one or two substituents  $R_8$  independently selected from the group consisting of  $C_1-C_4 \text{ alkyl}$ ,  $-C_3-C_8 \text{ cycloalkyl}$ ,  
25 hydroxy, chloro, bromo, iodo,  $CF_3$ ,  $-O-(C_1-C_6 \text{ alkyl})$ ,  $-O-(C_3-C_5 \text{ cycloalkyl})$ ,  $-O-CO-(C_1-C_4 \text{ alkyl})$ ,  $-O-CO-NH(C_1-C_4 \text{ alkyl})$ ,  $-O-CO-N(R_{24})(R_{25})$ ,  $-N(R_{24})(R_{25})$ ,  $-S(C_1-C_4 \text{ alkyl})$ ,  $-S(C_3-C_5 \text{ cycloalkyl})$ ,  $-N(C_1-C_4 \text{ alkyl})CO(C_1-C_4 \text{ alkyl})$ ,  $-NHCO(C_1-C_4 \text{ alkyl})$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-CONH(C_1-C_4 \text{ alkyl})$ ,  
30

-CON(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), CN, NO<sub>2</sub>, -OSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), S<sup>+</sup>(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl)I<sup>-</sup>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl); and wherein the C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylene, C<sub>5</sub>-C<sub>8</sub> cycloalkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkylene, and C<sub>5</sub>-C<sub>8</sub> heterocycloalkyl moieties of R<sub>1</sub> may optionally independently contain from one to three double or triple bonds; and wherein the C<sub>1</sub>-C<sub>4</sub> alkyl moieties and C<sub>1</sub>-C<sub>6</sub> alkyl moieties of R<sub>8</sub> can optionally independently be substituted with hydroxy, amino, C<sub>1</sub>-C<sub>4</sub> alkyl, aryl, -CH<sub>2</sub>-aryl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, or -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), and can optionally independently be substituted with from one to six fluoro, and can optionally contain one or two double or triple bonds; and wherein each heterocycloalkyl group of R<sub>1</sub> contains from one to three heteromoieties selected from oxygen, S(O)<sub>m</sub>, nitrogen, and NR<sub>12</sub>;

10 R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>1</sub>-C<sub>6</sub> alkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), aryl, -(C<sub>1</sub>-C<sub>6</sub> alkylene)aryl, or -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(aryl); wherein each of the foregoing R<sub>2</sub> groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, and C<sub>1</sub>-C<sub>6</sub> alkyl, wherein one of said one to three substituents can further be selected from bromo, iodo, C<sub>1</sub>-C<sub>6</sub> alkoxy, -OH, -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(O)(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), S<sup>+</sup>(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl)I<sup>-</sup>, CN, and NO<sub>2</sub>; and wherein the C<sub>1</sub>-C<sub>12</sub> alkyl, -(C<sub>1</sub>-C<sub>6</sub> alkylene), -(C<sub>5</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>5</sub>-C<sub>8</sub> cycloalkylene), and -(C<sub>5</sub>-C<sub>8</sub> heterocycloalkyl) moieties of R<sub>2</sub> may optionally independently contain from one to three double or triple bonds; and wherein each heterocycloalkyl group of R<sub>2</sub> contains from one to three heteromoieties selected from oxygen, S(O)<sub>m</sub>, nitrogen, and NR<sub>12</sub>;

or when R<sub>1</sub> and R<sub>2</sub> are as in -NHCHR<sub>1</sub>R<sub>2</sub>, -OCHR<sub>1</sub>R<sub>2</sub>, -SCHR<sub>1</sub>R<sub>2</sub>, -CHR<sub>1</sub>R<sub>2</sub> or -NR<sub>1</sub>R<sub>2</sub>, R<sub>1</sub> and R<sub>2</sub> of B may form a saturated 5- to 8-membered ring which may optionally contain one or two double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen, S(O)<sub>m</sub>, nitrogen or NR<sub>12</sub>; and which carbocyclic ring can optionally be substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, C<sub>1</sub>-C<sub>4</sub> alkyl, fluoro, chloro, bromo, iodo, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -NHCO(C<sub>1</sub>-C<sub>4</sub> alkyl), -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CONH(C<sub>1</sub>-C<sub>4</sub> alkyl), -CON(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), CN, NO<sub>2</sub>, -OSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO(C<sub>1</sub>-C<sub>4</sub> alkyl), and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), wherein one of said one to three substituents can further be selected from phenyl;

R<sub>3</sub> is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF<sub>3</sub>, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>2</sub> alkyl), N(CH<sub>3</sub>)<sub>2</sub>, -NHCOCF<sub>3</sub>, -NHCH<sub>2</sub>CF<sub>3</sub>, S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), CONH<sub>2</sub>, -CONHCH<sub>3</sub>, CON(CH<sub>3</sub>)<sub>2</sub>, -CF<sub>3</sub>, or CH<sub>2</sub>OCH<sub>3</sub>;

35 R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>5</sub> cycloalkylene)(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), cyano, fluoro, chloro, bromo, iodo, -OR<sub>24</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -O-(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -O-(C<sub>3</sub>-C<sub>5</sub> cycloalkylene)(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), -

CH<sub>2</sub>SC(S)O(C<sub>1</sub>-C<sub>4</sub> alkyl), -CH<sub>2</sub>OF<sub>3</sub>, CF<sub>3</sub>, amino, nitro, -NR<sub>24</sub>R<sub>25</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)-OR<sub>24</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)Cl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)NR<sub>24</sub>R<sub>25</sub>, -NHCOR<sub>24</sub>, -NHCONR<sub>24</sub>R<sub>25</sub>, -C=NOR<sub>24</sub>, -NHNOR<sub>24</sub>R<sub>25</sub>, -S(O)<sub>m</sub>R<sub>24</sub>, -C(O)R<sub>24</sub>, -OC(O)R<sub>24</sub>, -C(O)CN, -C(O)NR<sub>24</sub>R<sub>25</sub>, -C(O)NHNOR<sub>24</sub>R<sub>25</sub>, and -COOR<sub>24</sub>, wherein the alkyl and alkylene groups of R<sub>4</sub> may optionally independently contain one or two

5 double or triple bonds and may optionally independently be substituted with one or two substituents R<sub>10</sub> independently selected from hydroxy, amino, -NHCOCH<sub>3</sub>, -NHCOCH<sub>2</sub>Cl, -NH(C<sub>1</sub>-C<sub>2</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -COOH, -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> thioalkyl, cyano and nitro, and with one to four substituents independently selected from fluoro and chloro;

10 R<sub>5</sub> is aryl or heteroaryl and is substituted with from one to four substituents R<sub>27</sub> independently selected from halo, C<sub>1</sub>-C<sub>10</sub> alkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, nitro, cyano, -NR<sub>24</sub>R<sub>25</sub>, -NR<sub>24</sub>COR<sub>25</sub>, -NR<sub>24</sub>CO<sub>2</sub>R<sub>26</sub>, -COR<sub>24</sub>, -OR<sub>25</sub>, -CONR<sub>24</sub>R<sub>25</sub>, -CO(NOR<sub>22</sub>)R<sub>23</sub>, -CO<sub>2</sub>R<sub>26</sub>, -C=N(OR<sub>22</sub>)R<sub>23</sub>, and -S(O)<sub>m</sub>R<sub>23</sub>; wherein said C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>4</sub> alkylene), (C<sub>3</sub>-C<sub>8</sub> cycloalkyl), (C<sub>3</sub>-C<sub>8</sub> cycloalkylene), and (C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl) groups can be optionally substituted with from one to three substituents independently selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), C<sub>1</sub>-C<sub>4</sub> haloalkyl, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, nitro halo, cyano, -NR<sub>24</sub>R<sub>25</sub>, -NR<sub>24</sub>COR<sub>25</sub>, NR<sub>24</sub>CO<sub>2</sub>R<sub>26</sub>, -COR<sub>24</sub>, -OR<sub>25</sub>, -CONR<sub>24</sub>R<sub>25</sub>, CO<sub>2</sub>R<sub>26</sub>, -CO(NOR<sub>22</sub>)R<sub>25</sub>, and -S(O)<sub>m</sub>R<sub>23</sub>; and wherein two adjacent substituents of the R<sub>5</sub> group can optionally form a 5-7 membered ring, saturated or unsaturated, fused to R<sub>5</sub>, which ring optionally can contain one, two, or three heterologous members independently selected from O, S(O)<sub>m</sub>, and N, but not any -S-S-, -O-O-, -S-O-, or -N-S- bonds, and which ring is optionally substituted with C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), C<sub>1</sub>-C<sub>4</sub> haloalkyl, nitro, halo, cyano -NR<sub>24</sub>R<sub>25</sub>, NR<sub>24</sub>COR<sub>25</sub>, NR<sub>24</sub>CO<sub>2</sub>R<sub>26</sub>, -COR<sub>24</sub>, -OR<sub>25</sub>, -CONR<sub>24</sub>R<sub>25</sub>, CO<sub>2</sub>R<sub>26</sub>, -CO(NOR<sub>26</sub>)R<sub>25</sub>, or -S(O)<sub>m</sub>R<sub>23</sub>; wherein one of said one to four optional substituents R<sub>27</sub> can further be selected from -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -SO<sub>2</sub>NH(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -SO<sub>2</sub>NH(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -SO<sub>2</sub>NH<sub>2</sub>, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), -NHSO<sub>2</sub>(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), and -NHSO<sub>2</sub>(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl); and wherein the alkyl, and alkylene groups of R<sub>5</sub> may independently optionally contain one double or triple bond;

R<sub>11</sub> is hydrogen, hydroxy, fluoro, ethoxy, or methoxy;

R<sub>12</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

35 R<sub>22</sub> is independently at each occurrence selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), and (C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl);

R<sub>23</sub> is independently at each occurrence selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), aryl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl, piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, and thiomorpholine;

- 5 R<sub>24</sub> and R<sub>25</sub> are independently at each occurrence selected from hydrogen, -C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, especially CF<sub>3</sub>, -CHF<sub>2</sub>, CF<sub>2</sub>CF<sub>3</sub>, or CH<sub>2</sub>CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)OH, -(C<sub>1</sub>-C<sub>4</sub> alkylene)-O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkylene)-O-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl), aryl, and -
- 10 (C<sub>1</sub>-C<sub>4</sub> alkylene)(aryl), wherein the -C<sub>4</sub>-C<sub>8</sub> heterocycloalkyl groups can each independently optionally be substituted with aryl, CH<sub>2</sub>-aryl, or C<sub>1</sub>-C<sub>4</sub> alkyl, and can optionally contain one or two double or triple bonds; or, when R<sub>24</sub> and R<sub>25</sub> are as NR<sub>24</sub>R<sub>25</sub>, -C(O)NR<sub>24</sub>R<sub>25</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)NR<sub>24</sub>R<sub>25</sub>, or -NHCONR<sub>24</sub>R<sub>25</sub>, then NR<sub>24</sub>R<sub>25</sub> may further optionally form a 4 to 8
- 15 membered heterocyclic ring optionally containing one or two further hetero members independently selected from S(O)<sub>m</sub>, oxygen, nitrogen, and NR<sub>12</sub>, and optionally containing from one to three double bonds;


R<sub>26</sub> is independently at each occurrence selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), aryl, and -(C<sub>1</sub>-C<sub>4</sub> alkylene)(aryl); and

- 20 wherein each m is independently zero, one, or two,

with the proviso that heterocycloalkyl groups of the compound of formula I, II, or III do not comprise any -S-S-, -S-O-, -N-S-, or -O-O- bonds, and do not comprise more than two oxygen or S(O)<sub>m</sub> heterologous members.

2. A compound according to claim 1 of the formula

25



I

, wherein

A is N;

B is -NR<sub>1</sub>R<sub>2</sub>, -CR<sub>1</sub>R<sub>2</sub>R<sub>11</sub>, -C(=CR<sub>2</sub>R<sub>12</sub>)R<sub>1</sub>, -NHCHR<sub>1</sub>R<sub>2</sub>, -OCHR<sub>1</sub>R<sub>2</sub>, -SCHR<sub>1</sub>R<sub>2</sub>, -CHR<sub>2</sub>OR<sub>12</sub>, -CHR<sub>2</sub>SR<sub>12</sub>, -C(S)R<sub>2</sub> or -C(O)R<sub>2</sub>;

- 30 Z is NH, O, S, -N(C<sub>1</sub>-C<sub>2</sub> alkyl) or -C(R<sub>13</sub>R<sub>14</sub>), wherein R<sub>13</sub> and R<sub>14</sub> are each, independently, hydrogen, trifluoromethyl or methyl, or one of R<sub>13</sub> and R<sub>14</sub> is cyano and the other is hydrogen or methyl;

R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl which may optionally be substituted with one or two substituents R<sub>8</sub> independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkoxy, -O-CO-(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub>alkyl)CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -NHCO(C<sub>1</sub>-C<sub>4</sub> alkyl), -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CONH(C<sub>1</sub>-C<sub>4</sub> alkyl), -CON(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), CN, NO<sub>2</sub>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), and wherein said C<sub>1</sub>-C<sub>6</sub> alkyl and the (C<sub>1</sub>-C<sub>4</sub>)alkyl moieties in the foregoing R<sub>1</sub> groups may optionally contain one carbon-carbon double or triple bond;

R<sub>2</sub> is C<sub>1</sub>-C<sub>12</sub> alkyl, aryl or -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C<sub>1</sub>-C<sub>6</sub> alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R<sub>9</sub> wherein R<sub>9</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and wherein each of the foregoing R<sub>2</sub> groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C<sub>1</sub>-C<sub>4</sub> alkyl, or with one substituent selected from bromo, iodo, C<sub>1</sub>-C<sub>6</sub> alkoxy, -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, NO<sub>2</sub>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl), and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), and wherein said C<sub>1</sub>-C<sub>12</sub> alkyl and the C<sub>1</sub>-C<sub>4</sub> alkylene moiety of said -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR<sub>1</sub>R<sub>2</sub> or -CR<sub>1</sub>R<sub>2</sub>R<sub>11</sub> may form a saturated 5- to 8-membered carbocyclic ring which may optionally contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom;

R<sub>3</sub> is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF<sub>3</sub>, methylthio, methylsulfonyl, CH<sub>2</sub>OH, or CH<sub>2</sub>OCH<sub>3</sub>;

R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, fluoro, chloro, bromo, iodo, C<sub>1</sub>-C<sub>4</sub> alkoxy, trifluoromethoxy, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OF<sub>3</sub>, CF<sub>3</sub>, amino, nitro, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(CH<sub>3</sub>)<sub>2</sub>, -NHCOCH<sub>3</sub>, -NHCONHCH<sub>3</sub>, -SO<sub>n</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CHO, cyano or -COO(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein said C<sub>1</sub>-C<sub>4</sub> alkyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH<sub>3</sub>, -NH(C<sub>1</sub>-C<sub>2</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)<sub>2</sub>, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> thioalkyl, fluoro, chloro, cyano and nitro;

R<sub>5</sub> is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each of the above groups R<sub>5</sub> is substituted with from one to three substituents independently selected from fluoro, chloro, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro,

trifluoromethyl, amino,  $-(C_1-C_6 \text{ alkyl})O(C_1-C_6 \text{ alkyl})$ ,  $-NHCH_3$ ,  $-N(CH_3)_2$ ,  $-COOH$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-CO(C_1-C_4 \text{ alkyl})$ ,  $-SO_2NH(C_1-C_4 \text{ alkyl})$ ,  $-SO_2N(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$ ,  $-SO_2NH_2$ ,  $-NHSO_2(C_1-C_4 \text{ alkyl})$ ,  $-S(C_1-C_6 \text{ alkyl})$  and  $-SO_2(C_1-C_6 \text{ alkyl})$ , and wherein the  $C_1-C_4 \text{ alkyl}$  and  $C_1-C_6 \text{ alkyl}$  moieties of the foregoing  $R_5$  groups may optionally be substituted with one or two fluoro groups or with one

5 substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

$R_{11}$  is hydrogen, hydroxy, fluoro, or methoxy;

$R_{12}$  is hydrogen or  $C_1-C_4 \text{ alkyl}$ ; and

or a pharmaceutically acceptable salt of such compound.

3. A compound according to claim 2 wherein B is  $-NR_1R_2$ ,  $-NHCHR_1R_2$ ,  
10  $-SCHR_1R_2$  or  $-OCHR_1R_2$ ;  $R_1$  is  $C_1-C_6 \text{ alkyl}$ , which may optionally be substituted with one hydroxy, fluoro,  $CF_3$ , or  $C_1-C_2 \text{ alkoxy}$  group and may optionally contain one double or triple bond; and  $R_2$  is benzyl or  $C_1-C_6 \text{ alkyl}$  which may optionally contain one carbon-carbon double or triple bond, wherein said  $C_1-C_6 \text{ alkyl}$  or the phenyl moiety of said benzyl may optionally be substituted with fluoro,  $CF_3$ ,  $C_1-C_2 \text{ alkyl}$ , or  $C_1-C_2 \text{ alkoxy}$ .

15 4. A compound according to claim 2 wherein  $R_1$  is  $C_1-C_6 \text{ alkyl}$  which may be substituted by fluoro,  $CF_3$ , hydroxy,  $C_1-C_2 \text{ alkyl}$  or  $C_1-C_2 \text{ alkoxy}$  and which may optionally contain one carbon-carbon double or triple bond.

5. A compound according to claim 2 wherein  $R_2$  is  $C_1-C_4 \text{ alkyl}$  which may optionally be substituted by fluoro, chloro,  $CF_3$ ,  $C_1-C_4 \text{ alkyl}$  or  $C_1-C_4 \text{ alkoxy}$ .

20 6. A compound according to claim 2 wherein  $R_3$  is methyl, chloro, or methoxy.

7. A compound according to claim 2 wherein  $R_4$  is methyl,  $-CH_2OH$ , cyano, trifluoromethoxy, methoxy, chloro, trifluoromethyl,  $-COOCH_3$ ,  $-CH_2OCH_3$ ,  $-CH_2Cl$ ,  $-CH_2F$ , ethyl, amino or nitro.

25 8. A compound according to claim 2 wherein  $R_5$  is phenyl substituted with two or three substituents.

9. A compound according to claim 2 wherein  $R_5$  is pyridyl substituted with two or three substituents.

30 10. A compound according to claim 8 wherein said substituents are selected, independently, from fluoro, chloro, bromo, iodo,  $C_1-C_4 \text{ alkoxy}$ , trifluoromethyl,  $C_1-C_6 \text{ alkyl}$  which may optionally be substituted with one hydroxy,  $C_1-C_4 \text{ alkoxy}$  or fluoro group and which may optionally contain one carbon-carbon double or triple bond,  $-(C_1-C_4 \text{ alkylene})O(C_1-C_2 \text{ alkyl})$ ,  $C_1-C_3 \text{ hydroxyalkyl}$ , hydroxy, formyl,  $COO(C_1-C_2 \text{ alkyl})$ ,  $-(C_1-C_2 \text{ alkylene})\text{amino}$ , and  $-(C(O))(C_1-C_4 \text{ alkyl})$ .

35 11. A compound according to claim 9 wherein said substituents are selected, independently, from fluoro, chloro, bromo, iodo,  $C_1-C_4 \text{ alkoxy}$ , trifluoromethyl,  $C_1-C_6 \text{ alkyl}$  which may optionally be substituted with one hydroxy,  $C_1-C_4 \text{ alkoxy}$  or fluoro group and which may optionally contain one carbon-carbon double or triple bond,  $-(C_1-C_4 \text{ alkylene})O(C_1-C_2 \text{ alkyl})$ ,  $C_1-C_3 \text{ hydroxyalkyl}$ , hydroxy, formyl,  $-COO(C_1-C_2 \text{ alkyl})$ ,  $-(C_1-C_2 \text{ alkylene})\text{amino}$ , and  $-(C(O))(C_1-C_4 \text{ alkyl})$ .



12. A compound according to claim 1, wherein said compound is  
4-(1-ethyl-propoxy)-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine;  
[2,5-dimethyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-4-yl](1-ethyl-propyl)-amine;  
(1-ethyl-propyl)-[2-methyl-5-nitro-6-(2,4,6-trimethyl-pyridin-3-yloxy)-pyrimidin-4-yl]-amine;  
5 (N-(1-ethyl-propyl)-2-methyl-5-nitro-N'-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,6-  
diamine;  
4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;  
N-butyl-N-ethyl-2,5-dimethyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine; or  
6-(1-ethyl-propoxy)-2-methyl-N4-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5-diamine;  
10 or a pharmaceutically acceptable salt of one of the above compounds.
13. A pharmaceutical composition for the treatment of (a) a disorder or condition the  
treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to  
disorders induced or facilitated by CRF, or (b) a disorder or condition selected from inflammatory  
disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies;  
15 generalized anxiety disorder; panic; phobias, including social phobia, agoraphobia, and specific  
phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced  
by stress; pain perception such as fibromyalgia; mood disorders such as depression, including  
major depression, single episode depression, recurrent depression, child abuse induced  
depression, mood disorders associated with premenstrual syndrome, and postpartum  
20 depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced  
headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus;  
ulcer; diarrhea; stress-induced fever; human immunodeficiency virus infections;  
neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's  
disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa;  
25 hemorrhagic stress; chemical dependencies or addictions, including dependencies or addictions  
to alcohol, cocaine, heroin, benzodiazapines, or other drugs; drug or alcohol withdrawal  
symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of  
inappropriate antidiuretic hormone; obesity; infertility; head trauma; spinal cord trauma; ischemic  
neuronal damage, including cerebral ischemia, for example cerebral hippocampal ischemia;  
30 excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced  
immune dysfunctions, including porcine stress syndrome, bovine shipping fever, equine  
paroxysmal fibrillation, confinement dysfunction in chicken, sheering stress in sheep, and human-  
animal interaction stress in dogs; muscular spasms; urinary incontinence; senile dementia of the  
Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia;  
35 congestive heart failure; osteoporosis; premature birth; hypoglycemia, and Syndrome X in a  
mammal or bird, comprising an amount of a compound according to claim 1 that is effective in the  
treatment of such disorder or condition, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition according to claim 13 for the treatment of a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions; obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; and hypoglycemia in a mammal, including a human.

15. A method for the treatment of (a) a disorder or condition the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder or condition selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias, including social phobia, agoraphobia, and specific phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies or addictions, including dependencies or addictions to alcohol, cocaine, heroin, benzodiazapines, or other drugs; drug or alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone; obesity; infertility; head trauma; spinal cord trauma; ischemic neuronal damage, including cerebral ischemia, for example cerebral hippocampal ischemia; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions, including porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, confinement dysfunction in

chicken, sheering stress in sheep, and human-animal interaction stress in dogs; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; hypoglycemia, and Syndrome X in a mammal or bird, comprising administering to a subject in need of said treatment an amount of a compound according to claim 1, that is effective in treating such disorder or condition.

16. A method according to claim 15 for the treatment of a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions; drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; and hypoglycemia in a mammal, including a human.

17. A method of treating a condition comprising administering a compound of claim 1 in an amount effective to treat said condition, wherein said condition is selected from the group consisting of:

- a) abnormal circadian rhythm;
- b) depression, further wherein a second compound for treating depression is administered, said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist; and
- c) emesis.

18. The method of claim 17 wherein the condition is abnormal circadian rhythm, and the compound is comined with a second compound useful for treating a sleep disorder.

19. The method of claim 18, wherein said second compound is selected from the group consisting of tachykinin antagonists, agonists for GABA brain receptors, metalonergic

compounds, GABA brain receptor agonists, 5HT<sub>2</sub> receptor antagonists, and D4 receptor binding .

20. The method of claim 17 wherein said condition is depression, and wherein said second compound having delayed action for treating depression is selected from the group consisting of selective serotonin reuptake inhibitors, tricyclic antidepressants, norepinephrine uptake inhibitors, lithium, bupropion, sertraline, fluoxetine, trazodone, and a tricyclic antidepressant selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine, and pharmaceutically acceptable salts and esters of the above-recited compounds.

21. The method claim 17 wherein said condition is emesis, further comprising administering a second compound for treating emesis.

22. The method of claim 21 wherein said second compound for treating emesis is selected from the group consisting of tachykinin antagonists, 5HT<sub>3</sub> antagonists, GABA agonists, and substance P inhibitors.

23. A pharmaceutical composition for treating a condition comprising a compound of claim 1 in an amount effective to treat said condition and a pharmaceutically acceptable carrier, wherein said condition is selected from the group consisting of:

- a) abnormal circadian rhythm;
- b) depression, further wherein a second compound for treating depression is administered, said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist; and
- c) emesis.

24. A pharmaceutical composition according to claim 23, wherein the condition is abnormal circadian rhythm, and the compound is combined with a second compound useful for treating a sleep disorder.

25. A pharmaceutical composition according to claim 24, wherein said second compound is selected from the group consisting of tachykinin antagonists, agonists for GABA brain receptors, metalonergic compounds, GABA brain receptor agonists, 5HT<sub>2</sub> receptor antagonists, and D4 receptor binding .

26. A pharmaceutical composition according to claim 23 wherein said condition is depression, and wherein said second compound having delayed action for treating depression is selected from the group consisting of selective serotonin reuptake inhibitors, tricyclic antidepressants, norepinephrine uptake inhibitors, lithium, bupropion, sertraline, fluoxetine, trazodone, and a tricyclic antidepressant selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine,


clomipramine, maprotiline, and carbamazepine, and pharmaceutically acceptable salts and esters of the above-recited compounds.

27. A pharmaceutical composition according to claim 23 wherein said condition is emesis, further comprising administering a second compound for treating emesis.


- 5 28. A pharmaceutical composition according to claim 27 wherein said second compound for treating emesis is selected from the group consisting of tachykinin antagonists, 5HT3 antagonists, GABA agonists, and substance P inhibitors.

Abstract

Corticotropin-releasing factor (CRF) antagonists having the formulae




I



II

or



III

- 5 wherein the dashed lines, A, B, Y, Z, G, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>16</sub> and R<sub>17</sub> are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.